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ABSTRACT OF THE DISSERTATION 
 
Characterization of Fasting-Induced p21 Expression and Protection of Intestinal Stem Cells 
 
by 
Kelsey Lynn Tinkum 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Molecular Cell Biology) 
Washington University in St. Louis, 2014 
Professors Helen and David Piwnica-Worms 
 
The cyclin dependent kinase inhibitor, p21, plays a key role in cell cycle. Additionally, 
the p21 gene, Cdkn1a (hereafter, p21) is often used as a marker of cellular stress. To investigate 
p21 promoter activity under basal conditions and in response to various forms of stress, we 
generated knock-in imaging reporter mice that express firefly luciferase (FLuc) under the control 
of the endogenous p21 promoter. I demonstrated that FLuc expression and bioluminescence 
detection mirrored endogenous p21 protein levels and promoter activity in vivo. Contrary to 
previously known roles for p53-mediate expression of p21, imaging of reporter cells 
demonstrated that p53 prevented the ERK/MAPK pathway from activating p21 expression when 
quiescent cells were stimulated with serum to re-enter the cell cycle. In addition, low light 
bioluminescence imaging identified p21 expression in specific regions of individual organs that 
were not previously observed including the paraventricular, arcuate and dorsomedial nuclei of 
the hypothalamus - regions that detect nutrient levels in the blood stream and regulate 
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metabolism throughout the body. These results suggested a link between p21 expression and 
metabolic regulation. I found that food deprivation (fasting) potently induced p21 expression in 
tissues involved in metabolic regulation, including liver, pancreas, and hypothalamic nuclei. The 
ability of fasting to induce p21 expression was found to be independent of p53, but dependent on 
the transcription factor FOXO1, which was bound to the p21 promoter region only in fasted mice. 
Previous work has shown that short-term fasting protects mice from what would normally be 
lethal doses of etoposide. I hypothesized that p21 may be involved in this protection, as p21 
expression increased in response to both fasting and DNA damage. I demonstrated that fasting 
prior to a high dose of etoposide treatment enhanced survival by protecting small intestinal stem 
cells, but that p21 was not required for this protection. While high dose etoposide treatment 
caused complete destruction of the crypt-villus architecture and near complete loss of small 
intestinal stem cells in free-feeding mice, fasting prior to etoposide treatment enabled stem cell 
survival and subsequent reconstitution of the small intestinal crypts and villi. Using LacZ 
reporter mice and lineage tracing, I found that both crypt base columnar (CBC) and +4 stem cells 
contributed to crypt restoration in the fasted mice. Though etoposide in fed and fasted mice 
induced similar amounts of DNA double strand breaks (DSBs) immediately following treatment, 
resolution of DNA DSBs, as measured by loss of γH2AX staining, occurred more quickly in 
stem cells of fasted mice compared to those of fed mice.  
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CHAPTER 1 
Introduction 
 2 
Introduction 
Cell cycle regulation through cyclin-dependent kinase inhibitor p21 
 The cell division cycle is a tightly regulated process involving serial progression through 
four phases: G1, S, G2 and M, to ensure fidelity of cell division. Thus, cells have developed 
evolutionarily conserved positive and negative regulators for each stage of the cell cycle. One of 
the master regulators of cell cycle progression is the protein complex formed between cyclins 
and cyclin dependent kinases (CDKs). Activation of these cyclin/CDK complexes requires 
physical binding between the cyclin and CDK and a specific series of phosphorylation and 
dephosphorylation events. Furthermore, during periods of cellular stress, cell cycle progression 
can be inhibited through a class of proteins known as CDK inhibitors. 
CDK inhibitor proteins are broken down into two families. The first is the Cip/Kip family, 
which consists of p21Waf1/Cip1, p27Kip1, and p57Kip2. The Cip/Kip family primarily interacts with 
Cdk2, which promotes progression through G1 and S phases of the cell cycle. The second is the 
Ink4 family, which consists of p16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4d. The Ink4 family primarily 
interacts with CDK4/6 and cyclin D complex that promotes progression through the G1 cell 
cycle phase. Within each family, there are both redundant and unique roles for each CDK 
inhibitor.  
CDK inhibitors regulate a variety of complex and sometimes opposing processes. For 
example, the inhibition of cell cycle progression by p21 occurs as part of cell differentiation as 
well as in response to DNA damage and oxidative stress (Abbas and Dutta, 2009). p21 
preferentially binds CDK2 complexes and thereby inhibits the G1/S phase of the cell cycle (Chen 
et al., 1995; El-Deiry et al., 1993; Harper et al., 1993; Harper et al., 1995; Luo et al., 1995). 
However, it also helps sustain a G2 arrest by binding to CDK1 complexes (Agarwal et al., 1995). 
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Paradoxically, p21 can also positively regulates cell cycle progression by aiding in the assembly 
of stable CDK4/6-cyclin D complexes (Sherr and Roberts, 1995). 
 
Cell cycle-independent functions of p21 
 In addition to regulating cell cycle progression, p21 binds to proliferating cell nuclear 
antigen (PCNA), a DNA polymerase δ processivity factor, and blocks processive DNA synthesis 
(Luo et al., 1995). Interaction between p21 and PCNA has also been reported to hinder DNA 
repair (Cazzalini et al., 2010). p21 can also repress a subset of transcription indirectly by 
inhibiting cyclin-CDK complexes, which, in turn, prevent phosphorylation of Rb-family proteins 
(Sherr and Roberts, 1999). In addition, p21 can directly modulate transcription by binding to and 
enhancing / and inhibiting transcription factors, such as E2F1, STAT3 and MYC (Abbas and 
Dutta, 2009). 
The cytoplasmic pool of p21 has been shown to regulate apoptosis and alterations to the 
actin cytoskeleton. p21 inhibits apoptosis by binding to and inhibiting the activity of proteins that 
induce apoptosis, including procaspase 3, caspases 8 and 10, and the protein kinases SAPK and 
ASK1. p21 also regulates the actin cytoskeleton by inhibiting ROCK (Besson et al., 2008; Lee 
and Helfman, 2004). Together, these data demonstrate a wide range of cellular functions for p21. 
 
Transcriptional regulation of the p21 (Cdkn1a) promoter 
Given the multi-faceted and complex functions of p21, it is not surprising that the p21 
(Cdkn1a) promoter is controlled by a plethora of signaling pathways (EGF, NGF, TGF-β, IFN-γ, 
IL6, progesterone, Ras/Raf pathway) and transcription factors (p53, SP1/3, AP2, STAT1/3/5, 
E2F1/3, SMAD3/4, and c/EBPα/β)(Abbas and Dutta, 2009; Gartel and Tyner, 1999). 
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The tumor suppressor protein, p53, was one of the first transcription factors found to 
activate p21 transcription, especially during periods of cellular stress. In response to DNA 
damage, p53 is the major transcription factor which enhances expression of cell cycle inhibition 
genes as well as pro-apoptotic genes. Following DNA damage, p53-dependent upregulation of 
p21, acts to halt the cell cycle and allow time for DNA repair. Though p53-dependent regulation 
of p21 transcription during DNA damage is the most well-characterized, there are a growing 
number of p53-independent mediators of p21 transcription, including Ras signaling through 
E2F1, nuclear receptors such as progesterone acting through their cognate response elements, 
and TGFβ through a complex containing SMAD3/4 and FOXO (Seoane et al., 2004). More 
recently, microarray studies in fasted or calorie-restricted mice noted enhanced p21 expression in 
skeletal muscle and liver (Ebert et al., 2010; Estep et al., 2009). Ebert et al. (2010) demonstrated 
that p21 expression was induced upon ectopic overexpression of ATF4 in skeletal muscle.  
 
Basal p21 expression, in vivo 
Northern blot analysis and in situ hybridization have been used to examine p21 
expression in various mouse organs ex vivo at baseline and following various forms of genotoxic 
stress (Bouvard et al., 2000; Macleod et al., 1995; Parker et al., 1995). However, there are 
significant discrepancies among these studies regarding which tissues have high versus low 
versus undetectable levels of p21 mRNA as well as the contribution made by p53 to basal 
expression of p21. In particular, the small intestine has been reported to show undetectable 
(Wilson et al., 1998), low (Ohtani et al., 2007; Vasey et al., 2008), moderately high (Bouvard et 
al., 2000; Lee et al., 2006) and very high (Macleod et al., 1995) baseline levels of p21 expression. 
Because conventional biochemical techniques have limitations in sensitivity and specificity 
 5 
arising from variations in reagent fidelity, specimen preparation, and quantification difficulties in 
many organs, there is considerable interest in imaging gene expression and signaling pathways 
noninvasively within living organisms (Dothager et al., 2009; Gross and Piwnica-Worms, 2005b). 
With that intent, transgenic reporter mice carrying a p21 LacZ transgene (Vasey et al., 2008) as 
well as a p21 firefly luciferase (FLuc) transgene (Ohtani et al., 2007) have been published; 
however, design strategies have limited the physiological relevance of these reporter strains. For 
example, both studies used a truncated p21 promoter to drive reporter expression and therefore 
miss any regulation occurring in the more distal regions of the promoter region. Furthermore in 
one case, reporter mice contained 2, 3 or 22 copies of the p21 transgene and therefore did not 
accurately report endogenous levels of expression (Vasey et al., 2008). The lack of a faithful p21 
reporter has left many unanswered questions in the in vivo regulation of p21 expression.  
 
Nutrient sensing  
The ability of organisms to adapt to fluctuations in nutrient availability is a complex, 
multi-organ process utilizing several overlapping energy-sensing signaling pathways. The 
pancreas functions as a sensor of circulating glucose levels that coordinates with the liver to 
maintain glucose homeostasis during fasting. The liver regulates lipid metabolism and 
coordinates with white adipose tissue which functions as an energy-storage depot and an active 
participant in metabolic homeostasis control. The stomach and small intestine also release 
hormones in both a paracrine and an endocrine manner to communicate with multiple organs. 
Finally, the hypothalamus plays a critical role in integrating the signals from each of these organs 
and releasing hormones to control food intake and energy expenditure (Funahashi et al., 2003; 
Schwartz et al., 2000). 
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The hypothalamus contains different groups of neurons that control much of mammalian 
physiology, including feeding behavior, energy expenditure, body temperature and central 
circadian control (Coppari, 2012; Yeo and Heisler, 2012). Neurons within arcuate nuclei are 
activated by changes in blood glucose, fatty acids, and insulin. The POMC/CART and 
NPY/AGRP neurons of the arcuate communicate the metabolic status of the mouse to the 
paraventricular and dorsomedial nuclei. The paraventricular nucleus integrates signals from the 
arcuate, as well as other inputs, and signals to the hypothalamic pituitary axis. The 
paraventricular nucleus also releases corticotropin-releasing hormone (CRH), a peptide hormone 
and neurotransmitter involved in stress responses. Finally, the dorsomedial nucleus regulates 
thermogenesis, energy expenditure, autonomic stress and neuroendocrine stress.  
 
FOXO pathway 
The forkhead box O (FOXO) family of transcription factors are activated under 
conditions of nutrient stress, and FOXO1, 3 and 4 have overlapping and distinct roles in 
regulating gluconeogenesis, lipogenesis, food intake, autophagy, and cell cycle arrest 
(Eijkelenboom and Burgering, 2013; Zhang et al., 2012). In the presence of growth factors, 
canonical insulin signaling negatively regulates FOXOs by Akt-mediated phosphorylation, 
promoting binding of 14-3-3 protein and shuttling to the cytoplasm, inhibiting FOXO-mediated 
transcription (Brunet et al., 1999; Brunet et al., 2002; Brunet et al., 2004). Under cellular stress, 
including high levels of reactive oxygen species (ROS), FOXOs are phosphorylated by JNK and 
translocate to the nucleus, enhancing FOXO-mediated transcription (Essers et al., 2004; Oh et al., 
2005). Furthermore, AMP-activated protein kinase (AMPK), phosphorylates FOXO under 
nutrient stress. This phosphorylation does not alter the localization of FOXO but may induce a 
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different set of FOXO target genes (Greer et al., 2007). Both CDK1 and CDK2, inhibit FOXO1 
activity through phosphorylation (Huang et al., 2006; Liu et al., 2008; Yuan et al., 2008). 
Furthermore, FOXO1/3/4 have been shown to transcribe p21 mRNA in response to TGF-b 
signaling (Seoane et al., 2004). Interestingly, a proteomic screen has identified FOXO as a 
substrate for the DNA damage kinases ATM and ATR, though the functional relevance of this 
interaction remains unknown (Matsuoka et al., 2007).  
 
Fasting enhances survival following high-dose chemotherapy 
Recently, short-term food deprivation, caloric restriction, and protein restriction, have 
been shown to protect mice from lethal doses of chemotherapy (Brandhorst et al., 2013; 
Raffaghello et al., 2008). Fasting-mediated protection is effective against multiple forms of DNA 
damaging agents including etoposide (double strand breaks), doxorubicin (double strand breaks 
and intercalation), cisplatin (crosslink) and cyclophosphamide (crosslink) (Lee et al., 2012; 
Raffaghello et al., 2008). 
It has been proposed that fasting-mediated protection is due to reduced levels of 
circulating IGF-1(Raffaghello et al., 2008); however, protein restriction and caloric restriction 
reduce IGF-1 levels to that of a fasted mouse, but do not exhibit equivalent protection from 
doxorubicin treatment (Brandhorst et al., 2013). Therefore, the reduced levels IGF-1 alone 
cannot explain fasting-mediated survival following DNA damage. 
Treatments that reduce side effects of chemotherapy by protecting normal cells are 
irrelevant if the tumor cells are also protected. In the absence of chemotherapy, dietary restriction 
and fasting can reduce the tumor burden of mice, suggesting that some tumors are sensitive to 
these metabolic states (Kalaany and Sabatini, 2009; Lee et al., 2012). Interestingly, tumor 
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xenograph models testing the efficacy of chemotherapy after fasting show a heightened 
sensitivity of the tumors to DNA damage compared to chemotherapy or fasting alone (Lee et al., 
2012; Raffaghello et al., 2008). However, long-term studies show that a subset of cancer cells 
can become resistant to chemotherapy in fasted mice, but remain sensitive in fed mice 
(Raffaghello et al., 2008). The mechanism by which cells can become resistant to chemotherapy 
in fasted states is unknown and knowledge of such could either greatly enhance the efficacy of 
the therapy or reduce the side effects. Lethal doses of DNA damage are known to greatly affect 
both the hematapoetic system and the gastrointestinal system. To date, it is unclear how fasting 
protects one, or both, of these systems in response to lethal doses of DNA damage. 
 
Intestinal architecture and the intestinal response to DNA damage 
The absorptive surface of the small intestinal lumen contains numerous finger-like 
protrusions called villi and invaginations into the submucosa known as the crypts of Lieberkühn. 
The epithelial cells of the villi are terminally differentiated and completely turnover every 5 days. 
The proliferation giving rise to these epithelial cells occurs in the crypt compartment where 
tetrapotent stem cells give rise to rapidly proliferating, committed daughter cells called transient 
amplifying cells, whichin turn, produce terminally differentiated cells that become the villus 
epithelium. As an example of this proliferative capacity, each day the transient amplifying cells 
generate 300 new cells per crypt (Marshman et al., 2002). 
Due to the high rates of proliferation and rapid turnover of cells, high-dose gamma 
irradiation (IR) causes severe damage to the small intestine. IR leads to crypt atrophy, 
submucosal inflammation, and a loss of both absorptive and barrier functions of the 
gastrointestinal system. Histologically, this can be seen by an increase in crypt cell apoptosis and 
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subsequent shortening of the crypts and villi (Potten, 1990). Apoptosis occurs in both the 
transient amplifying cells and the stem cells; however, it is the loss of the stem cells that has the 
most profound and long-lasting effects (Booth et al., 2012). 
 
Intestinal Stem Cells 
There are two distinct well-studied intestinal stem cells, identified based on their location 
in the crypt. The first is the crypt base columnar (CBC) stem cell, often identified by its 
expression of the marker, Lgr5 (Barker et al., 2007). The second is the “+4” stem cell, termed for 
its position within the crypt, which was originally identified by its long-term label retention 
(Potten et al., 2002; Sangiorgi and Capecchi, 2008). Multiple markers are used to identify the +4 
cell, including Bmi1, mTERT and HopX. In homeostatic conditions, the +4 is quiescent whereas 
the CBC is actively cycling. 
Following IR treatment, both the CBC and +4 stem cells proliferate and contribute to 
repopulation of the crypts and villi (Metcalfe et al., 2014; Sangiorgi and Capecchi, 2008; Tian et 
al., 2011; Yan et al., 2012). Recent studies in which CBCs are specifically ablated through use of 
LGR5DT show that the CBC stem cell is not required for replenishment of crypt cells during 
homeostasis, but is required for crypt regeneration after DNA damage (Metcalfe et al., 2014). It 
is unknown if the +4 stem cell is also required for proper crypt regeneration after DNA damage. 
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Abstract 
 To interrogate endogenous p21WAF1/CIP1 (p21) promoter activity under basal conditions 
and in response to various forms of stress, knock-in imaging reporter mice that placed expression 
of firefly luciferase (FLuc) under the control of the endogenous p21 promoter within the Cdkn1a 
gene locus were generated. Bioluminescence imaging (BLI) of p21 promoter activity was 
performed noninvasively and repetitively in mice and in cells derived from these mice. We 
demonstrated that expression of FLuc accurately reported endogenous p21 expression at baseline 
and under conditions of genotoxic stress; that photon flux correlated with mRNA abundance and 
therefore, bioluminescence provided a direct readout of p21 promoter activity in vivo. BLI 
confirmed that p53 was required for activation of the p21 promoter in vivo in response to 
ionizing radiation. Interestingly, imaging of reporter cells demonstrated that p53 prevents the 
ERK/MAPK pathway from activating p21 expression when quiescent cells are stimulated with 
serum to re-enter the cell cycle. In addition, low light BLI identified p21 expression in specific 
regions of individual organs that have not been observed previously. This inducible p21FLuc 
knock-in reporter strain will facilitate imaging studies of p53-dependent and -independent stress 
responses within the physiological context of the whole animal. 
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Introduction 
 p21Waf1/CIP1 (p21 hereafter) encodes a member of the CIP/KIP family of cyclin-dependent 
protein kinase (CDK) inhibitors that regulates a variety of complex and sometimes opposing cell 
processes. One of the best-characterized properties of p21 is its ability to impair cell cycle 
advancement by binding to and inhibiting CDKs (Abbas and Dutta, 2009). Indeed, p21 is a 
transcriptional target of p53 and, in cells experiencing genotoxic stress, is critical for arresting 
cells in the G1-phase of the cell division cycle through its binding to CDK2 complexes (Sherr 
and Roberts, 1995). Furthermore, p21 helps to sustain a G2-arrest by binding to CDK1 
complexes. It has been reported that the ERK/MAPK pathway activates p21 expression in 
response to serum stimulation (Bottazzi et al., 1999; Liu et al., 1996), but the impact of p53 was 
not fully characterized. Paradoxically, p21 also positively regulates cell cycle progression by 
aiding in the assembly of stable CDK4/6-Cyclin D complexes (Sherr and Roberts, 1999). 
In addition to regulating cell cycle progression, p21 binds to proliferating cell nuclear 
antigen (PCNA), a DNA polymerase d processivity factor, thereby blocking processive DNA 
synthesis (Luo et al., 1995). Interactions between p21 and PCNA have also been reported to 
hinder DNA repair (Cazzalini et al., 2010). p21 can also repress transcription indirectly by 
inhibiting cyclin-CDK complexes, which in turn, prevent phosphorylation of Rb-family proteins 
(Sherr and Roberts, 1999). In addition, p21 can modulate transcription directly by binding to 
various transcription factors, such as E2F1, STAT3 and MYC (Abbas and Dutta, 2009). 
The cytoplasmic pool of p21 has been shown to regulate apoptosis as well as the actin 
cytoskeleton. p21 inhibits apoptosis by binding to and inhibiting the activity of proteins that 
induce apoptosis, including procaspase 3, caspases 8 and 10, and the protein kinases SAPK and 
ASK1. p21 also regulates the actin cytoskeleton by inhibiting ROCK (Besson et al., 2008; Lee 
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and Helfman, 2004). Inhibition of ROCK may also be selected for during tumor progression to 
enhance cell motility. Indeed, high levels of cytoplasmic p21 have been observed in a number of 
human cancers and are associated with high-grade tumor types and poor prognosis (Abukhdeir 
and Park, 2008). 
Given the multi-faceted and complex functions of p21 in vivo, it is not surprising that the 
p21 promoter is controlled by a plethora of signaling pathways (EGF, NGF, TGF-b, IFN-g, IL6, 
progesterone, Ras/Raf pathway) and transcription factors (p53, SP1/3, AP2, STAT1/3/5, E2F1/3, 
SMAD3/4, and c/EBPa/b) (Abbas and Dutta, 2009; Gartel and Tyner, 1999). Northern blot 
analysis and in situ hybridization have been used to examine p21 expression in various mouse 
organs ex vivo at baseline and following exposure of mice to various forms of genotoxic stress 
(Bouvard et al., 2000; Macleod et al., 1995; Parker et al., 1995). However, there are significant 
discrepancies among these studies regarding which tissues have high versus low versus 
undetectable levels of p21 mRNA as well as the contribution made by p53 to basal expression of 
p21. In particular, small intestine has been reported to show undetectable (Wilson et al., 1998), 
low (Ohtani et al., 2007; Vasey et al., 2008), moderately high (Bouvard et al., 2000; Lee et al., 
2006) and very high (Macleod et al., 1995) baseline levels of p21 expression. Because 
conventional biochemical techniques have limitations in sensitivity and specificity arising from 
variations in reagent fidelity, specimen preparation, and quantification difficulties in many 
organs, there is considerable interest in imaging gene expression and signaling pathways 
noninvasively in their normal physiological context within living organisms (Dothager et al., 
2009; Gross and Piwnica-Worms, 2005b). With that intent, transgenic reporter mice carrying a 
p21 LacZ transgene (Vasey et al., 2008) as well as a p21 firefly luciferase (FLuc) transgene 
(Ohtani et al., 2007) have been published. However, design strategies limited the output of these 
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reporter strains. For example, both studies used a truncated p21 promoter to drive reporter 
expression and therefore eliminated key signaling inputs regulating p21 promoter activity. In 
addition, in one case, reporter mice contained 2, 3 or 22 copies of the p21 transgene and 
therefore did not accurately report endogenous levels of expression (Vasey et al., 2008). 
Therefore, to monitor both p53-dependent and -independent regulation of the endogenous 
p21 promoter in the proper context of a vertebrate animal, we generated knock-in reporter mice 
that place expression of the FLuc gene under the control of the endogenous p21 promoter. We 
demonstrate that expression of luciferase accurately reports endogenous p21 expression at 
baseline and following ionizing radiation, enabling the activity of the endogenous p21 promoter 
to be dynamically monitored in real time in vivo, under a variety of experimental conditions. 
Known functions of p21 were validated non-invasively and in a tissue-specific manner. Imaging 
of reporter murine embryonic fibroblasts (MEFs) demonstrated that p53 prevents the 
ERK/MAPK pathway from activating p21 expression when quiescent cells are stimulated to re-
enter the cell cycle with serum, while imaging of reporter mice revealed novel sites of high-level 
p21 expression. 
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Results 
 
Generation of p21 reporter mice.  
Knock-in mice expressing firefly luciferase (P. pyralis) from the endogenous p21 
promoter were generated to monitor the spatial and temporal regulation of p21 (Cdkn1a) gene 
expression in vitro and in vivo by bioluminescence imaging (BLI) (Fig. 1A). Homologous 
recombination in ES cell clones was confirmed by Southern blotting (Fig. 1B and 1C) and PCR 
analysis (Fig. 1D and 1E) while genotyping of offspring was performed by PCR analysis of 
mouse-tail DNA (Fig. 1F). Whole body bioluminescence was detected in both heterozygous 
(+/FLuc) and homozygous (FLuc/FLuc) knock-in but not wild-type (+/+) mice (Fig. 1G). 
 
Characterization of p21 promoter activity in reporter-derived MEFs. 
Mouse embryonic fibroblasts (MEFs) were generated as a way to determine if FLuc 
expression accurately reflected endogenous p21 expression. Bioluminescence of MEFs derived 
from wild-type (p21+/+) mice was within background levels as expected, while bioluminescence 
of MEFs derived from heterozygous knock-in animals (p21+/FLuc) was 307-fold over background. 
Bioluminescence of MEFs derived from homozygous knock-in animals (p21FLuc/FLuc) was 2.2-
fold higher than MEFs derived from heterozygous (p21+/FLuc) littermates (Fig. 2A, B). p21+/+ 
MEFs contained ~ 1.5-fold more p21 mRNA than did p21+/FLuc MEFs (Fig. 2C). 
Correspondingly, FLuc mRNA was absent in p21+/+ MEFs and present at ~1.8-fold higher levels 
in p21FLuc/FLuc MEFs compared with p21+/FLuc MEFs (Fig. 2C). Western blotting revealed an 
approximate 50% decrease in p21 protein in p21+/FLuc MEFs relative to WT MEFs, and FLuc 
protein levels were ~2-fold higher in p21FLuc/FLuc MEFs relative to p21+/FLuc MEFs (Fig. 2D). 
Overall bioluminescence, mRNA and protein levels correlated with the p21 WT allele copy 
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number (Table 2.1). These results indicate that reporter activity accurately reflects basal p21 
promoter expression. 
 
Characterization of p21 promoter activity in reporter MEFs lacking p53. 
To monitor p21 promoter activity in both the presence and absence of p53, reporter mice 
along with their wild-type littermates were crossed to Trp53+/- mice, followed by intercrossing to 
obtain p21+/FLuc reporter mice with littermates wild-type or null for Trp53. Compared to p21+/FLuc 
littermates (p53 wild-type), no difference in baseline promoter activity was observed in whole 
body BLI (Fig. 3A, B) or in isolated organs of p53 null p21+/FLuc reporter mice, with the 
exception of white adipose tissue (WAT), where enhanced bioluminescence was measured in 
p53 null WAT relative to p53 WT WAT (p =0.016) (Fig. 3C). Early passage heterozygous 
reporter MEFs were also generated and subjected to BLI. In contrast to live mice, basal 
bioluminescence (Fig. 4A (panels 1, 3), B) measured in p21+/FLuc MEFs lacking p53 was ~20% 
of that measured in reporter MEFs with wild-type p53. mRNAs encoding p21 and FLuc were 
significantly reduced in p53 null heterozyous reporter MEFs relative to their p53 wild-type 
counterparts (9% and 10% of WT, respectively) (Fig. 4C). Similarly, both p21 and FLuc proteins 
were also reduced in the absence of p53 (Fig. 4D (lanes 1, 3)).  
Next MEFs were imaged to obtain baseline values and then either mock irradiated or 
exposed to 2.5 Gy irradiation (IR). Cells were then re-imaged at various time points after 
irradiation. Representative bioluminescent images are shown in Fig. 4A and data obtained at 4 
and 12 h post irradiation is displayed graphically (Fig. 4E). Results confirmed previously 
published findings (el-Deiry, 1998) demonstrating that IR activates the p21 promoter in a p53-
dependent manner and further validated that reporter MEFs accurately reflected endogenous p21 
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promoter activity in response to IR. Protein (Fig. 4D) as well as mRNAs encoding p21 and FLuc 
(Fig. 4F) accumulated concordantly in irradiated reporter MEFs in a p53-dependent manner. 
 
Regulation of p21 expression during cell cycle re-entry from quiescence. 
Next, the contribution made by p53 to the ability of MEFs to re-enter the cell cycle from 
quiescence was examined. p21+/FLuc reporter MEFs that were either wild-type or null for p53 
were cultured in 0.1% serum for 48 h in order to induce growth arrest (Fig. 5A). As seen in Fig. 
5B, there was a significant decrease in bioluminescence over the 48 h period and the observed 
loss of p21 expression was independent of p53 status. Interestingly, p21 expression was induced 
when p53 null but not p53 wild-type MEFs were cultured in 10% fetal bovine serum (FBS) to 
stimulate cell cycle re-entry (Fig. 5B). The ERK/MAPK pathway has been shown to activate p21 
expression in response to serum stimulation (Bottazzi et al., 1999; Liu et al., 1996). Therefore, 
we tested whether inhibition of MEK (with the kinase inhibitor U0126) blocked induction of p21 
expression by serum re-stimulation. Cells that had been cultured in 0.1% FBS for 47.5 h were 
treated with either vehicle (DMSO) or a range of U0126 concentrations for 30 min. After the 30 
min pre-incubation period, cells were cultured in media containing 10% FBS together with either 
DMSO or U0126 and BLI was performed at the indicated time points. Photon flux was 
normalized to baseline values obtained from cells cultured in 0.1% FBS for 48 h (t = 0 in Fig. 
5A). Note that an approximate 6-fold induction of bioluminescence was measured in p53 null 
cells within 5 h of culturing in 10% FBS (Fig. 5C) and a dose dependent inhibition of p21 
expression by U0126 was observed under these conditions (Fig. 5C, D). This suggests that in the 
absence of p53, serum stimulation acts through the ERK/MAPK pathway to activate p21 
expression. As was observed in Fig. 5B, serum stimulation was ineffective at inducing p21 
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expression in p53 wild-type MEFs (Fig. 5E) and in p53 wild-type MEFs, inhibition of p21 
expression was only observed at the very highest doses of U0126 (30 and 100 µM) where off 
target effects of the drug are expected (Fig. 5E, F). Western blotting revealed that p21 protein 
levels were also elevated when p53 null but not wild-type MEFs were stimulated with serum and 
the ability of serum to increase p21 was blocked by U0126 (Fig. 5G). Note that 10% FBS 
stimulated ERK phosphorylation and this was blocked with 10 µM U0126 in both p53 wild-type 
and null MEFs (Fig. 5H). Taken together these findings suggest that of p53 blocks quiescent 
MEFs from activating p21 expression in response to serum stimulation. Given that ERK 
phosphorylation is induced normally under these conditions, the block in signaling must be at a 
point downstream of ERK/MAPK activation (Fig. 6E). 
If p53 prevents the ERK/MAPK pathway from activating p21 expression in serum-
stimulated quiescent cells, then knockdown of p53 should result in activation of the p21 
promoter and increased levels of p21 protein in p53 wild-type MEFs under these conditions. As 
seen in Fig. 6A, efficient knockdown of p53 was achieved in p53 wild-type MEFs upon lentiviral 
infection. Importantly, when p53 was knocked down, p21 levels rose following serum 
stimulation (Fig. 6B (lanes 5, 6) and 6C) and this response was inhibited by U0126 (Fig. 6B 
(lanes 6, 8) and 6C). Bioluminescence followed similar trends in that knockdown of p53 now 
sensitized p21 expression to U0126 (Fig. 6D). As expected, p21 levels did not rise when 
quiescent p53 wild-type MEFs expressing scrambled shRNAs were cultured in 10% FBS (Fig. 
6B (lanes 1, 2) and 6C) and U0126-treatment did not decrease overall levels of p21 in these cells 
(Fig. 6B (lanes 2, 4), and 6C).  
 
Analysis of p21 promoter activity in individual organs of reporter mice. 
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Individual organs were freshly isolated from reporter mice to determine the localization 
and intensity of basal p21 promoter activity in vivo (Fig. 7 and 8). To account for size differences 
between various organs within a single mouse as well as the same organ in different mice, organ 
photon flux was normalized to organ weight. As seen in Fig. 7, values measured in individual 
organs ranged from 1x106 to 1x109 [photons/sec]/[gram]. Bioluminescence was detected in every 
organ that was examined; even the low signals measured in blood, heart, brain and spleen were 
above background levels. These results suggested that the p21 promoter was ubiquitously active 
in unperturbed mice. Within the quantitative limits introduced by different optical densities of 
the various tissues (Klerk et al., 2007), bioluminescence was greatest in penis, bladder, vagina, 
intestines, femur (containing bone marrow), skin and WAT. To confirm that FLuc mRNA levels 
accurately represented endogenous p21 mRNA levels, RNA was isolated from livers, spleens, 
kidneys, and small intestines of p21+/FLuc mice and p21 and FLuc mRNA levels were quantitated. 
As seen in Fig. 7B and C, p21 and FLuc mRNA levels were concordant in all tissues with the 
exception of liver where Fluc mRNA levels were slightly higher than p21 mRNA levels.  
 
Analysis of p21 promoter activity in irradiated reporter mice. 
Mice were subjected to whole body irradiation to determine if IR activates the 
endogenous p21 promoter in a p53-dependent manner in vivo. Baseline images were obtained 
and then mice were either mock irradiated or exposed to 2.5 Gy IR. Mice were then re-imaged at 
various times post-treatment. Representative images are shown at 0 and 8 h post-treatment (Fig. 
9A) and data are presented graphically in Fig. 9B. Whole body bioluminescence of p53 wild-
type reporter mice increased following IR-treatment and peaked by 8 h. Bioluminescence then 
steadily declined until 24 h post-IR and remained stable but above baseline out to 36 h. 
 21 
Enhanced bioluminescence was not observed in reporter mice lacking p53 relative to mock-
irradiated mice, confirming that p53 regulates the p21 promoter in response to IR in vivo. Note 
the small, but highly reproducible, p53-independent transient increase in bioluminescence for 
several hours after the procedure (perhaps related to handling the mice during transport to and 
from the irradiator), an apparent stress response we have observed in all groups during a variety 
of procedures.  
Next, individual organs were isolated 8 h following treatment to determine which organs 
contributed to the increase in whole body bioluminescence following IR (Fig. 9C, D). 
Bioluminescence was observed to increase in nearly all organs tested, but most significantly in 
small intestines and pancreas. Other organs that showed a significant increase were brain, large 
intestine, salivary gland, spleen, lung and heart (Mann-Whitney U Test, p-values, Fig. 9C). No 
significant change was detected in response to IR in the peritoneal lining, liver, kidney, stomach, 
skin, cecum, femur containing bone marrow or skeletal muscle (Fig. 9D). IR has previously been 
reported to increase p21 mRNA and protein levels in small and large intestines (Bouvard et al., 
2000; Macleod et al., 1995; Wilson et al., 1998), brain (Bouvard et al., 2000; Lee et al., 2006; 
Macleod et al., 1995), salivary gland (Humphries et al., 2006), spleen (Bouvard et al., 2000; Lee 
et al., 2006; Macleod et al., 1995), lung (Bouvard et al., 2000; Lee et al., 2006; Macleod et al., 
1995) and heart (Bouvard et al., 2000; Lee et al., 2006), but the observed increase in pancreas 
was a novel finding of our study.  
 
 
p21 promoter activity in specific regions of individual organs.  
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To localize the origin of luciferase activity within specific regions of individual organs, 
we employed low light microscopy (Fig. 10). Imaging was performed using microscopes with 
custom built, light-tight environmental chambers to avoid external light leaks and to control for 
temperature. Organs were isolated, immediately sectioned and then placed in appropriate buffers 
to maintain viability. In some cases, SYTO® 11 green fluorescent stain was used to visualize 
nucleic acid (nuclei) and SYPRO Ruby was used as a protein stain. Tissue autofluorescence 
(Autofluor) was used to complement bright field imaging. Bright field (Fig. 10, column 1) and 
bioluminescent images (Fig. 10, column 2) were acquired for all tissues; the latter are 
represented as pseudocolored heatmaps over the bright field images in column 3. p21 promoter 
activity was visualized throughout the villi of the small intestines and just inferior to the villi in 
the superior regions of crypts (Fig. 10A). This indicated that p21 expression was turned on as 
cells exited their proliferative phase and began to terminally differentiate into the various 
epithelial cell types of the small intestine. p21 promoter activity was widely dispersed throughout 
the liver and fractionation studies confirmed luciferase activity in freshly isolated hepatocytes 
(Fig. 10B). p21 promoter activity was also observed in the epithelial cell layer under the 
keratinized penile spines (Fig. 10C, D). The autofluorescence of the spine validated that 
luciferase activity originated from the base of the spine and not from within the spine itself (Fig. 
10D, columns 4,5). Finally, p21 promoter activity was localized to the epithelial cell layer of the 
vagina (Fig. 10E). The vaginal lumen was identified by bathing it in SYPRO Ruby protein stain 
prior to dissection (column 5). SYTO 11 nucleic acid stain was used to identify the adventitia 
and muscularis layers of the vagina (column 4). As seen in column 6, bioluminescence was 
detected between these two markers specifically in the epithelial cell layer. Immunofluorescent 
staining confirmed that FLuc protein was specifically localized to the epithelial cell layer of the 
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vagina (Fig. 11A) and IHC confirmed that FLuc is localized in the epithelium at the base of 
penile spines (Fig. 11B). Finally, laser capture microdissection followed by real time PCR 
confirmed that endogenous p21 mRNA was present in the epithelial layers of the vagina and 
penis (Fig. 12). Taken together, we conclude that the endogenous p21 promoter is widely active 
under basal conditions in organs throughout the body as well as in cell-type specific 
compartments and niches of these organs not previously appreciated. 
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Discussion 
We generated and characterized knock-in p21 luciferase reporter mice that enable non-
invasive, real-time monitoring of endogenous p21 promoter activity, both spatially and 
temporally, in the context of living mice and in cells derived from these mice. To validate these 
reporter mice, we asked whether p53 was required for basal and damage-induced expression of 
the p21 promoter in mice and in MEFs. In addition, we analyzed p53-dependent and -
independent regulation of p21 expression as cells re-enter the cell cycle from quiescence. 
Loss of p53 had profound effects on basal expression of the p21 promoter in cultured 
MEFs (Fig. 4). In contrast to live mice, there was a five-fold reduction in baseline 
bioluminescence measured in early passage MEFs obtained from p53 null mice compared with 
p53 wild-type mice. A decrease in p21 promoter activity was also validated at the level of both 
mRNA (Fig. 4C) and protein (Fig. 4E). These findings indicated that the p21 promoter was 
activated in MEFs in a p53-dependent manner as a result of culturing cells ex vivo, consistent 
with a process that has been termed “culture shock” (Sherr and DePinho, 2000). As expected, the 
ability of IR to induce p21 promoter activity in MEFs required a functional p53 pathway (Fig. 4). 
An increase of p21 promoter activity was also observed in reporter mice following IR exposure, 
which was also p53-dependent (Fig. 9). Organ analysis ex vivo demonstrated that post-IR signals 
increased in all organs tested, but most significantly in the small intestine, pancreas and brain. 
p21 expression has been shown to be activated in response to serum stimulation through 
the ERK/MAPK pathway. This leads to assembly of Cyclin D/CDK4 complexes in order to 
promote cell cycle progression (Bottazzi et al., 1999; Cheng et al., 1999; LaBaer et al., 1997; Liu 
et al., 1996; Macleod et al., 1995). We observed activation of p21 expression and increases in 
p21 protein when quiescent MEFs were stimulated by serum, but only in Trp53 null cells (Fig. 5, 
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6). The addition of serum to early passage quiescent Trp53 wild-type MEFs induced MEK 
activation as evidenced by increases in ERK phosphorylation but the p21 promoter was not 
activated (Fig. 6E). Thus, p53 appears to block quiescent wild-type MEFs from activating p21 
expression upon serum stimulation at a point downstream of ERK/MAPK activation. Future 
studies will examine p21 promoter occupancy by ERK/MAPK regulated transcription factors 
both in the presence and absence of p53.  
Previous studies of p21 expression levels in various organs of mice (at the level of 
endogenous protein, endogenous mRNA or in transgenic reporter mice) reported that baseline 
expression of p21 is independent of p53 status (Bouvard et al., 2000; Macleod et al., 1995; 
Ohtani et al., 2007; Vasey et al., 2008; Wilson et al., 1998). Of note, these observations were 
generally confirmed in our knock-in strain (Fig. 7, 8), but the sensitivity of bioluminescence 
imaging enabled us to detect effects of loss of p53 function on expression of p21 in mouse white 
adipose tissue (Fig. 3). In addition, several other organs trended towards significance. Due to the 
robust bioluminescence generated in our reporter mice, we were able to use micro-osmotic 
pumps to deliver a constant supply of D-luciferin to all tissues in selected experiments, which 
enabled protocols for imaging mice sequentially and repetitively over short or long intervals, 
therefore enhancing the capacity for dynamic analysis (Gross et al., 2007). 
In contrast to the knock-in mice reported here, previously published transgenic reporter mice 
carrying a p21 LacZ transgene (Vasey et al., 2008) or a p21 firefly luciferase (FLuc) transgene 
(Ohtani et al., 2007) did not accurately report p21 promoter activity in vivo. For example, 
baseline expression of the p21 promoter was reported to be highest in the kidney and forepaws, 
whereas the small intestine was one of the lowest expressing organs in the p21 FLuc transgenic 
strain (Ohtani et al., 2007). By contrast, in our knock-in reporter mice, the small intestine (Fig. 7, 
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8) was one of the highest expressing organs, as expected (Bouvard et al., 2000; Macleod et al., 
1995), while kidney (Fig. 7, 8) and forepaw (Fig. 8) were among the lowest. In the transgenic 
models, a truncated p21 promoter of 2.5 kb (Ohtani et al., 2007) or 4.5 kb (Vasey et al., 2008) 
drives reporter expression. In one case, the reporter strain contained 2, 3 or 22 copies of the 
transgene (Vasey et al., 2008), whereas in the other case, the number of copies was not 
documented (Ohtani et al., 2007). Baseline expression of the p21 promoter in the p21 LacZ mice 
was only detected in the strain with 21 copies of the transgene (Vasey et al., 2008) and 
bioluminescence in the p21 FLuc transgenic strain did not exceed 106 photons/sec (Ohtani et al., 
2007). This is in contrast to high baseline bioluminescence of 109 photons/sec measured in our 
reporter mice under similar conditions. The observed differences between the transgenic strains 
and our knock-in strain are likely due, in part, to the deletion of many important regulatory 
regions in the truncated promoters used to create the transgenic reporter lines, as well as gene 
loci and related positional effects on reporter activity (al-Shawi et al., 1990). 
Given recent advances in cooled CCD cameras and our interest in tracking p21 
expression at high resolution, low light bioluminescence microscopy allowed us to observe p21 
promoter activity within specific regions of mouse tissues. We observed p21 promoter activity in 
the differentiated epithelia of various organs (penis, vagina and small intestine) as well as in liver 
hepatocytes, a relatively quiescent cell population (Fig. 10). The observation of p21 expression 
in differentiated epithelia of the external genitalia was novel. The ability to use microscopy to 
visualize p21 expression provides an additional advantage as bioluminescence microscopy does 
not require potentially cytotoxic excitation light and typically has extremely low background 
signal (Flentie et al., 2008). The real-time nature of FLuc-based tracking of reporters in 
eukaryotic cells also allows serial measurements from the same region over time (Gross and 
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Piwnica-Worms, 2005a). Hence, bioluminescence microscopy is well suited to kinetic studies of 
p21 expression in specific regions of organs not previously amenable to analysis. 
In summary, we generated knock-in luciferase reporter mice targeting the p21 gene locus 
that will be particularly useful for elucidating more fully the many known upstream regulators of 
p21 promoter activity in vivo and, due to the ease of bioluminescence imaging, will be useful for 
characterizing novel p53-independent regulators of the p21 promoter in living mice. 
  
 28 
Materials and Methods 
This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The Committee on the 
Ethics of Animal Experiments at Washington University approved all animal protocols used in 
this study. 
 
Construction of the p21 targeting vector. PCR was used to amplify 129/SvJ genomic DNA 
encoding p21 (Invitrogen). The 5’ targeting arm was generated using primers 5’- GAT CCC 
CGG TCC TTG TGA A -3’ and 5’- CCA TGG TGC CTG TGG CTG AAA C -3’. This 
amplified 4.0 kb of p21 genomic DNA beginning within intron 1 and ending in exon 2 just after 
the start codon. The primer design inserted an Nco I site within the ATG start codon in exon 2. 
The 3’ targeting arm was generated using primers 5’- TGT CCG ACC TGT TCC GCA CAG – 3’ 
and 5’- GGT AAG ACC AGG GAA TCC CAC -3’. This amplified 1.8 kb of p21 genomic DNA 
extending from within exon 2 to noncoding sequences downstream of exon 3. PCR products 
were inserted into the Topo TA vector (Invitrogen). A Bam HI/Nco I fragment encoding the 5’ 
targeting arm was then inserted into Bgl II/Nco I sites of pGL3-Basic Vector (Promega) to 
generate pGL3-mp21/5 (8.8 kb). p1339 (Genbank Accession # AF335419) was used to assemble 
the targeting vector (gift from Siteman Cancer Center at Washington University). p1399 contains 
a lox-P flanked PGK-Neo cassette (phosphoglycerate kinase (PGK) promoter driving expression 
of neomycin (Neo) phosphotransferase). The 1.8 kb Eco RI/Eco RI 3’ arm was cloned into Eco 
RV digested p1339 to generate p1339-mp21/3. The 5.9 kb Mlu I/Bam HI fragment from pGL3-
mp21/5 was then cloned into Kpn 1 digested p1339-mp21/3 to generate the final targeting vector 
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(mp21-pGL3). 
 
Generation of reporter mice. RW4 ES cells (Siteman Cancer Center at Washington University) 
were electroporated with Not I linearized targeting vector and selected with Geneticin (G418; 
Invitrogen) using established protocols (Siteman Cancer Center Murine Embryonic Stem Cell 
Core). A total of 144 G418-resistant ES cell colonies were analyzed for homologous 
recombination. Genomic DNA was digested with Eco RV followed by Southern blotting using 
the 5’ Southern probe (primers: Forward 5’- GCG ATA TCC AGA CAT TCA GAG -3’, Reverse 
5’- GGA ATC CCT AGA AAC ATT GGC-3’). ES cell clone #70 was selected and homologous 
recombination was confirmed for the 3’ arm by PCR using two primers (5’-TCT TGT GTT TCA 
GCC ACA GGC -3’ and 5’- CAA TGC AGG GGG TTG CCA CT-3’). ES cell clone #70 was 
determined to have a normal karyotype and was expanded and electroporated with a plasmid 
encoding Turbo-Cre recombinase under the control of the chicken beta-actin promoter to remove 
the PGK-Neo cassette. A total of 51 ES cell clones were analyzed for excision of the PGK-Neo 
cassette. Genomic DNA was digested with Eco RV followed by Southern blotting with the 5’ 
Southern probe and PCR using the same primers as described above for the 3’ arm to identify 
clones lacking the Neo cassette. ES cell clone #70-58 was selected and found to have a normal 
karyotype. This clone was microinjected into C57BL/6 blastocysts, which were subsequently 
implanted into the uteri of pseudopregnant C57BL/6 x C3H foster mothers. Male chimeras 
selected by percentage of agouti color were mated to C57BL/6 females. Germ line transmission 
was determined by agouti coat color. F1 animals were tested for the targeted p21 allele by PCR 
analysis of tail DNA (see SI Text for PCR primers). PCR analysis of tail DNA was performed 
with three primers (a: 5’-TCT TGT GTT TCA GCC ACA GGC-3’, b: 5’-CTG TCA GGC TGG 
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TCT GCC TCC-3’, c: 5’ CGA ACG GAC ATT TCG AAG TAC-3’). The sizes of the WT and 
recombinant alleles were 453 bp and 208 bp, respectively. The Trp53+/- mouse line was obtained 
from Jackson labs (000058). All mice were crossed to 129X1/SvJ and B6(Cg)-Tyrc-2J/J to obtain 
a white coat color for imaging.  
 
Generation and culturing of murine embryonic fibroblasts (MEFs). MEFs were generated as 
described (Ferguson et al., 2005), cultured in a 5% O2 incubator and frozen down at passage 2. 
MEFs were cultured in complete MEF media consisting of DMEM (High Glucose with L-
Glutamine, Gibco,) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
U/mL streptomycin (Gibco), 2 mM L-Glutamine (Gibco), 100 µM non-essential amino acids 
(Gibco) and 140 µM 2-mercaptoethanol (Biorad). Imaging experiments were performed in 
black-walled 24-well plates (Midwest Scientific, St. Louis MO) in media lacking phenol red and 
containing 0.5 mM D-luciferin (Biosynth). All experiments were conducted with early passage 
cells (P2 to P5) and at least three different lines were used for each genotype. Cells were 
irradiated in a 60Co source. Serum starvation experiments were performed with cells plated at 
subconfluency. 0.2 to 0.7 x 104 cells were seeded in 24-well black walled tissue culture dishes for 
BLI and 0.5 to 2 x 105 cells were seeded in 10 cm tissue culture dishes for Western blotting. One 
day after plating, cells were washed twice with low serum MEF media (0.1% FBS) and cultured 
in low serum media for 48 h. Cells were then incubated in low serum media with the indicated 
concentrations of U0126 (Promega) in DMSO (Sigma) or DMSO alone for 30 min, followed by 
incubation in MEF media containing 10% FBS and supplemented with the indicated 
concentrations of U0126 or vehicle (DMSO). Bioluminescence imaging was performed using an 
IVIS Lumina or IVIS 50 (Caliper) with identical instrument, field-of-view, f-stop, exposure and 
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binning settings within an experiment (Gross and Piwnica-Worms, 2005a). 
 
shRNA. For shRNA knockdown, lentiviruses were produced using pLKO.1 plasmids that 
contained shRNA sequences and were cotransfected with packaging plasmids as described 
(Stewart et al., 2003). shRNA sequences were tested for p53 knockdown (pLKO.1 shTrp53: 
CCG ACC TAT CCT TAC CAT CAT) (RNAi Consortium) and compared to scrambled control 
(pLKO.1 Scr: CCTAA GGTTA AGTCG CCCTC GCTCT AGCGA GGGCG ACTTA ACCTT 
AGG) (Addgene)(Sarbassov et al., 2005). All cells were selected in puromycin (2 µg/mL, 
Invitrogen). 
 
Real-Time PCR. RNA was isolated from MEFs using the RNeasy kit (Qiagen). RNA was 
reverse-transcribed with random primers (SuperScript II, Invitrogen). Standard curves were 
generated using cDNA from p53+/+ and p53-/- MEFs of each sample within an experiment. The 
standard curve for each primer was generated from the logarithmic equation fitting the cycle 
thresholds for 400, 200, 100, 25, 12.5 and 1 ng and all R2 values were greater than 0.99. The 
standard curve was run on each plate in at least duplicate. Each sample was tested in triplicate at 
50 ng cDNA, except in the p53-/- samples where p21 and FLuc levels at 50 ng were outside the 
linear range of the standard curve, so these samples were run in triplicate undiluted from the 
cDNA reaction. Real-time PCR was performed with SYBR Green master mix (Agilent) and 100 
nM of the specific primer set, in a BioRad CFX96 PCR instrument (95°C 10 min, then 40 cycles 
of 95°C for 30 sec, 61°C for 1 min and 74°C for 1 min). Primers were: p21 forward: 5’- GAC 
AAG AGG CCC AGT ACT TCC T – 3’; p21 reverse: 5’- CAA TCT GCG CTT GGA GTC 
ATA – 3’; FLuc forward: 5’ - CGT CGC CAG TCA AGT AAC AAC C – 3’; FLuc reverse: 5’ - 
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CAC GGC GAT CTT TCC GCC – 3’; 18S forward: 5’ - CAT TCG AAC GTC TGC CCT ATC 
3’; 18S reverse: 5’ – CCT GCT GCC TTC CTT GGA -3’.  
For whole tissue RNA extraction, mice were perfused with DEPC-treated PBS, followed 
by a 3 min perfusion with RNALater (Ambion). Organs were then dissected and flash frozen in 
RNALater. RNA was isolated from homogenized whole tissues using Trizol (Invitrogen). 
Quality of whole tissue RNA was determined by gel electrophoresis or spectrophotometry and 
only intact samples were analyzed. RNA was reverse-transcribed with random primers 
(SuperScript II, Invitrogen). cDNA was pooled from whole tissue lysates to generate a standard 
curve. All samples were run in triplicate with 50 ng cDNA. Real-time PCR was performed as 
described above. 
RNA was isolated from laser capture microdissected tissue using the RNeasy Micro kit 
(Qiagen). RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). Real-time PCR was performed using TaqMan primers and probes for 
p21 (Mm00432448_m1) and actin (4352341E) (Applied Biosystems). Due to the small volume 
of RNA isolated from laser capture microdissection, a standard curve could not be generated and 
the delta CT method was used for analysis. Relative expression of p21 and FLuc were calculated 
by normalizing to actin or 18S levels (Fig. 2, 4C, 7B) and then to mock irradiated samples within 
each genotype (Fig. 4F), to p21 mRNA (Fig. 7C) or to wild-type control levels (Fig. 12).  
 
Western blotting. Cells were lysed in mammalian cell lysis buffer (MCLB) [50 mM Tris-HCl 
pH 8.0, 2 mM DTT, 5 mM EDTA, 0.5% NP-40, 100 mM NaCl, 1 mM microcystin (Sigma 
Chemical Co.), 1 mM sodium orthovanadate, 2 mM PMSF] supplemented with protease (Sigma 
Chemical Co.) and phosphatase inhibitor cocktails (Calbiochem). Clarified lysates were resolved 
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by SDS-PAGE (10%/15% layered SDS gel) and transferred to nitrocellulose membranes for 
Western blotting. Membranes were blocked in TBST (20 mM Tris HCl, pH 7.6, 137 mM NaCl, 
0.1% Tween 20) containing 5% nonfat milk and incubated overnight in primary antibody diluted 
in either TBST/1% nonfat milk or TBST/5% BSA containing 0.05% sodium azide. Membranes 
were washed in TBST, incubated with fluorescence- or HRP-conjugated secondary antibody for 
1 h in TBST/1% nonfat milk, and washed again in TBST. Blots were analyzed using the Odyssey 
imaging system (LI-COR Biosciences) or incubated with ECL (Pierce) and exposed to film. 
Quantification was preformed in ImageJ (Abramoff et al., 2004). Primary antibodies included 
anti-p21 at 1:1000 (Santa Cruz, F5), anti-FLuc at 1:10,000 (Santa Cruz, sc-32896), anti-actin at 
1:10,000 (Sigma Chemical Co., A4700), anti-p53 at 1:1000 (Cell Signaling, 1C12), anti-Tubulin 
at 1:1000 (AbCam, YL1/2), anti-CyclophillinA at 1:1000 (Cell Signaling, 2175), anti-phospho-
p44/42 Erk1/2 at 1:1000 (Cell Signaling, D13.14.4E), and anti-p44/42 Erk1/2 at 1:2000 (Cell 
Signaling, L34F12). Secondary antibodies for Odyssey system were from LI-COR Biosciences 
and included donkey anti-rabbit IRDye-800CW, donkey anti-mouse IRDye-800CW and donkey 
anti-mouse IRDye680CW. Secondary antibodies for autoradiography were peroxidase-
conjugated, AffiniPure Goat anti-Mouse (Jackson), HRP-Rabbit anti-Rat (Zymed) and HRP-
Goat anti-Rabbit (Invitrogen). 
 
Immunohistochemistry. Mouse tissues were fixed in Bouin’s solution (Sigma Chemical Co.) 
overnight, progressively dehydrated through gradients of ethanol and then paraffin embedded. 
Tissues were sectioned at a thickness of 5 µm. Trilogy (Cell Marque) was used for 
deparafinization, rehydration and antigen retrieval. Vaginal sections were blocked using Rodent 
Block M (Biocare), and then incubated with anti-FLuc antibody (sc-32896, Santa Cruz) diluted 
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1:1000 in PBS containing 3% nonfat milk and 0.1% Triton-X at 4oC overnight. Sections were 
washed and then incubated with secondary antibody Alexa-Fluor-594 goat anti-rabbit 
(Invitrogen) at room temperature for 1 h. Secondary antibody was diluted 1:1000 in Fluorescent 
Diluent (Biocare) with XR Factor (Biocare, 1:300). Images were acquired on an Olympus BX61 
microscope with Hamamatsu ORCA R2 monochrome camera using the Microsuite Biological 
Suite software. Images were processed equally for signal intensity and color merge using ImageJ 
(Abramoff et al., 2004). Penis sections were prepared and incubated with anti-FLuc antibody as 
described above with an additional blocking step of 3% H2O2 in methanol for 30 min to block 
endogenous peroxidase activity immediately following antigen retrieval. Tissue sections were 
washed in PBS and incubated with secondary antibody anti-rabbit HRP (no dilution) (DAKO) at 
room temperature for 1 h. Slides were washed in PBS, incubated in freshly made DAB substrate 
(Invitrogen) for 5 min, rinsed in distilled water followed by PBS and counterstained with 
hematoxylin (Invitrogen). Images were acquired with an Olympus BX51 microscope with 
Olympus DP71 color camera using the Olympus Controller software. 
 
Bioluminescence imaging of mice and organs. Reporter mice were implanted with micro-
osmotic pumps (Alzet 1007D; 0.5 µL/h for 7 days) containing 100 µL of 50 mg/mL D-luciferin 
(Biosynth) as described previously (Gross et al., 2007). Pumps were implanted at least 16 h 
before the start of the experiment to allow for equilibration of D-luciferin and mouse recovery. 
For irradiation experiments, mice were placed in a chamber, transported to a 137Cs source 
irradiator and exposed to the indicated dose of IR or remained outside the irradiator chamber 
(mock group). Imaging was preformed using an IVIS Lumina (Caliper) and mice were 
anesthetized with 1.5% isoflurane through a O2 flow modulator. Mice were anesthetized for 10 
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min in a holding tank, equilibrated in the IVIS for 15 min and then the image was acquired (60 
sec, binning 4). Photon flux was measured at baseline by drawing a rectangular region of interest 
(ROI) from the forepaws to slightly above the genitals for each mouse. The ROI was duplicated 
each time the mouse was imaged. The genitals and bladder were eliminated from the ROI 
because of the large variation in signal generated from this region of the mouse by excretion of 
D-luciferin. Data were expressed as total photon flux (photons/sec) or as fold-initial, expressed 
as post-treatment/pre-treatment images. For ex vivo experiments, a pre-dissection image was 
taken as described above. Mice were then sacrificed and organs were rapidly removed, weighed, 
placed in individual wells of a 24-well black wall plate and imaged within 25 min of sacrifice 
(30 sec exposure; binning 4). Corresponding grayscale photographs and color luciferase images 
were superimposed and analyzed with LivingImage 3.2 (Caliper) and Igor (Wavemetrics) image 
analysis software.  
 
Low light microscopy. Male and female p21+/FLuc mice were sacrificed and organs isolated 
(small intestine, liver, penis or vagina). Organs were placed in ice cold Hanks Buffered Saline 
Solution (HBSS, pH 7.4) (Sigma Chemical Co.). Livers were sectioned into 200 µm sections on 
a vibratome (immersed in HBSS maintained at 4°C) and the small intestine and vagina were cut 
into 200 µm sections using a tissue chopper. Penises were cut longitudinally to create a flat 
surface and then sections were cut using two attached razor blades with a 300 µm spacer 
between them. Organ sections were placed on an organotypic Millicell culture insert (Millipore) 
in a 35 mm Petri dish containing HEPES-buffered DMEM supplemented with B27 (Invitrogen), 
0.1 mM D-luciferin (BioThema) and 100 U/mL penicillin, 100 U/mL streptomycin (Gibco). 
Small intestines were incubated in crypt culture media composed of Advanced DMEM/F12 
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(Gibco), 50 ng/ml EGF (Peprotech Inc.), 100 ng/ml Noggin (Peprotech Inc.), 500 ng/ml R-
Spondin (R&D Systems) containing 10 µM D-luciferin (BioThema) (Sato et al., 2009). All 
images were completed within 3 h of organ isolation. Penises and vaginas were incubated in 1 
nM SYTO® 11 green fluorescent nucleic acid stain (Invitrogen). To orient vaginal tissue, the 
lumen was stained with SYPRO Ruby (Invitrogen), a protein-binding fluorescent dye. All 
images were obtained with a Versarray back-thinned illuminated CCD camera (Princeton 
Instruments) or an iXon DU-897E EM CCD camera (Andor Technology). Cameras were 
coupled to TE-2000 Nikon inverted microscopes equipped with custom light tight environmental 
chambers (InVivo Scientific) that prevented light leaks and kept a constant temperature of 37°C. 
Image acquisition was controlled with Winview32 and Micro-Manager (www.Micro-
Manager.org) software packages. Image processing was performed with ImageJ software 
(Abramoff et al., 2004) and included subtraction of a background image, removal of random 
bright spots (using despeckle filtering algorirthm, ImageJ) and adjusting the brightness and 
contrast equally across the entire image. Intensity scale ramps were scaled and normalized to the 
time over which the image was acquired and are represented as RLU/minute. Pseudocolored 
images were generated using the RainbowRGB look-up table (LUT) on the bioluminescence 
image that was then merged to the brightfield image. 
 
Isolation and culturing of primary hepatocytes from reporter mice. Primary hepatocytes 
were isolated from p21+/FLuc mice by hepatic portal collagenase perfusion as described 
previously (Klaunig et al., 1981a; Klaunig et al., 1981b). Briefly, the liver was perfused with 
collagenase (Sigma Chemical Co.), the liver sheath was disrupted and cells were passed through 
a 70 µm filter. Cells were washed twice with DMEM and double nucleated hepatocytes were 
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pelleted at 65 x g, and plated in collagen-1 coated 6-well plates (BD Biosciences) in DMEM 
(Invitrogen) supplemented with 10% fetal bovine serum (non-heat inactivated), 100 U/mL 
penicillin, 100 U/mL streptomycin (Gibco). The next day, the media was changed to hepatocyte 
imaging media (same as above except phenol-red free DMEM (Gibco) and 0.5 mM D-luciferin 
(Biosynth)). Cells were allowed to equilibrate for 1 h and bioluminescence was measured using 
the IVIS Lumina (Caliper) as described for MEFs. 
 
Laser capture microdissection. Tissues were dissected from p21+/+ or p21FLuc/FLuc mice, 
immediately frozen in optimal cutting temperature (OCT, TissueTek) compound, and stored at -
80°C. 15-20 µm sections were cut on a cryostat and sections were placed on PEN membrane 
slides (Leica). Unstained slides were stored in a desiccator at -80°C. Tissues were fixed in 70% 
ethanol (20 sec) and rehydrated in RNAse-free water (10 times). Nuclei were stained with 
methyl green (10 times) (Vector), rinsed in RNAse-free water, counterstained with EosinY (2 
times), and dehydrated in ethanol (70%, 95%, 95%, 100% and 100%) for 1 min each. Slides 
were rinsed in xylene and dried in a dessicator for at least 5 min immediately prior to laser 
capture microdissection. Tissue sections were dissected using the Leica LMD7000 laser capture 
microdissection system.  
 
Statistics. All statistics were performed using Graphpad Prism software or SPSS software. 
Specific statistical tests performed are noted with the data. All error bars are SEM. 
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Figures 
 
Fig. 2.1 Generation of p21-FLuc reporter mice.  
(A) Structure of the targeting vector, wild-type p21 genomic allele (+), and recombinant allele 
before (r) and after (FLuc) Cre-mediated excision. The coding region of the mouse p21 gene was 
disrupted by insertion of codon-optimized firefly luciferase cDNA (FLuc) containing SV40 
poly(A) sequences and a neomycin phosphotransferase cDNA cassette (Neo) driven by the 
phosphoglycerine kinase promoter as a selectable marker. Upon homologous recombination, the 
FLuc cDNA utilizes the ATG start codon of endogenous p21 in exon 2. The orientation of 
neomycin cassette coding sequences was opposite to that of FLuc. Exons are represented by 
black boxes; Eco RV sites are denoted by RV; loxP sites by blue triangles; the 5’ Southern probe 
by a gray box; 3’ PCR primers by red arrows and genotyping primers by black arrows and lower 
case letters. Sizes of expected Southern and PCR products are indicated. (B) Genomic DNA 
from ES cell clone #70 was digested with Eco RV. Southern blotting was performed using the 5’ 
probe represented by the gray box in Fig. 1A. The wild-type allele (+) gives rise to a 5.9 kb 
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digestion product and the recombined allele (r) gives rise to a 9.6 kb digestion product. (C) 
Genomic DNA from ES cell clone #70-58 was digested with Eco RV. Southern blotting was 
performed using the 5’ probe represented by the gray box in Fig. 1A. The wild-type allele (+) 
gives rise to a 5.9 kb digestion product, the recombined allele (r) with the Neo cassette still 
present gives rise to a 9.6 kb digestion product and the recombined allele with the Neo cassette 
removed gives rise to a 7.7 kb product. Size markers are indicated on the left and product sizes 
on the right. (D) Genomic DNA isolated from either a BAC clone containing p21, tail DNA from 
a wild type mouse (WT) or two ES cell clones, was amplified using PCR primers represented by 
red arrows in Fig. 1A. The wild-type allele (+) gives rise to a 1.9 kb product and the recombined 
allele (-) gives rise to a 5.6 kb product. (E) Genomic DNA isolated from ES cell clone #70 (+/r) 
and #70-58 (+/FLuc) was amplified using PCR primers represented by red arrows in Fig. 1A. 
The wild-type allele (+) gives rise to a 1.9 kb product and the recombined allele (-) with the Neo 
cassette still present gives rise to a 5.6 kb product and the recombined allele with the Neo 
cassette removed gives rise to a 3.8 kb product. Size markers are indicated on the left and 
product sizes on the right. (F) PCR analysis of tail DNA from wild type (WT, +/+), 
heterozygous (HT, +/FLuc) or homozygous (KI, FLuc/FLuc) knock-in mice amplified with 
primers indicated by black arrows (a, b, c). The WT (+) allele produced a 453-bp product with 
primers a and b and the recombinant (FLuc) allele produced a 208-bp product from primers a and 
c. (G) WT, HT or KI mice were shaved and implanted with D-luciferin micro-osmotic pumps 
and imaged using the IVIS Lumina system (Caliper). Representative images of mice at baseline 
are shown. Photon flux is indicated by pseudocolored heatmap. 
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Fig. 2.2 p21 promoter activity in reporter MEFs.  
MEFs of the indicated genotypes were plated at equal densities in quadruplicate and 
bioluminescence activity was acquired. Representative wells are depicted by a pseudocolored 
heatmap in (A) and photon flux is plotted in (B). Relative levels of p21 and FLuc mRNAs were 
determined by qRT-PCR in MEF lines and values were normalized to 18S rRNA (C). Western 
blotting was performed to determine relative levels of p21 and FLuc in each MEF line and actin 
was used as a loading control (D).  
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Fig. 2.3 p21 expression in wild-type and Tpr53 null mice.  
p21+/FLucTrp53+/+ (n = 14) and p21+/FLucTrp53-/- (n = 9) mice were implanted with D-luciferin 
micro-osmotic pumps and whole body images were obtained. Compiled results are plotted in (A) 
and representative mice are show in (B). Mice were sacrificed and individual organs were 
isolated, weighed and then imaged ex vivo (C). Bioluminescence of each organ is represented as 
photon flux/sample weight (photons/sec/gram). Individual mice (squares/circles) and the group 
average (bar) are shown. The Mann-Whitney U Test p-values are included in the top of each 
column.  
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Fig. 2.4 IR activates the p21 promoter in a p53-dependent manner in vitro.  
All experiments were from p21+/FLuc MEFs with the indicated p53 status. MEFs were plated at 
equal densities and bioluminescence was measured at baseline (t = 0) and at 4 and 12 h following 
mock irradiation or exposure to 2.5 Gy IR. Representative images of MEFs obtained 12 h after 
IR are shown in (A). Absolute photon flux values at baseline are shown graphically in panel B (* 
p=0.015, two tailed t-test). To plot the response to IR, data were normalized to the baseline value 
for each replicate and then to the mock irradiated sample (E; p<0.001 by 2-way ANOVA 
comparing Trp53+/+ MEFs to Trp53-/- MEFs and *** is p<0.001 by Bonferoni post-test of 2-way 
ANOVA). Additionally, MEFs were mock irradiated or exposed to 2.5 Gy IR and 12 h later 
mRNA was isolated. Levels of p21 and FLuc mRNA 12 h post-IR relative to a standard curve 
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and 18S rRNA (C) as well as normalized to mock-irradiated samples within each genotype (F). 
MEFs were mock irradiated or exposed to 5 Gy IR, harvested 4 h later and Western blotting was 
performed for the indicated proteins (D). Different exposures using the Odyssey imaging system 
are shown. A higher intensity (I) is equivalent to a longer exposure time. For experiments 
involving BLI and relative mRNA determinations, 3 separate MEF lines were used per genotype 
and each line was plated in at least triplicate per treatment.  
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Fig. 2.5 Regulation of p21 expression during cell cycle re-entry from quiescence. 
The overall experimental strategy for panels B-H is illustrated in panel A. Cells were plated at 
subconfluency and the following day incubated in media containing 0.1% FBS for 47.5 h. Cells 
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were then cultured in media (0.1% FBS) in the absence or presence of DMSO for 30 min, 
followed by culturing in media containing 10% FBS in the presence or absence or DMSO. BLI 
was performed at the indicated time points (B). Photon flux measured at each time point was 
normalized to photon flux measured prior to serum starvation. A Bonferonni post-test of a 2-way 
ANOVA showed significance between Trp53+/+ and Trp53-/- response. Differences were not 
observed between DMSO and untreated cells within a given genotype (*** indicates p<0.001). 
Cells were plated at subconfluency and the following day incubated in media containing 0.1% 
FBS for 47.5 h. Cells were then cultured in media (0.1% FBS) containing DMSO or the 
indicated concentrations of U0126 for 30 min, followed by culturing in media containing 10% 
FBS together with either DMSO or U0126. BLI (C-F) and Western blotting (G, H) were 
performed at the indicated times. Photon flux was normalized to baseline values obtained from 
cells cultured in 0.1% FBS for 48 h (panels C, D) followed by normalization to DMSO treated 
samples (panels D, F). The inset in panel D is a dose-response curve generated from the data 
shown in panel D for the 4 h time points. The inset in panel E is the same data shown in E but 
expanded on a different scale. Asterisks in panels C to F represent significance as tested by 
Bonferonni post-test comparing U0126 doses to DMSO from a 2-way ANOVA (*** is p<0.001, 
* is p<0.05, ns is non-significant). Cells were harvested at the 4 h time point for Western blotting 
(G, H). Film exposure times in panel G were 15 s (p21 short exposure); 5 min (p21 long 
exposure), 30 min (tubulin) and in panel H were 5 s (pERK), 30 sec (ERK) and 30 s (tubulin). 
Relative p21 expression shown in panel G was first normalized to tubulin, followed by 
normalization to indicated control sample. 
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Fig. 2.6 p53 inhibits activation of p21 promoter during cell cycle re-entry from quiescence. 
(A) MEFs infected with recombinant lentiviruses encoding either control or p53-specific shRNA 
were lysed and analyzed by Western blotting. The displayed data are representative of 3 
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independent experiments performed in three different MEF lines. (B-D) MEFs expressing 
control or p53-specific shRNAs were plated and treated as illustrated in Fig. 5A. Representative 
Western blots are shown in panel B and compiled data from three separate experiments are 
shown graphically in panel C. Exposure times in panel B were 2 min (tubulin, p21 (Trp53-/- 
samples)) and 10 sec (p21 (Trp53+/+ samples)). BLI was performed at indicated time points. 
Photon flux was normalized to baseline values obtained from cells cultured in 0.1% FBS for 48 h 
followed by normalization to DMSO treated samples (D). Asterisks in panel D represent 
significance as tested by Bonferonni posttest comparing U0126 doses to DMSO from a 2-way 
ANOVA (*** is p<0.001, ns is non-significant). (E) Model based in data shown in Fig. 5 and 6. 
t.f. (transcription factor). 
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Fig. 2.7 Reporter expression in individual mouse organs.  
p21+/FLuc mice were implanted with D-luciferin micro-osmotic pumps for 1 to 3 days. Mice were 
sacrificed and organs were imaged ex vivo. To account for variation in organ size from mouse to 
mouse, organ weight was determined prior to BLI. Bioluminescence of each organ is represented 
as photon flux / sample weight (photons/sec/gram) in panel A. The graph is plotted using a 
logarithmic scale and the dotted line represents background signal detected in organs of WT 
mice. Relative levels of p21 and FLuc mRNA were determined by qRT-PCR in indicated organs 
of p21+/FLuc mice (n=3 mice) and values were normalized to 18S rRNA (B), followed by 
normalization to p21 mRNA (C). Asterisks note where RNA isolated was not of a high enough 
quality for analysis. 
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Fig. 2.8 Bioluminescence in individual organs of reporter and control mice.  
p21+/FLuc and p21+/+ mice were implanted with D-luciferin micro-osmotic pumps. Organs were 
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dissected and bioluminescence acquired within 25 min of sacrifice. Organs from the same female 
reporter mouse (p21+/FLuc) are shown in panel A and the penis from a male p21+/FLuc reporter 
mouse is also shown in this panel. Organs isolated from a male wild-type control mouse (p21+/+) 
are shown in panel B. Organ bioluminescence is represented as a pseudocolored heatmap 
superimposed on the organ in the upper panel and the same photograph of the organ is provided 
in the lower panel. Scale bar for the heatmap is provided in each panel. 
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Fig. 2.9 IR activates p21 promoter in a p53-dependent in vivo.  
p21+/FLucTrp53+/+ and p21+/FLucTrp53-/- mice were imaged (time = 0) and then either mock-
irradiated or exposed to 2.5 Gy IR. Whole body bioluminescence was acquired at the indicated 
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times post-treatment. Representative mice are shown in (A) and bioluminescence relative to 
value at time 0 is displayed graphically in panel B. * is p<0.05 and ** is p<0.01 by Bonferroni 
post-tests of a 2-way ANOVA. (C,D) p21+/FLucTrp53+/+ mice were either mock-irradiated or 
exposed to 2.5 Gy IR, organs were harvested 8 h later and immediately imaged. To account for 
variation in organ size from mouse to mouse, organ weight was determined prior to BLI. 
Normalized photon flux of each organ is represented as photon flux / sample weight 
(photons/sec/gram). Individual mice (squares/circles) and the group average (bar) are shown. 
The Mann-Whitney U test p-value is included in each column. 
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Fig. 2.10 Bioluminescence microscopy reveals p21 promoter activity within organs.  
Tissue sections of small intestine (A), liver (B), penis (C, D) and vagina (E) isolated from 
p21+/FLuc mice were incubated with D-luciferin containing media and BLI was performed. 
Column 1 is the bright-field image, column 2 is the bioluminescent image, and column 3 is the 
pseudocolor overlay of bioluminescence on bright field. In some cases, tissue autofluorescence 
(Autofluor) was photographed and tissues were stained with SYPRO Ruby protein stain and/or 
with SYTO® 11 green fluorescent nucleic acid stain. Pseudocolor overlays of fluorescence and 
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bioluminescence are depicted. Scale bars are 200 µm (for 10X magnifications) and 50 µm (40X 
magnifications).  
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Fig. 2.11 Localization of FLuc protein in vagina and penis.  
Tissue sections of vaginas (A) and penises (B) isolated from p21FLuc/FLuc and p21+/+ mice 
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were stained with antibodies specific for FLuc (red, panel A; brown, panel B) and counterstained 
with DAPI for nuclei (blue, panel A) or hematoxylin in panel B. Representative images in panel 
A are shown at 10X and 40X magnification and in panel B at 100X magnification. Arrows are 
included in B to mark the epithelial cells. Scale bar: 100 mm.  
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Fig. 2.12 Localization of p21 mRNA in epithelial cells of vagina and penis.  
Epithelial cells from vaginas and penises isolated from p21+/+ (n=3 for each sex) and p21FLuc/FLuc 
(n=2 for each sex) mice were isolated using laser capture microdissection, mRNA was isolated, 
and relative levels of p21 mRNA was determined by normalizing to Actin mRNA and p21+/+ 
samples. Individual mice (circles/squares) and the group average (bar) are shown. Each sample 
was tested in triplicate and SEM error is shown. 
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Table 2.1 Pearson coefficients for baseline bioluminescence, mRNA and protein within p21+/+, 
p21+/FLuc and p21FLuc/FLuc MEFs   
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Abstract 
Reporter mice that enable the activity of the endogenous p21 promoter to be dynamically 
monitored in real time in vivo and under a variety of experimental conditions revealed ubiquitous 
p21 expression in mouse organs including the brain (Tinkum et al., 2011). Low light 
bioluminescence microscopy was employed to localize p21 expression to specific regions of the 
brain. Interestingly, p21 expression was observed in the paraventricular, arcuate and dorsomedial 
nuclei of the hypothalamus, regions that detect nutrient levels in the blood stream and signal 
metabolic actions throughout the body. These results suggested a link between p21 expression 
and metabolic regulation. We found that short-term food deprivation (fasting) potently induced 
p21 expression in tissues involved in metabolic regulation including liver, pancreas and 
hypothalamic nuclei. Conditional reporter mice were generated that enabled hepatocyte-specific 
expression of p21 to be monitored in vivo. Bioluminescence imaging demonstrated that fasting 
induced a seven-fold increase in p21 expression in livers of reporter mice and Western blotting 
demonstrated an increase in protein levels as well. The ability of fasting to induce p21 expression 
was found to be independent of p53 but dependent on FOXO1. Finally, occupancy of the 
endogenous p21 promoter by FOXO1 was observed in the livers of fasted but not fed mice. Thus, 
fasting promotes loading of FOXO1 onto the p21 promoter to induce p21 expression in 
hepatocytes.  
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Introduction 
The p21Waf1/CIP1 protein (hereafter called p21) is a cyclin-dependent protein kinase (CDK) 
inhibitor that binds to cyclin-CDK complexes, as well as free CDKs, to inhibit cell cycle 
progression. Inhibition of cell cycle progression by p21 occurs during cell differentiation and in 
response to DNA damage and oxidative stress (Abbas and Dutta, 2009). Paradoxically, low 
levels of p21 positively regulate cell cycle progression by aiding in the assembly of stable 
CDK4-Cyclin D complexes. p21 also binds to and inhibits pro-apoptotic factors and binds to 
PCNA to regulate DNA replication and repair. Several signaling pathways impact the regulation 
of p21 at the level of transcriptional activation, mRNA elongation, and protein stability.  
Transcriptional regulation of the gene encoding p21, Cdkn1a (hereafter called p21), is 
controlled through many signaling pathways. The tumor suppressor protein p53 was one of the 
first transcription factors found to activate p21 transcription, particularly when cells are exposed 
to various forms of stress. While many upstream signals activate p21 through p53, there are a 
growing number of p53-independent mediators of p21 transcription. A subset of these p53-
independent mechanisms includes Ras signaling through E2F1, nuclear receptors such as 
progesterone acting through their cognate response elements, and TGFβ through a complex 
containing SMAD3/4 and FOXO (Seoane et al., 2004).  
To monitor upstream signaling pathways that specifically regulate p21 promoter activity, we 
previously generated and characterized reporter mice that enable noninvasive and repetitive 
imaging of p21 promoter activity in vivo using molecular imaging strategies (Tinkum et al., 
2011). p21 was ubiquitously expressed in reporter mice including in cells and organs that are 
relatively quiescent with respect to proliferation, such as hepatocytes and brain. 
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In this study, low light bioluminescent imaging was employed to localize p21 expression to 
specific regions of the brain. Interestingly, bioluminescence was detected in the hypothalamus 
and in particular hypothalamic nuclei involved in metabolic regulation. This prompted us to 
examine p21 expression under conditions of short-term starvation (fasting). We report that p21 
expression is robustly activated in several tissues in response to the metabolic stress induced by 
fasting, including metabolic organs. Furthermore, we demonstrate that this stress response is 
independent of p53. Instead, FOXO1 was demonstrated to bind to the p21 promoter in the fasted, 
but not fed state, and to be necessary for activation of p21 expression during fasting.  
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Results 
p21 promoter is active in a subset of hypothalamic nuclei.  
We previously reported the generation and characterization of knock-in reporter mice that 
enable endogenous Cdkn1a (hereafter, p21) promoter activity to be monitored dynamically using 
bioluminescence imaging (BLI) (Tinkum et al., 2011). p21+/FLuc reporter mice express firefly 
luciferase (FLuc) cDNA under control of the endogenous p21 promoter. We detected p21 
promoter activity in most organs of the mouse, including the brain. To localize p21 promoter 
activity within specific regions of the brain, live brain slices were imaged ex vivo using low light 
microscopy (Marpegan et al., 2011). Brains were isolated from p21+/FLuc mice, placed in buffers 
to maintain viability, immediately sectioned, then bathed in media containing D-luciferin. p21 
promoter activity was localized to several hypothalamic nuclei, including the paraventricular, 
arcuate, periventricular, and dorsomedial nuclei (Fig. 3.1). These regions of the hypothalamus 
are involved in modulating stress, hunger, and whole body metabolic homeostasis.  
 
Fasting activates p21 promoter in mice.  
Given that p21 was specifically expressed in regions of the hypothalamus involved in 
metabolic regulation, we asked if fasting modulated p21 expression. p21+/FLuc littermates were 
allowed to feed ad libitum or were fasted for 48 h. Mice were subjected to whole-body BLI at 
baseline and after 24 and 48 h of fasting. As seen in Fig. 3.2 (panels A and B), p21 promoter 
activity in mice fasted for 24 h was 8-fold higher than that in fed littermates and rose to 13-fold 
higher in mice fasted for 48 h. As seen in Fig. 3.2 (panels C and D), fasting induced p21 
expression in several mouse organs and differences between fed and fasted states reached 
statistical significance in liver, pancreas, brain, lung, salivary gland, heart, kidney, and bladder. 
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To determine if increased p21 promoter activity led to a corresponding increase in endogenous 
p21 protein, lysates were prepared from livers of fed and fasted p21+/FLuc mice, and p21 was 
analyzed by Western blotting. As seen in Fig. 3.2E, endogenous p21 protein was higher in livers 
of fasted mice compared with livers of fed littermates. Thus, fasting induced p21 expression and 
led to an increase in p21 protein in liver. 
To obtain a more uniform genetic background for metabolic studies, p21+/FLuc reporter 
mice (of the mixed background 129/SvJ and C57BL/6J) were backcrossed to Albino-B6 
(B6(Cg)-Tyrc-2J/J) mice for at least 3 generations. Albino-B6 mice are derivatives of C57BL/6J 
mice that carry a mutant Tyrosinase gene resulting in a white coat color, enabling enhanced 
sensitivity for detecting bioluminescence in vivo. Inbred progeny obtained after 3 rounds of 
backcrossing died if they were fasted for 48 h, so all subsequent fasting experiments performed 
in this study were performed for 24 h.  
 
Fasting activates the p21 promoter in specific hypothalamic nuclei. 
We next asked if fasting increased p21 expression in the paraventricular, arcuate, 
periventricular and dorsomedial nuclei of the hypothalamus. Brains were isolated from mice that 
had been allowed to feed ad libitum or that had been fasted for 24 h. Brains were subjected to 
coronal sectioning in buffers that maintained tissue viability. Brain sections through the 
hypothalamus at Bregma -0.58, -1.82, and -1.94 were bathed in media containing D-luciferin and 
bioluminescence was detected using low-light imaging (LLI) microscopy. Within each section, 
photon output was quantified from the known location of the target region and normalized to a 
non-target region to control for background (Figs. 3.3A, 3.3B). Fasting resulted in a trend 
towards increased bioluminescence within each nucleus, although differences between fed and 
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fasted states did not reach significance. To test the p21 response in an independent assay, we 
performed laser-capture microdissection followed by real-time, quantitative PCR (Fig. 3.3C). 
Results confirmed that endogenous p21 mRNA increased in the paraventricular nucleus, arcuate 
nucleus and dorsomedial hypothalamus in fasted mice compared to fed littermates. Due to 
technical limitations, we were unable to measure p21 mRNA levels in periventricular nuclei. 
Together, these data demonstrate that fasting increases p21 expression in the metabolic 
regulatory regions of the hypothalamus. 
 
Generation of conditional mice that report liver-specific p21 expression.  
To monitor tissue-specific and temporal regulation of p21 expression in individual mouse 
tissues, knock-in mice that conditionally express click beetle (Pyrophorus plagiophthalamus) red 
luciferase (CBRLuc) under the control of the endogenous p21 promoter were generated (Fig. 
3.4A). Successful homologous recombination of the conditional p21-CBRLuc targeting vector in 
ES cell clones was confirmed by Southern blotting (Fig. 3.4B and 3.4C). PCR analysis of tail 
DNA confirmed the expected recombination within the p21 locus (Fig. 3.4D). In order to 
examine p21 promoter activity specifically within hepatocytes, conditional floxed stop p21-
CBRLuc (p21f/+) reporter mice were crossed with transgenic mice expressing Cre under the 
control of the albumin promoter (hereafter, Alb-Cre+) (Postic and Magnuson, 2000) to generate 
Alb-Cre+; p21f/+ mice (hereafter p21Liv-Luc/+). Liver-specific expression was chosen because of 
the primary role that the liver plays in regulating systemic metabolism. PCR analysis of liver 
DNA demonstrated Cre-mediated recombination of the p21 allele (Fig. 2.4E). Importantly, 
bioluminescence was detected in the abdominal region of p21Liv-Luc/+ mice but not in littermates 
lacking the Albumin-Cre allele (hereafter, p21f/+) (Fig. 3.4F) and ex vivo BLI confirmed that 
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bioluminescence was restricted to the liver (Fig. 3.4F). p21Liv-Luc/+ mice were backcrossed for 3 
generations to Albino-B6 mice to generate mice with light coat color. p21Liv-Luc/+ mice were 
fasted to monitor liver-specific dynamics of p21 promoter activity in real-time. Baseline images 
of p21Liv-Luc/+ mice were obtained, and then mice were randomly assigned to fed or fasted groups. 
As seen in Fig. 3.5, a 7-fold increase in p21 expression was observed in the livers of mice that 
had been fasted for 24 h.  
 
Activation of p21 promoter is a cellular response to metabolic stress. 
Next, experiments were carried out to determine if activation of the p21 promoter was a 
cellular response to metabolic stress or if p21 plays a role in maintaining metabolic homeostasis. 
Several parameters were measured in male mice that were either wild type (WT) or null (KO) for 
p21. Significant differences in steady-state body weight were not detected between p21 WT and 
p21 KO mice (p=0.06), although p21 KO males trended towards weighing less than p21 WT 
littermates (Fig. 3.6A). Plasma collected from male mice that had been fasted for 24 h was 
assayed for levels of glucose, free fatty acids, triglycerides and cholesterol. Mice were fasted for 
24 h in these experiments, rather than the more commonly chosen times of 4 to 16 h in metabolic 
studies to allow for significant activation of p21 expression. Significant differences were not 
detected in the levels of any of these metabolites between p21 WT and p21 KO mice in either the 
fed or fasted states (Fig. 3.6B-E). Livers isolated from male littermates that had been fed or 
fasted for 24 h were homogenized, glycogen was hydrolyzed to glucose, and glucose levels were 
used to calculate glycogen levels. As seen in Fig. 3.6F, glycogen levels were similar in p21 WT 
and p21 KO mice in both the fed and fasted states. Thus, loss of p21 did not impact the ability of 
glucose to be stored as glycogen in the livers of fed or fasted mice. 
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Activation of p21 promoter by fasting is p53-independent. 
Given that p53 regulates p21 expression in response to a variety of stress stimuli, we 
asked if p53 regulated p21 promoter activity in response to fasting. p21+/FLuc mice were crossed 
to Trp53-/- mice, and progeny were intercrossed to obtain reporter mice that were either wild-type 
for Trp53 (p21+/FLucTrp53+/+) or null for Trp53 (p21+/FLucTrp53-/-), hereafter referred to as p53 
WT or p53 KO, respectively. Mice were imaged to obtain baseline bioluminescence and then 
randomly assigned to fed or fasted groups. As seen in Fig. 3.7 (panels A and B), whole body 
bioluminescence demonstrated that p53 loss had no effect on the induction of p21 expression in 
fasted mice. In addition, BLI of individual organs revealed that p53 loss did not impact the 
effects of fasting on p21 promoter activity in liver, pancreas, brain, small intestine, large intestine 
or skeletal muscle (Fig. 3.7C). Thus, p53 was not required for enhanced p21 expression during 
fasting.  
 
FOXO1 contributes to activation of p21 promoter during fasting.  
Lowered IGF-1 levels during fasting increases the transcriptional activity of FOXO 
(Biggs et al., 1999; Brunet et al., 1999; Jacobs et al., 2003; Kops et al., 1999) and the 
FOXO/Smad3/4 complex has been shown to activate the p21 promoter in response to TGF-β 
signaling (Seoane et al., 2004). Therefore, we asked if FOXO regulated p21 promoter activity in 
response to fasting. p21Liv-Luc mice were infected with recombinant adenoviruses expressing 
wild-type FOXO1 or a dominant negative form of FOXO3 (FOXO3NT) that encodes the DNA 
binding domain but not the transactivation domain of FOXO3 (Nakae et al., 2000; Seoane et al., 
2004). Analysis of mice that can be conditionally deleted for each family member either alone or 
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in combination in the liver suggests functional redundancy between FOXO 1, 3 and 4. For 
example, hepatic glucose production in mice conditionally deleted for all three family members 
in the liver is more severely impaired than in mice with liver-specific deletion of FOXO1 
(Haeusler et al., 2010). Given that the DNA binding domains of FOXO1 and FOXO3 exhibit 
88% homology, FOXO3NT was expressed with the intent to generally block FOXO activity in 
the liver. Reporter mice were subjected to whole-body BLI at baseline and every 3 days after 
adenoviral infection. No difference was detected in basal p21 promoter activity between 
FOXO1WT- and FOXO3NT-expressing mice during this time. On Day 9 post infection, mice 
were subjected to BLI at baseline and again after 24 h of fasting. As seen in Fig. 3.8A, the ability 
of fasting to induce p21 expression was attenuated in the livers of mice expressing FOXO3NT 
relative to FOXO1WT. 
Next, we asked if FOXO1 regulated p21 promoter activity in response to fasting. Foxo1f/f 
mice with targeted insertion of loxp sites in the endogenous Foxo1 locus on a C56BL/6J 
background (Paik et al., 2007) were backcrossed to Albino-B6 mice until they acquired a white 
coat. These mice were then crossed to p21Liv-Luc mice that express Cre recombinase from the 
albumin promoter. Progeny were intercrossed to obtain reporter mice that were either wild-type 
for FOXO1 (p21Liv-Luc Foxo1w/w) or reporter mice that could be made null for FOXO1 in 
hepatocytes after Cre-mediated excision (p21Liv-Luc Foxo1f/f). These mice enable real-time 
monitoring of p21 expression in hepatocytes that were WT or null for FOXO1. Mice of each 
genotype were imaged at 4 to 6 weeks of age to obtain baseline bioluminescence and then 
randomly assigned to fed or fasted groups. As seen in Fig. 3.8B, the ability of fasting to induce 
p21 expression was attenuated in FOXO1-deficient hepatocytes.  
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Given that the p21 promoter has binding sites for FOXO1 (Seoane et al., 2004), we asked 
if FOXO1 bound to the p21 promoter during fasting. Hepatocytes were isolated from wild-type 
mice that had been fed or fasted and analyzed for FOXO1 occupancy on the p21 promoter by 
ChIP. FOXO1 was detected at the forkhead-binding region of the p21 promoter in the fasted, but 
not fed state. Additional controls demonstrated that FOXO1 was not bound to a region of DNA 
1kb distal (upstream) of the forkhead-binding region on the p21 promoter and that no binding to 
the p21 promoter was detected when control IgG antibody was used (Fig. 3.8C). 
  
 72 
Discussion 
Two types of reporter mice were used in this study to monitor endogenous p21 
expression, one that enables p21 expression to be visualized throughout the whole mouse and the 
other that enables specific tissues of the mouse to be interrogated. In the first model, firefly 
luciferase was expressed whenever the endogenous p21 promoter was active. Using these mice, 
we previously demonstrated that expression of firefly luciferase accurately reports endogenous 
p21 expression, enabling the activity of the endogenous p21 promoter to be dynamically 
monitored in real time in vivo and under a variety of experimental conditions (Tinkum et al., 
2011). In the second model, conditional knock-in mice were generated such that click beetle red 
luciferase is expressed in a tissue-specific manner whenever the endogenous p21 promoter is 
active. We chose to monitor p21 expression in hepatocytes using this model.  
Using the first mouse model, we demonstrated that fasting potently induces p21 
expression in several mouse tissues. Intriguingly, fasting induced significant increases in p21 
expression in post-mitotic cells of the brain and liver. Enhanced p21 expression following fasting 
was also measured in other relatively quiescent organs including pancreas, lung, salivary gland, 
heart and kidney. In the case of the brain, p21 expression was increased in the dorsomedial, 
paraventricular and arcuate nuclei of the hypothalamus. These regions detect nutrient levels in 
the blood stream and signal metabolic actions throughout the body (Yeo and Heisler, 2012). 
Neurons within arcuate nuclei are activated by modulation in blood glucose, fatty acids and 
insulin. The POMC/CART and NPY/AGRP neurons of the arcuate communicate the metabolic 
status of the mouse to the paraventricular and dosromedial nuclei. The paraventricular nucleus 
integrates signals from the arcuate, as well as other inputs, and signals to the hypothalamic 
pituitary axis. The paraventricular nucleus also releases corticotropin-releasing hormone (CRH), 
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a peptide hormone and neurotransmitter involved in stress responses. Finally, the dorsomedial 
nucleus regulates thermogenesis, energy expenditure, autonomic stress and neuroendocrine stress.  
Microarray studies conducted in mice that were fasting or put on a caloric restricted diet 
noted enhanced p21 expression in skeletal muscle and liver (Ebert et al., 2010; Estep et al., 2009). 
Ebert et al. (2010) demonstrated that p21 expression was induced upon ectopic overexpression of 
ATF4 in skeletal muscle. However, a demonstration that ATF4 was directly responsible for this 
effect was not provided. 
p53 responds to numerous extrinsic and intrinsic stresses, including DNA damage, 
oncogene activation, hypoxia, and lack of nutrient availability to promote a variety of responses 
(Maddocks and Vousden, 2011). Therefore, it was somewhat surprising to find that the ability of 
short-term starvation to activate p21 expression was normal in p53-deficient mice. This result led 
us to investigate other transcription factors that might be responsible for inducing p21 expression 
under conditions of fasting. 
The forkhead box O (FOXO) family of transcription factors become activated under 
conditions of nutrient stress and FOXO1, 3 and 4 have overlapping and distinct roles in 
regulating gluconeogenesis, lipogenesis, food intake, autophagy and cell cycle arrest 
(Eijkelenboom and Burgering, 2013; Zhang et al., 2012). Furthermore, FOXO1/3/4 have been 
shown to transcribe p21 mRNA in response to TGF-b signaling (Seoane et al., 2004). Therefore, 
we tested if expression of dominant negative FOXO3 in the liver would impair the induction of 
p21 expression during fasting. Expression of dominant negative FOXO3 was found to impair the 
ability of fasting to induce p21 expression in the livers of infected mice. Next, we generated p21 
reporter mice where Foxo1 could be conditionally deleted in hepatocytes. This was 
accomplished by breeding our conditional p21 reporter mice with transgenic mice that drive Cre 
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expression from the albumin promoter. In this way Cre recombinase removes the lox-stop-lox 
codon immediately preceding the CBRLuc cDNA in the p21 reporter in the same hepatocytes 
where Foxo1 is undergoing Cre-mediated deletion. Using these mice, we demonstrated that 
FOXO1 was required for full activation of the p21 promoter upon fasting, but loss of FOXO1 did 
not completely ablate the fasting-induced activation of p21 expression. Thus, additional 
transcription factors including FOXO 3 and 4, which are also expressed in the liver (Furuyama et 
al., 2000), likely contribute to activation of p21 expression under conditions of low nutrient 
availability. Importantly, ChIP experiments performed with liver RNA demonstrated that 
FOXO1 was bound to the p21 promoter during fasted but not fed conditions. Taken together, 
these results demonstrate that FOXO1 binds to and activates the p21 promoter, resulting in an 
increase in p21 expression and protein in livers of mice during fasting.  
The question remains whether p21 induction provides cells with a survival advantage 
under conditions of low nutrient availability. Loss of p21 did not impact levels of blood glucose, 
free fatty acids, triglycerides and cholesterol or liver glycogen at either baseline or after fasting. 
Thus, p21 has no apparent intrinsic role in metabolic regulation. It is also unlikely that its role as 
a cell cycle inhibitor is important under conditions of low nutrient availability in nondividing 
cells (hypothalamus, hepatocytes). However, p21 induction may serve to block apoptosis under 
conditions of severe nutrient deprivation. p21 has been shown to protect against apoptosis in 
response to growth factor deprivation, p53 overexpression, low density culture, and during 
monocyte differentiation (Abbas and Dutta, 2009; Roninson, 2002). Thus, p21 expression has an 
anti-apoptotic function distinct from its cell cycle inhibitory activities. The anti-apoptotic 
function of p21 may relate to its ability to regulate gene transcription and/or bind and inhibit 
proteins directly involved in apoptosis (Abbas and Dutta, 2009; Roninson, 2002). For example, 
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cytoplasmically localized p21 binds to and inhibits the activity of procaspase 3, caspase 8, 
caspase 10, stress-activated protein kinases (SAPKs) and apoptosis signal-regulating kinase 1 
(ASK1). Furthermore, p21 can mediate the upregulation of genes encoding secreted factors with 
anti-apoptotic activities (Roninson, 2002). p21 also suppresses the induction of pro-apoptotic 
genes by MYC and E2F1 through direct binding and inhibition of their transactivation functions 
(Abbas and Dutta, 2009; Roninson, 2002). We have not observed enhanced apoptosis in the 
cells/organs of fasted p21 null mice (data not shown). However, other family members (p27) 
may compensate for loss of p21 function under these conditions. Additional studies will be 
required to mechanistically decipher the contributions of p21 under conditions of metabolic 
stress. 
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Materials and Methods 
This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The Committee on the 
Ethics of Animal Experiments at Washington University approved all animal protocols used in 
this study. 
 
Construction of conditional p21CBRLuc targeting vector. DNA sequences of the mouse p21 
chromosome locus and its transcript were obtained from Ensembl Mouse Genome Database. 
PCR was utilized to amplify DNA encoding p21 from mouse 129/SvJ genomic DNA 
(Invitrogen). The 5’ arm was generated using primers 5’- GAT CCC CGG TCC TTG TGA A -3’ 
and 5’- CCA TGG TGC CTG TGG CTG AAA C -3’ to amplify 4.0 kb of p21 genomic DNA 
beginning within intron 1 and extending to immediately after the start codon in exon 2. The 
primer design inserted an Nco I site after the ATG start codon in exon 2. The second PCR 
reaction generated the 3’ arm using primers 5’- TGT CCG ACC TGT TCC GCA CAG – 3’ and 
5’- GGT AAG ACC AGG GAA TCC CAC -3’ to amplify 1.8 kb extending from inside exon 2 
to the noncoding sequences downstream of exon 3. A modified version of pBigT was used as the 
backbone for inserting the 5’ and 3’ homologous arms and the Luciferase gene. pBigT contains a 
lox-P flanked PGK-NEO cassette (phosphoglycerate kinase promoter driving expression of 
neomycin phosphotransferase) and was modified with the sequence TAG TAA TGA C TAG 
TAA TGA C TAG TAA TGA between neomycin and the first poly(A) to provide three 
additional stop codons in each reading frame (pMBigT). The 4.0 kb Bam HI/Nco I 5’ arm blunt 
fragment was cloned into Sna BI digested pMBigT. The 1.8 kb Eco RI/Eco RI 3’ arm blunt 
fragment was cloned into Asc I digested pMBigT. A 1.6 kb Nco I/Xba I blunt fragment from 
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pCBR (Promega) encoding Click Beetle Red Luciferase was cloned into Nhe I/Sac I-digested 
pMBigT. Constructs were initially sequenced to confirm no point mutations and junctions were 
sequenced with each round of cloning.  
 
Generation of mice harboring the conditional p21CBRLuc allele. SSC10 ES cells (Siteman 
Cancer Center at Washington University) were electroporated with 13.4 kb Pac 1 linearized 
targeting vector and selected with Geneticin (G418; Invitrogen) using established protocols 
(Siteman Cancer Murine Embryonic Stem Cell Core). A total of 144 G418-resistant ES colonies 
were analyzed for homologous recombination. Genomic DNA was digested with Nde I followed 
by Southern blotting with the 5’ probe (primers: Forward 5’-GCG ATA TCC AGA CAT TCA 
GAG-3’, Reverse 5’-GGA ATC CCT AGA AAC ATT GGC-3’) and with Bgl II/Sph I followed 
by Southern blotting with the 3’ probe (primers: Forward 5’-CCA GTT GGG GTT CTC AGT 
GAC-3’, Reverse 5’-TCT CGT GAG ACG CTT ACA ATC-3’). The sizes of the WT and 
recombinant alleles probed with the 5’ probe were 10.5 kb and 15.0 kb, respectively, and with 
the 3’ probe were 8.5 kb and 5.9 kb, respectively. Four were positive for homologous 
recombination. ES cell clones #2, 4, 12 and 48 were karyotyped and clones #2 and 4 were 
microinjected into C57BL/6 blastocysts and subsequently implanted into the uteri of 
pseudopregnant C57BL/6 x C3H foster mothers. Male chimeras were selected by percentage of 
agouti color and were mated to C57BL/6 females. Germ line transmission was determined by 
agouti coat color. Progeny from ES clone #2 were selected for further propagation. F1 animals 
were tested for the targeted p21 allele by PCR analysis of tail DNA. PCR analysis was 
performed with three primers (A: 5’-TCT TGT GTT TCA GCC ACA GGC-3’, B: 5’-CTG TCA 
GGC TGG TCT GCC TCC-3’, C: 5’-TGC TAA AGC GCA TGC TCC AGA C-3’). The sizes of 
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the WT and recombinant alleles were 453 and 160, respectively, when probed with primers A, B 
and C. In the recombinant locus, we knocked-in the CBRLuciferase gene into the endogenous 
p21 locus; however, CBRLuciferase was not expressed, as it is downstream of 3 stop codons in 
each reading frame. The mice were crossed with transgenic mice expressing Cre under control of 
the Albumin promoter (Postic and Magnuson, 2000). To confirm Cre-mediated excision of the 
stop codon, DNA was isolated from livers and PCR analysis was performed with four primers 
(A-C above and D: 5’-CTA ACG ACG TCG TTC ATC TTG T-3’). The sizes of the WT, 
recombinant pre-Cre-mediated excision and recombinant post-Cre-mediated excision were 453, 
160 and 350, respectively, when probed with primers A, B, C and D.  
 
Mouse husbandry. Unless otherwise stated, equivalent numbers of male and female mice at 4-6 
weeks of age were used. p21+/FLuc mice were previously published (Tinkum et al., 2011) and 
were backcrossed at least 3 times to B6(Cg)-Tyrc-2J/J (B6-albino, Jackson Laboratory), as were 
all mice used for bioluminescence imaging (BLI). Albumin-Cre mice were provided by Dr. Shin 
Imai and FOXO1 floxed mice were provided by Dr. Ronald DePinho. Wild type mice used in the 
studies were littermates of p21+/FLuc mice on the B6-albino background. All experimental mice 
were housed singly on aspen bedding. 
 
Bioluminescence Imaging. BLI was performed as previously published for studies carried out in 
vivo and ex vivo (Tinkum et al., 2011) except that a wire rack was placed in each cage to prevent 
mice from eating bedding during the fasting period and a 14-day osmotic pump (Durect) was 
used in experiments involving adenoviral infections. 
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Western Blotting. Livers isolated from p21+/Fluc and p21FLuc/FLuc mice were flash frozen. Livers 
were thawed followed by homogenization in mammalian cell lysis buffer (MCLB (50 mM Tris-
HCl pH 8.0, 2 mM DTT, 5 mM EDTA, 0.5% NP-40, 100 mM NaCl, 1 mM microcystin (Sigma 
Chemical Co.), 1 mM sodium orthovanadate, 2 mM PMSF)) supplemented with 1 mM sodium 
fluoride, protease inhibitor cocktail (Sigma Chemical Co.) and phosphatase inhibitor cocktail 
(Calbiochem). Clarified lysates were resolved directly by SDS-PAGE (10%/15% layered SDS 
gel) and transferred to nitrocellulose membranes for Western blotting. Membranes were blocked 
in TBST (20 mM Tris HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20) containing 5% nonfat milk 
and incubated overnight in primary antibody diluted in TBST/1% nonfat milk. Membranes were 
washed in TBST, incubated with HRP-conjugated secondary antibody for 1 h in TBST/1% 
nonfat milk, and washed again in TBST. Membranes were incubated with ECL (Pierce) and 
analyzed using a GelDoc Imaging System (BioRad). Primary antibodies included anti-p21 at 
1:1000 (Santa Cruz, F5), and anti-Actin at 1:10,000 (Sigma Chemical Co., A4700). Secondary 
antibodies were HRP-conjugated, AffiniPure goat anti-mouse (Jackson). 
 
Low light microscopy. Male and female p21+/FLuc mice were allowed to feed ad libitum or were 
fasted for 24 h. Mice were sacrificed and brains were isolated. Isolated brains were placed in ice 
cold Hanks Buffered Saline Solution (HBSS, pH 7.4) (Sigma Chemical Co.) and cut into 200 µm 
sections on a vibratome (immersed in HBSS maintained at 4°C). Three brain slices containing 
the hypothalamus at -0.58 mm, -1.82 mm, and -1.94 mm Bregma were placed on separate 
organotypic Millicell culture inserts (Millipore) in a 35 mm Petri dish containing HEPES-
buffered DMEM supplemented with B27 (Invitrogen), 0.1 µM D-luciferin (BioThema), 100 
U/mL penicillin, and 100 U/mL streptomycin (Gibco). All images were initiated within 45 min 
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of organ isolation. To allow for imaging multiple tissues from within one mouse, three low light 
imaging systems were utilized and kept consistent for each region: a Versarray back-thinned 
illuminated CCD camera (Princeton Instruments), and an iXon DU-897E EM CCD camera 
(Andor Technology), each coupled to TE-2000 Nikon inverted microscopes were equipped with 
custom light tight environmental chambers (InVivo Scientific) that prevented light leaks and 
allowed maintenance of a constant temperature of 37°C, or in a light tight box with an intensified 
CCD camera (XR/Mega-10Z; Stanford Photonics Inc.) (Marpegan et al., 2011). Image 
acquisition was controlled with Winview32 and Micro-Manager (www.Micro-Manager.org) 
software packages. Image processing of target regions identified by comparison to a mouse brain 
atlas (Paxions and Franklin, 2001) was performed with ImageJ software (Abramoff et al., 2004) 
and included subtraction of a background image, removal of random bright spots (using 
despeckle filtering algorirthm, ImageJ) and adjusting the brightness and contrast equally across 
the entire image. Intensity scale ramps were scaled and normalized to the time over which the 
image was acquired and are represented as RLU/minute. Pseudocolored images were generated 
using the RainbowRGB look-up table (LUT) on the bioluminescence image. ROIs were analyzed 
using ImageJ and were normalized as target region to non-target region. 
 
Laser capture microdissection. Brains were dissected from p21+/+ or p21FLuc/FLuc mice, sliced 
coronally into three sections using a coronal brain tissue matrix, immediately frozen in optimal 
cutting temperature (OCT, TissueTek) compound, and stored at -80°C. 30 µm sections ranging 
from Bregma -0.58 to -0.82 mm (paraventricular nucleus) and from Bregma -1.70 mm to -1.94 
mm (arcuate nucleus and dorsomedial hypothalamus) were cut coronally on a cryostat and 
sections were placed on PEN membrane slides (Leica). Unstained slides were stored in a 
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desiccator at -80°C. Tissue-mounted slides were fixed in 100% ethanol (30 sec), rehydrated in 
ethanol (95%, 75%, 50%) for 30 sec each, stained in 1% Crystal Violet (Sigma Chemical Co) in 
RNAse-free water (1 min) and dehydrated in ethanol (50%, 75%, 95%, 100%, and 100%) for 30 
sec each. Slides were rinsed in xylene and dried in a desiccator for at least 5 min immediately 
prior to laser capture microdissection. Sections were dissected using the Leica LMD7000 laser 
capture microdissection system. 
 
Real-Time PCR. RNA was isolated from laser capture microdissected tissue using the RNeasy 
Micro Kit (Qiagen). Isolated RNA was treated with DNaseI (Qiagen and Ambion) and quality of 
RNA was determined by chip electrophoresis (BioRad) and only high quality samples were 
analyzed. RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). Real-time PCR of laser-captured samples was performed as 
previously reported (Tinkum et al., 2011). Relative expression of p21 to Actin in laser capture 
microdissection was calculated using the 2-ΔCT method. 
 
Chromatin Immunoprecipitation. Occupancy of the p21 promoter by FOXO1 was determined 
using published procedures (Chaya et al., 2003; Sengupta et al., 2010) with the following 
modifications. Livers of p21+/+ mice were perfused with PBS containing 50 ng/mL heparin 
followed by PBS containing 1% formaldehyde. Livers were incubated in PBS/1% formaldehyde 
for 5 min, dissected and incubated at 30°C for 5 min. Crosslinking was halted by the addition of 
ice-cold glycine. Hepatocytes were isolated by mincing the liver, manually disrupting the tissue 
between 2 frosted slides, passing mixture through a 70 µm filter and centrifuging flow through 
for 5 min at 50 x g. Hepatocytes were resuspended in nuclear lysis buffer (50 mM Tris-HCl pH 
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7.5, 10 µM EDTA, 1% SDS in ddH2O with Protease Inhibitor Cocktail (Roche)), and sonicated 
30 times (30 sec on, 60 sec off) at 60% amplitude. Cleared lysates were diluted in RIPA buffer 
(50mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% Sodium Dodecylsulfate, and 
0.5% Sodium Deoxycholate), pre-cleared with Dynal beads (Invitrogen), and incubated 
overnight with FOXO1 antibody (gift from Anne Brunet) or IgG (Invitrogen) coated Dynal 
beads (5 µg/50 µL beads in 1 mL PBS supplemented with 5 mg/mL BSA) rocking at 4°C. 
Precipitates were washed sequentially with Low Salt Wash Buffer (once), High Salt Wash Buffer 
(twice), LiCl Buffer (3 times) and TE Buffer (twice) (Upstate), followed by elution in a 1% SDS, 
0.1M NaHCO3 buffer at 65°C for 2 h. Eluates were incubated at 65°C overnight followed by 
phenol-chloroform extraction and PCR cleanup (Qiagen). PCR was performed with 2x Brilliant 
PCR Mix (Agilent), containing 250 nM of each primer and 1 µL of 1:50 diluted chromatin 
immunoprecipitation sample in a Applied Biosystem Venti 96-well Thermal-Cycler (95°C 10 
min, then 35 cycles of 95°C 30 sec, 63°C 1 min, 72°C 30 sec, followed by 72°C 4 min). PCR 
products were analyzed on a 2% Agarose gel. PCR primers were as follows: FHB forward 
primer: CCTGGAGGCCAAGGGGATTTGG; FHB reverse primer: CAG GGG CCA GCA 
CAG GAT GTC A; Distal fwd: TGG GCA GCT TGC CAG AGG TC; Distal rev: AGC CGC 
CAG GCT CCT TAC CT. 
 
Metabolic Analysis. Plasma was isolated from 5-week old male p21+/+ and p21FLuc/FLuc 
littermates that had been allowed to feed ad libitum and from the same mice one week later after 
a 24 h fast. 100 µL of heparinized blood was centrifuged and plasma was isolated. Total 
triglycerides, cholesterol, glucose and free fatty acids were quantified using previously published 
protocols (Marshall et al., 1999). Triglycerides, cholesterol and glucose were measured using 
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Infinity reagents (Thermo Scientific) and free fatty acids were measured using reagents provided 
by Wako Chemicals.  
Four to six week old p21+/+ and p21FLuc/FLuc male littermates were allowed to feed ad 
libitum or were fasted for 24 h. Livers were isolated, weighed and flash frozen. Glycogen was 
analyzed according to recommendations of the manufacturer (Abcam).  
 
Generation of recombinant adenoviruses. pCMV5 encoding HA-FOXO1 (plasmid 12142) and 
Flag-pCMV5 encoding the N-terminus of FOXO3 (FOXO3NT, plasmid 14938) were purchased 
from Addgene. PCR reactions were carried out to add 5’ Xho 1 and 3’ Hind III restriction sites to 
each cDNA using the following 5’-CCATGGACTACAAGGACGAC and 5’-
ACTGGGGAGGGGTCACAG. Reaction products were sequenced and cDNAs were cloned into 
Xho I/Hind III digested pAdTrack. Recombinant adenoviruses were generated using the 
pAdEasy protocol (He et al., 1998).  
 
Adenoviral Infections. p21Liv-Luc/+ mice were implanted with a 14-day, 0.5 µL/hr flow rate 
microosmotic pump (Durect), loaded with D-luciferin as described previously (Gross et al., 
2007). Photon flux was measured at baseline, and recombinant adenovirus encoding FOXO3NT 
or FOXO1WT was delivered by tail vein injection of 5 x 1010 viral particles per 4-6 week old 
mouse. BLI was measured three, six and nine days post injection and mice were fasted for 24 h 
at nine days post injection. Livers were isolated after 24 h of fasting, fixed, frozen in OCT and 5 
µm sections were analyzed to determine efficiency of viral infection by quantification of the 
percent of GFP positive cells within 5 fields of view. 
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Figures 
 
Figure 3.1 p21 expression detected in metabolic organizing center of brain.  
Coronal brain sections from male and female p21+/FLuc mice containing (A) paraventricular 
nucleus, (B) arcuate nucleus, and (C) both dorsomedial hypothalamus and periventricular 
nucleus were incubated with D-luciferin-containing media to maintain viability, followed by BLI. 
The left column is a representation of each brain region, modeled from the Paxions and Franklin 
mouse brain atlas, with the bioluminescence signal-containing region shaded in red. The middle 
column contains a pseudocolored heatmap of the bioluminescence (relative to each region) and 
the right column shows the heatmap overlaid on the bright field image. Scale bars are 0.5 mm. 
Images from representative mice are shown. Regions of the hypothalamus were abbreviated as 
follows: 3V is third ventricle, PaV is paraventricular; Arc is arcuate, Peri is periventricular and 
DM is dorsomedial. 
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Figure 3.2 Fasting induces p21 promoter activity and p21 protein expression.  
p21+/FLuc male and female mice, 5-12 weeks of age, were implanted with D-Luciferin 
microosmotic pumps, subjected to BLI (time zero) and then were allowed to feed ad libitum or 
were fasted for 48 h. Whole-body BLI was performed at the indicated times. (A) Representative 
images of mice (n=4 fed, n=12 fasted) and (B) Bioluminescence quantified from a region of 
interest drawn from below the forpaws to the above the genitals for each mouse at time zero and 
applied identically to subsequent timepoints. Bioluminescence relative to the value at time zero 
is displayed graphically. *, p<0.05 and ****, p<0.0001 by Bonferroni multiple comparisons 
posttest of a two-way ANOVA. (C and D) p21+/FLuc mice were fed or fasted (48 h), and the 
indicated organs were harvested, weighed and imaged immediately. The normalized photon flux 
of each organ is represented as the photon flux/sample weight (photons/s/g). Individual mice 
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(squares and circles) and group averages (bar) are shown (n=3 fed, n=4 fasted). The Mann-
Whitney U Test p value is displayed at the top of each column. (E) p21+/Fluc and p21FLuc/FLuc mice 
were fed (FD) or fasted (FS) for 48 h. Western blotting was performed on lysates prepared from 
isolated livers for the indicated proteins. 
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Figure 3.3 Fasting increased p21 expression in metabolic regulatory regions of the brain.  
Brain sections containing the paraventricular nucleus (Para), arcuate nucleus (Arcuate), 
dorsomedial hypothalamus (DMH), and periventricular nucleus (Peri) isolated from fed or fasted 
(24 h) p21+/Fluc mice, male and female, were incubated with D-luciferin-containing media and 
BLI was performed. (A) Representative images with pseudocolor heatmap of bioluminescence 
are shown for each region. (B) Bioluminescence in the regions of interest (target), shown by 
dotted lines, was quantified as the ratio of target to non-target regions to normalize for inherent 
variation in thickness (Para: n=5 fed, n=5 fasted; Arcuate: n=5 fed, n=5 fasted; DMH/Peri: n=4 
fed, n=3 fasted; unpaired, two-tailed t-test; Para p=0.48, Arcuate p=0.29, DMH p=0.20, and Peri 
p=0.52). (C). p21+/+ mice were fed or fasted (24 h), brains were isolated, and laser-capture 
microdissection of hypothalamic nuclei was performed. cDNA was prepared from RNA isolated 
from each region. Levels of p21 and Actin expression were determined by real-time qRT-PCR 
and the 2-dCT values are represented graphically (n=3 fed, n=4 fasted; unpaired, two-tailed t-test; 
Para p=0.07, Arcuate p=0.02, and DMH p=0.05). 
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Figure 3.4 Generation and characterization of conditional p21-Luciferase reporter mouse. 
(A) Structure of the targeting vector, wild-type p21 genomic allele (+), and recombinant allele 
before (f) and after (L) Cre-mediated excision. The coding region of the mouse Cdkn1a gene was 
disrupted by insertion of a neomycin phosphotransferase cDNA cassette followed by a modified 
stop cassette (Neo-STOP) with each of the 3 stop codons in each reading frame (to reduce any 
read-through driven by the phosphoglycerine kinase promoter), followed by a codon-optimized 
click-beetle red luciferase cDNA (Luc) and bovine growth hormone polyadenylation sequences. 
Upon homologous recombination, the Luc cDNA utilizes the ATG start codon of endogenous 
p21 in exon 2. Exons are represented by black boxes; 5’ and 3’ arms are highlighted in teal; Sph 
I sites are denoted by S; Nde I sites are denoted by N; Bgl II sites are denoted by Bg; loxp sites 
are shown by blue triangles; the 5’ Southern probe is shown by a gray box; the 3’ Southern probe 
is shown by a red box; PCR primers are shown by black arrows and lowercase letters. Sizes of 
expected Southern blotting and PCR products are indicated. (B) Genomic DNA from an ES cell 
clone was digested with Bgl II and SphI. Southern blotting was performed using the 5’ probe 
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shown in panel A. The wild-type allele (+) gave rise to a 10.5-kb digestion product, and the 
recombined allele (f) gave rise to a 15.0-kb digestion product. (C) Genomic DNA from an ES 
cell clone was digested with Bgl II and Sph I, and Southern blotting was performed using the 3’ 
probe shown in panel A. The wild-type allele (+) gave rise to a 8.5-kb digestion product, and the 
recombined allele (f) gave rise to a 5.9-kb product. (D) PCR analysis of tail DNA from a wild-
type mouse (+/+), conditional mouse without liver-specific Cre (f/+), and conditional mouse with 
liver-specific Cre (L/+) amplified with primers indicated by the black arrows (a, b, and c) in 
panel A. The WT (+) allele produced a 453-bp product with primers a and b, and the recombined 
alleles (f and L) produced a 160-bp allele, regardless of liver-specific Cre expression, with 
primers a and c. (E) PCR analysis of liver DNA from a wildtype (+/+), conditional mouse 
without liver-specific Cre (f/+), and conditional mouse with liver-specific Cre (L/+) amplified 
with the indicated primer combinations. Addition of the “d” primer distinguished between the 
conditional mouse without liver-specific Cre (r/+), and conditional mouse with liver-specific Cre 
(L/+) by a 350-bp product. (F, G) Conditional mice with and without the Albumin-Cre allele 
were shaved and injected with 150 mg/kg D-luciferin and imaged using the IVIS Lumina system 
(Caliper). Mice were sacrificed and all organs located in the bioluminescence region were 
isolated and then imaged ex vivo. Photon flux is indicated in the pseudocolored heat maps.  
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Figure 3.5 Dynamics of p21 expression in the fasted liver.  
p21Liv-Luc/+ male and female mice were subjected to BLI (time zero) and then allowed to feed ad 
libitum or were fasted (24 h). Mice were re-imaged at the indicated time points. (A) 
Representative images of mice, photon flux is indicated in the pseudocolored heat map; (B) 
bioluminescence relative to the value at time zero, displayed graphically (n=6 fed, n=7 fasted). 
**, p<0.01 by Tukey posttest of a 2-way ANOVA.  
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Figure 3.6 p21 is not required for metabolic homeostasis.  
(A) Male p21+/+ (p21 WT) and p21FLuc/FLuc (p21 KO) littermates were weighed at 5 weeks of age. 
Body weights of p21 KO mice were normalized to that of their p21 WT littermates. Each mouse 
is represented as a circle and the mean is represented by a solid black line. p=0.06 by a two-tailed 
paired t-test. (B-E) Plasma was isolated from 5 week old fed mice and 1 week later plasma was 
isolated from the same mice after a 24 h fast. Plasma levels of triglycerides (B), glucose (C), 
cholesterol (D) and free fatty acids (E) were determined. Each mouse is represented as a circle, 
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the mean for p21 WT mice is represented by a solid black line and the mean for p21 KO mice is 
represented by a dashed black line. (F) Liver glycogen levels in 4-6 week old p21 WT and KO 
mice that were fed or fasted for 24 h were quantified and normalized to µg of liver tissue. 
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Figure 3.7 Fasting-induced p21 expression is p53-independent.  
p21+/FLucTrp53+/+ and p21+/FLucTrp53-/- male and female mice, hereafter referred to as p53 WT 
and p53 KO, respectively, were imaged (time zero) and then were allowed to feed ad libitum or 
were fasted for 24 h. Whole-body bioluminescence was determined at the indicated times during 
treatment. (A) Representative images; (B) bioluminescence relative to the value at time zero, 
displayed graphically. ***, p<0.001 as determined by Tukey multiple-comparison posttest of a 
2-way repeated measure ANOVA between the fed and starved groups within the same genotype 
at 24 h, no significant difference was detected between fasted p53 WT and p53 KO mice. (C) At 
24 h of treatment, organs were harvested and immediately imaged. The normalized photon flux 
of each organ is represented as the photon flux/sample weight (photons/s/g) to control for 
variation in organ size. Individual mice (squares, circles and triangles) and the group average 
(bar) are shown (p53 WT: n=6 fed, n=7 fasted; p53 KO: n=5 fed, n=6 fasted). The Mann-
Whitney U test p value is included in each column.  
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Figure 3.8 Fasting-induced expression of p21 requires FOXO1.  
(A) p21Liv-Luc male mice were imaged and then infected with recombinant adenoviruses encoding 
either FOXO1WT or FOXO3NT. After nine days of recovery, mice were reimaged (baseline), 
fasted for 24h and then reimaged (FOXO1WT n=4, FOXO3NT n=6. ***, p<0.001 by an 
unpaired, two-way t-test). (B) p21Liv-LucFoxo1w/w and p21liv-LucFoxo1f/f male mice were imaged 
(time zero) and then were allowed to feed ad libitum or were fasted. Liver-specific 
bioluminescence was measured at the indicated times during treatment (p21Liv-LucFoxo1w/w fed 
n=6, p21Liv-LucFoxo1w/w fasted n=10, p21Liv-LucFoxo1f/f fed n=7, p21Liv-LucFoxo1f/f fasted n=13. *, 
p<0.05; ***, p<0.001, n.s., not significant as determined by Tukey multiple-comparison posttest 
of a 2-way repeated measure ANOVA between the indicated group at 24 h). (C) p21+/+ mice 
were fed (FD) or fasted for 24 h (FS) and livers standard chromatin-immunoprecipitation for 
Foxo1 or control IgG was performed and PCR of Foxo1 and IgG bound DNA amplified the p21 
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promoter Forkhead Binding Region and a control region 1-kb distal; representative experiment is 
shown.  
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CHAPTER 4 
Fasting protects mice from lethal DNA damage through enhanced survival of intestinal 
stem cells and inhibition of inflammatory responses. 
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Abstract 
Short-term fasting protects mice from what would normally be lethal doses of etoposide. 
In this study, we demonstrate that fasting prior to high dose etoposide treatment enhances the 
survival of mice by protecting small intestinal stem cells. Nearly all small intestinal stem cells 
were lost when mice fed ad libitum were treated with high doses of etoposide. By contrast, many 
stem cells survived when fasted mice were similarly treated and these stem cells were able to 
reconstitute small intestinal crypts and villi. Both crypt base columnar (CBC) and +4 stem cells 
contributed to the restoration of crypt architecture in fasted mice. Etoposide treatment induced 
DNA double strand breaks (DSBs) in CBC cells of both fed and fasted mice. However, 
resolution of DNA DSBs, as measured by loss of gH2AX staining, occurred more quickly in the 
CBC cells of fasted mice compared to those in fed mice. Strikingly, large numbers of neutrophils 
infiltrated into the small intestines of mice that had been allowed to feed ad libitum resulting in a 
complete separation of many crypts from their corresponding villi. Neutrophils were not 
observed to infiltrate into the small intestines of fasted mice following etoposide treatment. Thus, 
fasting preserves small intestinal architecture and barrier function by preserving small intestinal 
stem cells and preventing pro-inflammatory responses to high levels of DNA damage. 
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Introduction 
Chemotherapeutic drugs and radiation therapy are widely used in the clinic for treating 
cancer patients. However, these treatments are not selective for cancer cells and can cause severe 
side effects through damage of normal tissues. Proliferative cells, including intestinal stem cells 
and hematopoietic cells, are most commonly affected by these cancer treatments. Such side 
effects can prevent the use of chemotherapy entirely in some patients while restrict the tolerable 
dose in other patients. Therefore, protecting these normal cells from detrimental effects of 
chemotherapy and radiation therapy is of great clinical significance. To date, several pathways 
have been identified to reduce the side effects of chemotherapy including those involved in the 
cell division cycle, cellular differentiation, oxidative stress response and immune regulation 
(Kim et al., 2012; Lee et al., 2009; Potten, 1995; Potten et al., 1997; Takemura et al., 2014). 
Recently, short-term food deprivation (fasting), caloric restriction, and protein restriction, were 
shown to protect mice from lethal doses of chemotherapy (Brandhorst et al., 2013; Raffaghello et 
al., 2008). Fasting-mediated protection is effective against multiple forms of DNA damaging 
agents including etoposide (double strand breaks), doxorubicin (double strand breaks and 
intercalation), cisplatin (crosslink) and cyclophosphamide (crosslink) (Lee et al., 2012; 
Raffaghello et al., 2008). However, the underlying mechanism of fasting-induced 
chemoprotection has remained illusive.  
Raffaghello et al. (2008) proposed that reduced level of circulating IGF-1 may be 
responsible for fasting-induced chemo-protection (Raffaghello et al., 2008). However, despite 
similar reduction in IGF-1 levels, protein restriction and caloric restriction fail to provide 
equivalent protection from doxorubicin when compared to the fasted mice (Brandhorst et al., 
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2013). Therefore, in addition to IGF-1 levels other metabolic factors likely contribute towards 
the fasting-mediated protection from DNA damage. 
Here, we demonstrate fasting protects the small intestine leading to the survival high-
dose etoposide. The absorptive surface of the small intestinal lumen contains numerous finger-
like protrusions called villi and invaginations into the submucosa known as the crypts of 
Lieberkühn. The epithelial cells of the villi are terminally differentiated and are repopulated 
every 5 days by transiently amplifying cells that generate 300 new cells per crypt (Marshman et 
al., 2002). Transiently amplifying cells are rapidly proliferating, committed daughter cells of 
tetrapotent stem cells residing in the crypts. There are two well-established intestinal stem cells, 
the crypt base columnar (CBC) and the +4 stem cell (Barker et al., 2007; Sangiorgi and Capecchi, 
2008). To date, the CBC and +4 stem cells have been shown to have both overlapping and 
distinct functions. In homeostatic conditions, the +4 is quiescent whereas the CBC is actively 
cycling. However, following high dose radiation, both stem cells proliferate and contribute to 
repopulation of the crypt and villi (Metcalfe et al., 2014; Sangiorgi and Capecchi, 2008; Tian et 
al., 2011; Yan et al., 2012). 
Currently, the underlying mechanism of chemo-protective effects of fasting is unknown. 
Here, we demonstrate that fasting protects small intestinal stem cells from high dose of etoposide 
to promote survival. Lethal dose of etoposide eliminated majority of small intestinal stem in 
mice that were fed ad libitum, and resulted in complete destruction of crypt-villus architecture 
and eventual death of the mice. On the other hand, 24 h fasting before etoposide treatment 
promoted survival of a small fraction of +4 and CBC stem cells that repopulated the crypt 
epithelial cells within 4 days of etoposide treatment. These results provide mechanistic insight 
into how fasting protects mice from lethal doses of a DNA damaging agent. 
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Results 
Fasting protects the small intestine from lethal doses of etoposide. 
Mice subjected to short-term fasting are protected from high doses of etoposide that 
otherwise kill their fed littermates (Raffaghello et al., 2008). We confirmed this finding by 
treating mice that had been allowed to feed ad libitum or had been fasted for 24 h with 100 
mg/kg etoposide (Fig 4.1A). Both fed and fasted mice were provided food at the time of 
etoposide treatment. Mice that been allowed to feed ad libitum died between 5 and 6 days 
following etoposide administration (Fig 4.1B) whereas fasted mice survived. A steady decline in 
body weight was measured in etoposide-treated, fed mice reaching a 40% reduction at the time 
of death. A 20% decrease in body weight was measured in fasted mice within 24 h of etoposide 
treatment. However, within 48 h body weight was restored to 90% of initial weight and full 
weight recovery was achieved by day 9 (Fig 4.1C). These data are consistent with previously 
published findings (Raffaghello et al., 2008).  
Strikingly, the small intestines of fed mice displayed significant atrophy on day 4 post 
etoposide-treatment (Fig 4.1D). A significant shortening of villi, a significant reduction in the 
number of crypts and fewer cells per crypt were observed in fed mice exposed to high dose 
etoposide (Fig 4.1E-G). Interestingly, small intestinal crypts were larger and contained more 
cells in etoposide-treated fasted animals compared with saline-treated counterparts (Fig 4.1E, 
S4.2). Crypt number and villi height were similar in the two fasted experimental groups (Fig 
4.1F,G). The overall architecture of large intestines were similar in all four treatment groups (Fig. 
S4.1). 
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Active neutrophil recruitment destroys crypt architecture in fed, etoposide-injected mice. 
Small intestines were collected at 24, 48 and 72 h post etoposide-treatment from both fed 
and fasted mice and the number of apoptotic bodies per individual crypt was determined. Similar 
numbers of apoptotic bodies were observed in the crypts of fed and fasted mice by 24 h post 
etoposide-treatment, but significantly less apoptotic bodies were counted in the crypts of fed 
mice compared to fasted mice by 48 h post etoposide-treatment (Fig 4.2A). Strikingly, by 48 h 
large numbers of neutrophils infiltrated into the small intestines of fed mice and this resulted in a 
complete separation of many crypts from their corresponding villi (Fig 4.2B). Neutrophils were 
not observed to infiltrate into the small intestines of fasted mice following etoposide treatment 
(Fig 4.2B). The neutrophils may have been responsible for clearing the apoptotic cells in the 
crypts of fed, etoposide-treated mice at the 48 h time point. 
A neutrophil-depleting antibody (α-Ly6G) was administered to mice in the presence or 
absence of antibiotics to determine if any of the phenotypes observed in fed, etoposide-treated 
mice could be rescued. Although neutrophil invasion was eliminated in fed, etoposide-treated 
mice by this treatment, bacterial colonization was observed in the villus compartment of fed, 
etoposide-treated mice that received α-Ly6G. This was not observed in fed, etoposide-treated 
mice that received α-IgG (Fig S4.3) or in mice that had been fasted prior to receiving etoposide 
treatment (data not shown). This suggests that high dose etoposide compromised barrier function 
in the small intestines of fed mice and that neutrophils kept bacterial colonization at bay. 
Blocking neutrophil infiltration also prevented crypts from being dislodged from the overlaying 
villus compartment in the small intestines of fed, etoposide-treated mice. Instead, crypt 
epithelium detached from the underlying lamina propia in fed, etoposide-treated mice 
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administered α-Ly6G. Thus neutrophils are responsible for crypt destruction in fed mice exposed 
to high doses of etoposide (Fig. S4.3) 
 Next fed and fasted mice were treated with a 10 day course of broad-spectrum antibiotics 
(ABX) or water as a control prior to and after etoposide treatment. A significant reduction in 
blood neutrophils was observed by 48 h after α-Ly6G administration in both fed and fasted mice 
(Fig 4.2D). The weight loss observed in fed, etoposide treated mice was significantly curtailed 
when these mice were treated with antibiotics or antibiotics together with α-Ly6G (Fig. 4.2E). 
Antibiotic treatment also resulted in a significant increase in the number of crypt epithelial cells 
undergoing proliferation in fed, etoposide-treated mice (Fig. 4.2F). This is consistent with reports 
demonstrating that germ-free mice exhibit increased resistance to DNA damage (Crawford and 
Gordon, 2005). Thus, antibiotic treatment alone or in combination with α-Ly6G provided 
protection from the deleterious effects of high dose etoposide in fed mice.  
 
Fasting does not alter early responses of small intestinal epithelial cells to etoposide 
The effects of etoposide on epithelial cell proliferation in small intestinal crypts were measured 
following 24 h of fasting. Mice were injected with BrdU 90 min prior to sacrifice and small 
intestines were harvested for analysis. As seen in Fig. S4.4A, a significant reduction in BrdU 
incorporation was measured in crypt epithelial cells of fasted animals relative to their fed 
counterparts. Next, mice that had been fasted for 24 h or allowed to feed ad libitum were injected 
with either etoposide or saline and 22.5 h later with BrdU. Mice were sacrificed 90 min later and 
intestines were harvested for analysis. Significant differences were not observed between the 
four treatment groups. Although BrdU incorporation trended towards being significantly reduced 
in the fed, etoposide treated group relative to the fasted, etoposide treated group (Fig. S4.4A). 
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The number of crypt epithelial cells undergoing apoptosis was determined by staining for 
cleaved caspase 3 (Fig. S4.4B) and the number of cell with DNA double strand breaks (DSBs) 
was determined by staining for γH2AX (Fig. S4.4C). The number of crypt epithelial cells 
staining positive for cleaved caspase 3 and γH2AX were similar in all treatment groups. 
 
Small intestinal stem cells are viable in fasted, etoposide-treated mice.  
Next, we specifically focused on small intestinal stem cells as fasting provided protection 
to small intestinal epithelial cells following high dose etoposide treatment (Fig. 4.1). Mice that 
had been allowed to feed ad libitum or were fasted for 24 h were injected with etoposide and 24 
h later the small intestinal crypts were isolated (Fig 4.3A). Crypts were plated in matrigel with 
conditioned media that promotes growth of a spheroid that contains stem and progenitor cells 
(Miyoshi et al., 2012; Miyoshi and Stappenbeck, 2013). Significantly more spheroids formed in 
crypts of the fasted, etoposide group compared to the fed, etoposide group (Fig. 4.3B, C). 
Interestingly, not all stem cells were protected in the fasted mice as less spheroids formed in 
crypts isolated from fasted, etoposide-injected mice compared to saline-treated mice (Fig. 4.3B, 
C). However, once a spheroid formed, it could be split and passaged, regardless of which 
treatment group of origin (Fig S4.5). Thus, fasting protects a subset of intestinal stem cells from 
lethal doses of etoposide. 
Multiple small intestinal stem cells have been shown to proliferate after low-level DNA 
damage (Metcalfe et al., 2014; Montgomery et al., 2011; Sangiorgi and Capecchi, 2008; Yan et 
al., 2012). Therefore, we tested which type(s) of intestinal stem cells were protected in the fasted, 
etoposide-injected mice. Three mouse lines in which a tamoxifen-inducible Cre is driven by the 
stem cell marker were obtained and were then crossed each to a reporter where Cre-mediated 
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excision results in permanent LacZ expression. Lgr5EGFP-IRES-CreERT2 (hereafter, Lgr5GFP::CreER); 
R26R mice were used to study the response of the crypt base columnar (CBC) stem cell and both 
Bmi1CreER ; R26R and HopXCreER; R26R were used to study the response of the +4 stem cell. 
Since we needed to use genetically modified mice that were heterozygote for critical 
alleles, we determined the appropriate etoposide dose where fasted mice were still protected and 
fed mice still died for each strain (Fig S4.6). This dose was 80mg/kg for Lgr5GFP::CreER; R26R 
mice and was 100mg/kg for both Bmi1CreER; R26R and HopXCreER; R26R mice. To increase the 
number of crypts that could be analyzed, a program to quantify the number and size of stained 
crypts visualized as colonies in the whole mounts was generated (Fig S4.7, S4.8), allowing 
analysis of approximately 1200 crypts in each image for a total of at least 3600 analyzed crypts 
per mouse. 
Mice that had been allowed to feed ad libitum or fasted for 24 h were injected with 
etoposide and then 1 and 3 h later with tamoxifen to induce lineage tracing (Fig 4.3D). Small 
intestines were isolated on day 5 and stained for LacZ expression. The number of fully traced 
crypts were significantly increased in fasted, etoposide-injected mice compared to fed, 
etoposide-injected. Significant differences were observed in all three stem cell lines (Fig. 4.3E-
G). Consistent with previously published results, saline-injected mice had fully traced crypts 
derived from Lgr5+ cells but rarely from Bmi1+ and HopX+ cells. In all lines, lineage tracing 
was confined to the crypts of fasted mice at 4 d post-etoposide; however, tracing extended to the 
tips of villi by 8 d post-etoposide (Fig S4.9). Thus, both the CBC stem cell and the +4 stem cell 
can clonally populate all cells of the intestinal epithelium in fasted, etoposide-injected mice.  
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DNA Damage resolves faster in Lgr5+ cells of fasted, etoposide-protected mice 
Small intestines of Lgr5GFP::CreER mice (Fig S4.10) were collected at 1.5, 3, 6, 9 and 12 h 
post-etoposide from both fed and fasted mice and the number of apoptotic bodies were individual 
crypt was determined. Few apoptotic bodies were detected in the crypts of fed and fasted mice 
by 1.5 h post etoposide-treatment, but significantly more apoptotic bodies were counted in the 
crypts of fed mice compared to fasted mice by 3 h post etoposide-treatment (Fig. 4.4A). The 
number of apoptotic bodies that were counted peaked and was no longer significantly different 
between fed and fasted mice by 6 h post etoposide-treatment (Fig. 4.4A). 
In order to have an unbiased understanding of how fasting protects the small intestinal 
stem cells from lethal doses of etoposide, we performed a microarray on RNA isolated from the 
crypt base of fed and fasted mice at 3 h post etoposide-treatment. In addition to changes in nearly 
every metabolic pathway, GO-term analysis showed an upregulation of DNA repair and DNA 
damage response genes in the lower crypt isolated from fasted, etoposide-injected mice 
compared to fed, etoposide-injected mice (Fig S4.11). More analysis is needed; however, 
preliminary analysis suggested the stem cells of fasted mice responded more aggressively with 
DNA repair pathways post etoposide-treatment. 
Therefore, the effects of fasting on the DNA damage response was analyzed in CBC cells. 
Lgr5GFP::CreER mice were injected with BrdU at 60 min prior to sacrifice and small intestines were 
harvested for analysis. The number of Lgr5+ cells reduced over time but was not significantly 
different in fed and fasted mice post etoposide-treatment (Fig 4.4B). As seen in Fig. 4.4C, a 
significant reduction in BrdU incorporation was measured in Lgr5+ cells of fasted mice 
compared to their fed counterparts. However, significant differences in BrdU incorproation were 
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not observed in Lgr5+ cells between fed and fasted mice at 1.5 and 3 h post etoposide-treatment 
(Fig 4.4C). 
The number of CBC cells with DNA DSBs was determined by co-staining for γH2AX 
and GFP. The number of CBC cells staining positive for γH2AX was similar between fed and 
fasted mice at 1.5 h post etoposide-treatment (Fig. 4.4D, E). Interestingly, γH2AX staining in 
CBC cells was significantly reduced in fasted mice compared at 3h post etoposide-treatment 
compared to their fed counterparts (Fig 4.4D, F). Thus, DNA DSBs are repaired in faster CBC 
cells of fasted mice following etoposide treatment. 
Finally, the number of CBC cells undergoing apoptosis was determined by co-staining 
for cleaved caspase 3 and GFP. More mice remain to be analyzed; however, the number of CBC 
cells undergoing apoptosis may be reduced in fasted mice compared their fed counterparts 
following etoposide treatment (Fig. 4.4G, H). Taken together, this data demonstrates that fasting 
does not alter the DNA damage caused by etoposide, but does improve the DNA repair rate and 
may reduce apoptosis within the pool of Lgr5+ stem cells. 
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Discussion 
Gastrointestinal damage is a common reported side effect of most chemotherapeutic 
drugs. These drugs destroy the intestinal architecture and compromise its absorptive and barrier 
functions. Here, we report that fasting mice for 24 hour prior to etoposide treatment can prevent 
etoposide-induced gastrointestinal damage. Fasting alters the behavior of the intestinal stem cells, 
as well as the immune system, and allow mice to survive a lethal dose of etoposide.  
Small intestine is a highly proliferative tissue whose architecture is maintained by two 
distinct stem cells. The first is the crypt base columnar (CBC) stem cell, often identified by its 
expression of the marker Lgr5 (Barker et al., 2007). The other known intestinal stem cell is the 
“+4” stem cell, termed for its position within the crypt, and was originally identified by its long-
term label retention (Potten et al., 2002; Sangiorgi and Capecchi, 2008). Multiple markers are 
used to identify the +4 cell, including Bmi1, mTERT and HopX. Using an in vitro crypt culture 
system, we found fasting protected a subset of small intestinal stem cells from high-dose 
etoposide.  
It has been previously reported that both the CBC and the +4 stem cells can clonally 
regenerate crypts after DNA damage (Montgomery et al., 2011; Sangiorgi and Capecchi, 2008; 
Takeda et al., 2011). Recent studies in which CBCs are specifically ablated through use of 
LGR5DT show that the CBC stem cell is not required for homeostasis but is required for crypt 
regeneration after DNA damage (Metcalfe et al., 2014). It is unknown if the +4 is also required 
for crypt regeneration after DNA damage. Here, we report lineage tracing experiments indicated 
that chemo-protective effects of fasting were limited to only a small fraction of stem cells as seen 
by a substantial reduction in frequency of colonies traced. However, there were no significant 
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differences between the two stem cells. Both these stem cells were equivalently protected and 
were able to repopulate the intestinal crypt in the fasted mice treated with etoposide.  
Additionally, as part of this investigation, we generated an image-analysis code to 
increase the number of crypts that could be analyzed in the tracing experiments. The code was 
designed as an unbiased, more quantifiable approach to identify a positively traced crypt region 
and has application to lineage tracing as well as other image analysis. 
In order to determine how fasting protected the stem cells, we performed a microarray at 
3h post-etoposide from fed and fasted mice. For this, we did not purify through FACS sorting but 
isolated the lower portion of the crypt that contains the +4, CBC as well as a non-stem cell that is 
known to communicate with the stem cells, the paneth cell. Unsurprisingly, pathway analysis 
showed a large number of metabolic pathways were upregulated in the fasted, etoposide-injected 
mice compared to fed, etoposide-injected. Additional identified pathways include DNA damage, 
cell stress, receptor signaling, defense to bacteria, wound response, immune response, cell death, 
cell cycle, and transcription. Therefore, by 3h post-etoposide, there is a dramatic differential 
response between fed and fasted mice. 
Since both the CBC and +4 stem cells were protected from etoposide, we chose to focus only 
on the CBC stem cell to elucidate the mechanism of protection. We considered the cell cycle, 
DNA damage and cell death pathways identified in the microarray, and tested if they were 
indeed functionally altered in Lgr5+ cells. First, fasting alone reduced BrdU incorporation in 
CBC stem cells indicating lower number of Lgr5+ cells in S-phase after fasting. Topoisomerase 
II levels are highest during S, G2 and M phase and sensitivity to etoposide, a topoisomerase II 
inhibitor, is known to be highest in these phases Thus, one could hypothesize that fasting-
induced reduction in the Lgr5+ cells in S-phase limits etoposide-induced damage and thereby 
 112 
protects them from cell death. Although fasting did result in a reduction in S-phase cells 
(measured by BrdU labeling), we found that greater than 99% of CBC stem cells had DNA 
double strand breaks in both the fed and fasted states. The equivalent DNA damage levels 
despite reduced active proliferation in fasted mice may be due to re-feeding of fasted mice or cell 
cycle-independent effect of etoposide on DNA damage. Fasted mice were re-fed immediately 
after the etoposide injection. This may release the arrest in the 10% of CBC cells that were 
arrested in the fasted state compared to fed, rendering them equally sensitive to DNA damage. 
Moreover, etoposide has been shown to induce damage outside S-phase as well. In embryonic 
stem cells topoisomerase II occupies active promoters, presumably independent of cell cycle 
stage, and etoposide treatment induces DNA double strand breaks at these sites (Thakurela et al., 
2013). However, the effect of etoposide outside the S-phase in intestinal cells remains unknown. 
While there was equivalent amount of DNA damage initially, we found that CBC cells of fasted, 
etoposide-injected mice resolved their DNA damage much faster when compared to those of fed, 
etoposide-injected mice. Furthermore, between 1.5 and 6 h post DNA damage, we observed 
fewer apoptotic CBC stem cells in the fasted mice. This is consistent with our observation that 
more stem cells from fasted mice survive in culture when compared to the fed mice. The exact 
mechanism by which DNA damage repair is expedited within fasted stem cells remains unknown.  
In addition to protection of intestinal stem cells, we also found that fasting reduced the 
number of infiltrating immune cells in etoposide-injected mice. Fasting protected the crypts from 
immune cell infiltration, but it is unclear if it is direct inhibition or indirect lack of activation of 
pro-inflammatory factors. Chemotactic signals post DNA damage are well-described (Coppe et 
al., 2008; Pazolli et al., 2009; Rodier et al., 2009), and collateral damage of immune infiltration 
is seen in intestinal inflammatory disease (Garrett et al., 2010). Therefore, it remains possible 
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that fasting alters local levels of cytokines and chemokines at baseline or in response to DNA 
damage. 
To determine if the neutrophils were playing a detrimental role in their response to 
etoposide in free feeding mice, we tested if free feeding mice that were treated with a neutrophil 
depleting antibody were protected from etoposide. Due to the bacterial invasion seen when we 
depleted the neutrophils, it was required that we treat mice with broad-spectrum antibiotics when 
depleting the neutrophils. It has previously been shown that germ-free mice have reduced 
proliferation rates (Savage et al., 1981), and that they are resistant to high-dose ionizing radiation 
(Crawford and Gordon, 2005). Moreover, germ-free mice have less lymphoid follicles, immature 
Peyer’s patches and immature mesenteric lymph nodes that results in a dampened immune 
response (Round and Mazmanian, 2009). Therefore, it was expected that the antibiotic-treated 
mice would have altered the baseline communication with the immune system and reduced 
proliferation rates and that this alone could protect the mice from etoposide to some extent. 
Neutrophil depletion in antibiotic-treated mice did increase the number of proliferating, protected 
crypts, suggesting even further protection than the antibiotics alone. It remains to be investigated 
how exactly fasting alters the immune response at baseline and in response to DNA damage. 
The data presented here reveals the location of fasting-mediated protection from high-
dose DNA damage. Our data demonstrates that this mechanism results in heightened DNA repair, 
reduced apoptosis, and inhibition of immune infiltration, but further studies would be required to 
delineate the specific signaling pathways underlying fasting-induced chemo-protection. 
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Materials and Methods 
This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The Committee on the 
Ethics of Animal Experiments at Washington University approved all animal protocols used in 
this study. 
 
Mouse husbandry. Mice at 4-6 weeks of age were used in this study. The following mice were 
purchased from Jackson Laboratory: Bmi1CreERT/+ (Stock No: 010531)(Sangiorgi and Capecchi, 
2008), Lgr5EGFP-IRES-CreERT2/+ (Stock No: 008875)(Barker et al., 2007), Rosa26R/+ (Stock No: 
003474) (Soriano, 1999), and C57Bl6/J (Stock No: 000664). HopXCreERT/+ mice were kindly 
provided by Dr. Jonathan Epstien(Takeda et al., 2011). All LacZ tracing experiments were 
conducted with the Cre and LacZ alleles as heterozygous. All immunofluorescence and FACS 
experiments were conducted with the GFP allele as heterozygous. All experimental mice were 
housed singly on aspen bedding. Bmi1CreERT/+Rosa26R/+, Lgr5EGFP-IRES-CreERT2/+Rosa26R/+, and 
Lgr5EGFP-IRES-CreERT2/+Rosa26+/+ mice were on the C57Bl6/J background and were not injected 
with tamoxifen when used in non-lineage tracing experiments. The strain was kept consistent 
within each experiment.  
 
Etoposide treatment. Etoposide (NDC: 63323-104-50) dose was determined for each strain. 
Mice were allowed to feed ad libitium or were fasted for 24 h, which was followed by etoposide 
injection in the tail vein. The etoposide dose started at 100 mg/kg etoposide (i.v), and was 
lowered if needed. The final doses used in this study were: 100mg/kg for wildtype, 
Bmi1CreERT/+Rosa26R/+, and HopXCreERT/+Rosa26R/+; and 80mg/kg for Lgr5EGFP-IRES-
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CreERT2/+Rosa26R/+ and Lgr5EGFP-IRES-CreERT2/+. After etoposide injection, food was immediately 
returned to the cages of fasted mice, and wetted food pellets were placed at the bottom of all 
cages. Survival was monitored daily for 2 weeks post injection. Additionally, mice and food 
were weighed daily. 
 
LacZ Tracing. Tamoxifen (Sigma-Aldrich T5648) was sonicated until dissolved in sunflower 
seed oil (Sigma-Aldrich, S5007) at a final concentration of 10 mg/mL. Mice were pulsed at both 
1 and 3h post-etoposide injection with 1 mg tamoxifen per 20 g body weight. At 4 days post-
etoposide injection, small intestines were harvested and stained for LacZ expression using 
previously established protocols (Alien et al., 1988). In brief, the proximal 10 cm of the small 
intestine was flushed first with phosphate buffered saline (PBS; 137.0 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 2.0 mM KH2PO4, in MilliQ water with pH 7.4), next with with PBS 
containing 1.0% paraformaldhyde, 0.2% gluteraldehye and 0.02% NP-40 (LacZ fixative 
solution), and then cut longitudinally, pinned out on a black wax box, and fixed for 30 minutes at 
4°C in the LacZ fixative solution. After fixation, the small intestines were quickly rinsed with 
PBS and gently rocked overnight in PBS containing 4.0 mM K3Fe(CN)6, 4.0 mM K4Fe(CN)6, 40 
mM MgCl2, and 800 µg/mL 5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside (X-gal, 
Biosynth, B-7150). Stained intestines were rinsed with PBS, and fixed in 10% neutral buffered 
formalin overnight.  
 
Quantification of LacZ Whole Mounts. To increase the number of crypts that could be 
analyzed compared to a cross section, we analyzed whole mount LacZ stained samples. In order 
to see the crypts, villi were removed using curved forceps from a 1.5 cm section. Analyzed 
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regions were 3-5 cm from the proximal end of the small intestine. Since tracing was too frequent 
to be separated into single colonies at 5cm in Lgr5EGFP-IRES-CreERT2/+; R26R mice, analyzed 
regions were 8 cm from the proximal end. Pictures were taken using an Olympus SZX12 
microscope with Olympus DP70 camera at 90X magnification. 3-9 non-overlapping pictures 
were acquired per mouse.  
LacZ-stained, shaved, whole mount specimens were analyzed with a custom image 
segmentation algorithm using MatLab (The Mathworks R2013a, Natick Mass.). Images were 
converted from Red Green Blue (RGB) color space to the CIE L*a*b* (Lab) color space. This 
alternate image representation transforms the three RGB color coordinates to a separate three-
coordinate system, where L represents overall brightness and a and b represent color dimension. 
The Lab color space correlates to human perception of color and better represents differences in 
perceived color than RGB space. LacZ stained images were converted to Lab color space and 
each each pixel was classified as positive (LacZ) or negative (background) by comparison to 
example positive and negative Lab colors. A pixel was considered positive if the Euclidean 
distance in Lab color space to the nearest example positive value was shorter than the distance to 
the nearest example negative value. The example positive and negative colors in Lab space were 
empirically determined by a “user-in-the-loop” method using a training set of representative 
images spanning all of the samples. Using this method, a positive and a negative pixel were 
identified for each image in the training set. The cumulative list of positive and negative pixels 
was input into the image analysis program and applied to all of the training set images. 
Misclassified pixels were identified, selected and modified in the training set. This process was 
repeated until visually accurate. Using the trained program, all whole mount, LacZ stained 
images were processed to generate a binary image with positive and negative pixels. To separate 
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LacZ stained colonies that were incorrectly identified as a single colony, each colony was 
subjected to a watershed transformation of the L-channel. For each identified colony, the 
underlying L-channel data was extracted where low values of L correspond to the darkest blue 
regions. The watershed transform identifies dark blue regions that are separated by lighter 
regions. Therefore, improperly merged colonies are split apart and single colonies that have only 
one dark center remain unchanged. Regions of images that were poorly segmented after these 
steps were censored from the following analysis. 
To compare across conditions, image data were pooled within mice and averaged across 
mice for a given condition. The positive signal in the image data was examined using size 
distribution analysis methods commonly employed in the polymer and aerosol fields to examine 
the numbers, sizes, and quantities of molecules or particles created in a process. To examine the 
number of regions at different sizes, a region-number probability distribution was generated to 
show the relative probability of finding a region of a specific size. To examine differences in 
total numbers of regions rather than just their frequency, this distribution was scaled by number 
of regions per unit area analyzed. To summarize this distribution information for biological 
interpretation, the fraction of regions above and below the size of a standard crypt (measured at 
2200 pixels in our analyses) was computed.  
 
Immunohistochemistry and Immunofluorescence. Variations in fixation, antigen retrieval, 
blocking and diluents were optimized within each experiment and kept consistent throughout 
each experiment. Specific protocols are available upon request. Mouse small intestines and 
colons were isolated, first flushed with PBS, then flushed in either 10% neutral buffered formalin. 
Next the tissue was cut longitudinally, pinned flat in a wax box and kept in 10% neutral buffered 
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formalin either overnight or for 4h. Fixed tissue was embedded in ddH2O containing 2% agar 
and then paraffin embedded. Tissues were sectioned at a thickness of 5µm. Either Triology (Cell 
Marque) was used for deparrafinization, rehydration and antigen retrieval according to 
manufacturer’s protocol or xylene was used for deparrafinization, followed by rehydration 
through gradients of ethanol and antigen retrieval was performed by boiling in 10 mM sodium 
citrate (pH 6.0). If staining for BrdU incorporation, sections were incubated at 37°C with 5 
U/mL DNaseI (Sigma) in diluent (Dako). Sections were blocked using either PBS containing 3% 
bovine serum albumin with 0.1% Tween-20 or protein block (Dako). Following blocking, 
sections were incubated for 1h at room temperature or at 4°C overnight with primary antibody 
diluted in either PBS containing 3% bovine serum albumin with 0.1% Tween-20 or antibody 
diluent (Dako). Primary antibody concentrations were as follows: anti-GFP 1:500 or 1:5000 
(Abcam, ab13970), anti-BrdU 1:200 (Serotec, OBT0030G), anti-BrdU 1:200 (Abcam, ab1893), 
anti-phospho-Histone H2AX 1:500 (Cell Signaling, 9178), and anti-cleaved caspase 3 1:500 
(Cell Signaling, 9664 and 9661). Sections were washed an then incubated with secondary 
antibody for 30 minutes at room temperature, in the same antibody diluent used for the primary 
antibody. Secondary antibody were 1:400 for all of the following: Alexa-Fluor 488 donkey anti-
chicken (Jackson), alexa-fluor 594 donkey anti-rabbit (Jackson and Life Technologies), alexa-
fluor 647 goat anti-sheep (Life Technologies), alexa-fluor 594 goat anti-sheep (Life 
Technologies), alexa-fluor 647 donkey anti-rat (Life technologies or Jackson) and Envision+ 
HRP anti-rabbit (Dako). Sections for immunofluorescence were washed with PBS, 
counterstained with DAPI (1 µg/mL) in PBS, washed and coverslip mounted using either 
prolong gold antifade (Life Technologies) or fluorescent mounting media (Dako). Sections for 
immunohistochemistry were washed in PBS, incubated in freshly made diaminobenzidine 
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substrate (Invitrogen) for 5-20 minutes, rinsed in distilled water followed by PBS, and 
counterstained with hematoxylin. Fluorescent images were acquired using a Nikon Eclipse 90i 
microscope, with Nikon CFI Plan Fluor 20x/0.50 objective, Photometrics CoolSNAP HQ2 CCD 
camera, and NISElements Advanced Research software. 
To assess proliferation, mice were pulsed with BrdU (150mg/kg). The thymidine analog 
was allowed to incorporate for either 60 or 90 minutes. The timing was kept consistent within 
each experiment. 
 
Crypt Culture. Mice were fed or fasted and treated with etoposide as described above. Crypt 
isolation (Guo et al., 2009) and culture (Miyoshi et al., 2012; Miyoshi and Stappenbeck, 2013) 
followed previously published protocols. Specifically, at 24h after etoposide treatment, the small 
intestine was removed, flushed with PBS (Ca2+ and Mg2+ free, CellGro) containing 2 mM EDTA, 
and 4 cm of the small intestine (starting 5 cm from the stomach) was isolated. The small intestine 
sample was cut longitudinally and the Peyer’s patches and mesentery were removed. Each 
sample was placed on ice in PBS (Ca2+ and Mg2+ free) containing 2 mM EDTA while the 
remaining samples were collected. After collection of all samples, intestinal sections were 
incubated in PBS (Ca2+ and Mg2+ free) with 2 mM EDTA for 10 minutes then transferred to 
HBSS (Ca2+ and Mg2+ free, Life Technologies) with 2 mM EDTA. Sections were vortexed at 
1600 rpm in HBSS (Ca2+ and Mg2+ free) wit 2 mM EDTA for 5 minutes, changed to fresh HBSS 
(Ca2+ and Mg2+ free) with 2 mM EDTA, vortexed at 1600 rpm for 3 minutes, changed to fresh 
HBSS (Ca2+ and Mg2+ free) with 2 mM EDTA and vortex at 1600 rpm for a final 8 minutes. All 
vortexing was conducted at 4°C. Supernatant from the third vortex was filtered through 80µm 
filters (BD) and crypts were pelleted at 100 x g at 4°C. Crypts were resuspended in 
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ADMEM/F12 (D6421, Sigma Chemical Co) supplemented with 10% fetal bovine serum, 
10U/mL penniclin, 10ug/mL streptomycin and 2mM L-glutamine and centrifuged at 400 x g at 
4°C. Isolated crypts for plating were serially diluted 1:4 and the second and third dilution were 
centrifuged at 250xg and resuspended in 80 uL matrigel. Each crypt sample was plated in 4 wells 
of a 96-well plate (8.5 µL of sample), one well of a 24-well plate (15 µL of sample), and 2 
locations of a p100 (8.5 µL of sample). After solidification of matrigel at 37°C, 50% LWRN 
conditioned media was supplemented with both 10 uM Y27632 (Sigma Chemical Co) and 10 
mM SB431542 (EMD Chemicals) and supplemented media was added to each well. The number 
of crypts plated for each condition was quantified from two-8.5-uL matrigel/crypt aliquots that 
were fixed with ice-cold methanol. The number of spheroids formed in each well of the 96-well 
plate was quantified 2 days post-plating. All counts were completed blind to the treatment 
condition. Media was changed every two days. On the third day, samples were trypsizinzed and 
passaged to a new 96-well plate. Representative images were taken using an Nikon TS100 
Microscope with a QiClick (QImaging) camera.  
 
Laser Capture Microdissection. Intestines were harvested 3h post-etoposide or saline injection, 
flushed with PBS, and flushed with ice-cold methacarn (60% methanol, 30% Chloroform, 10% 
Acetic Acid) to fix the tissue while preserving RNA integrity. Fixed intestines were rinsed with 
70% ethanol, embedded in 2% agar followed by paraffin embedding. Sections were 
deparrafinized and dehydrated through xylene and an increasing gradient of ethanol. Laser 
capture microdissection was performed using the Acturus PixCell IIe, with the following 
settings: Spot size Power 80, Duration 1 ms, Repeat 0.2 s, Target 0.150V, Current 1.82 mA. 
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RNA was isolated from the CapSure HS LCM Caps (Applied Biosystem) using the PicoPure 
RNA Isolation kit (Applied Biosytems). All RNA samples were treated with DNaseI (Qiagen).  
 
Microarray. Quality of RNA was analyzed using eukaryote Total RNA Nano chips (Agilent). 
Sample was amplified using WTA2 (Sigma), hybridized, and run on an Affimetrix 4x44 chips. 
Analysis was performed by the Jingsheng Yu, statistician at Washington University Genome 
Technoogy Access Center using Partek Geneomics Suite. Specifically, non-normalized linear 
data values retrieved by Partek Genomics Suite were normalized by IRON method (iterative rand 
order normalization), and then log2 transformed data were used in statistical analysis. 
Differential gene-lists were created with p<0.05 and FDR q<0.25. DAVID (Huang da et al., 
2009a, b) was used to generate KEGG and GO pathways. Due to the large number of genes, the 
first pass pathway analysis repetitively identified similar pathways. Therefore, an iterative 
approach was used where the genes that were not placed in a pathway were subsequently run 
through the program again. 
 
Neutrophil Depletion Studies. To deplete the microbiome, Lgr5EGFP-IRES-CreERT2/+ mice were 
treated with a 10-day course of broad-spectrum antibiotics or vehicle-control according to 
published protocols (Hill et al.). On the 10th day, mice were fed ad libitum or fasted for 24h. 
Then, both groups were injected with etoposide (80mg/kg, i.v) Beginning at 9 hr post-etoposide, 
mice were injected (i.p.) with 1 mg of either anti-Ly6G (1A8, BioXCell) or control-IgG2a (2AE 
BioXCell). Mice were treated with the antibodies every day. Peripheral blood was taken from the 
tail vein at 48h post-etoposide, but prior to α-Ly6G or α-IgG treatment. The DCM diagnostic 
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laboratory at Washington University in St Louis conducted quantification of blood. Small 
intestines were isolated 4 d post etoposide-treatment and embedded as described above
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Figures 
 
Figure 4.1. Fasting protects mice from lethal doses of etoposide through protection of the 
small intestine.  
Experiments were performed with male and female wild-type mice at 4-6 weeks of age. Mice 
were randomly assigned to 4 treatment groups (n = 6 per group unless stated otherwise). These 
included mice that were allowed to feed ad libutum (fed) and treated with either saline or 
etoposide, and mice that were deprived of food for 24 h (fasted), and treated with either saline or 
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etoposide. Etoposide was administered i.v. at a dose of 100 mg/kg on day one. Food was 
replenished in all cases immediately after treatment. (A) The experimental timeline is illustrated. 
(B) Survival was monitored daily for two weeks. (C) Individual mouse body weights were 
measured daily and were normalized to the starting weight. (D) Representative images of H & E 
stained jejenum harvested from mice on day 5 of the experiment. Scale bar is 200 µm. A 
representative crypt is shown in the inset for each treatment, scale bar is 25 µm. (E) The heights 
of 30 villi were measured for each day 5 sample and the average value per mouse is plotted. (F) 
The number of crypts per length (~ 20 mm) of small intestine was quantified in nine separate 
fields (at 4X magnification) for each sample harvested at day 5. The average number of crypts 
per mm is plotted. (G) The number of cells per crypt was determined for 45 crypts for each 
harvested at day 5. The average number of cells per crypt is plotted. n.s. is non-significant, * is 
p<0.05, *** is p<0.005 by Tukey post-test of a 1-way ANOVA. n=7 for fasted, saline-injected 
mice in panels E-G. 
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Figure 4.2. Influx of neutrophils in fed, etoposide-injected mice is partially responsible for 
intestinal damage.  
All experiments were performed with male and female Lgr5EGFP-IRES-CreER/+ mice at 4-6 weeks of 
age. (A) Small intestines were isolated at the indicated times post- treatment. Apoptotic bodies 
were counted in 50 small intestinal crypts for each sample (n=4 mice per group). The average 
number of apoptotic bodies determined in four individual mice per treatment group is plotted 
(p<0.001 by 2-way ANOVA comparing fed etoposide and fasted etoposide over time, and *** is 
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p<0.001 by Bonferoni post-test of 2-way ANOVA). (B) Representative images of day 3, H & E 
stained jejenum are shown Neutrophil influx was seen only in fed, etoposide-injected mice on 
day 3. Scale bar is 100 µm, 25 µm in magnified, blue arrows point to neutrophils (C-F) To 
determine the involvement of neutrophils, mice received daily injections of either neutrophil 
depleting α-Ly6G antibody or isotype α-IgG control. To counter the invasion and colonization of 
bacteria in neutrophil depleted, fed, etoposide-injected mice, mice were pretreated with a 10-day 
course of broad spectrum antibiotics and remained on the antibiotics throughout the experiment. 
(C) Timeline for antibiotic, neutrophil depletion experiment. (D) Individual mouse body weights 
were measured daily, normalized to the weight on day 0. *** is p<0.001, * is p<0.05 by Tukey 
post-test of repeated measures, 2-way ANOVA. (E) To confirm neutrophil depletion, blood 
smears were analyzed from peripheral blood isolated on day 3. The percentage of neutrophils in 
the blood is reported. (G) Small intestines were harvested on day 5. The number of proliferating 
crypts per cm was counted in 4 cm of each jenejum. A proliferating crypt was identified as full 
crypt with mitotic bodies and a hyperproliferative crypt. (F) Representative images of H & E 
stained jejenum harvested on Day 5 are shown. Scale bar is 200 µm, 50 µm in magnified, ABX 
is antibiotic treatment. For panel F, n=3 for H2O, Fed Etoposide, Ly6G and ABX, Fed Etoposide, 
IgG; n=2 for ABX, Fasted Etoposide Ly6G and ABX, Fed Etoposide, Ly6G . 
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Figure 4.3. Fasting protects both the CBC and +4 small intestinal stem cells from lethal 
doses of etoposide.  
(A) Timeline for panels B and C is shown. (B) Small intestinal crypts were isolated from 
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Bmi1CreER/+; R26R mice on day 2. Isolated crypts were plated in matrigel with 50% L-WRN 
conditioned media. Spheroid growth was quantified 2 days post-isolation and plating. The 
number of spheroids formed was normalized to the number of crypts originally plated, n=3 mice 
per group. * is p<0.05 by two-tailed, students t-test. (C) Representative pictures of spheroids at 2 
days post-plating, scale bar is 250 µm. (D) Timeline for data in panels E through G is shown. (E-
G) Tamoxifen-mediate linage tracing in Lgr5eGFP-IRES-CreER/+; R26R, Bmi1CreER/+; R26R, and 
HopXCreER/+; R26R mice demonstrated full-crypt lineage traced cells by day 5. Small intestines 
of indicated genotypes and treatments were harvested and the whole-mount tissue was stained 
for LacZ-expression, n=6 mice per group. (E) Representative images of nuclear fast red-stained 
cross sections of LacZ-stained jejenums are shown. Scale bar is 100 µm. (F) In order to increase 
the number of crypts we could quantify, villi were removed from a 2-cm section of the LacZ-
stained whole mount and 3-9 fields of view (90x) were taken per mouse. Representative images 
are shown. Scale bar is 100 µm. (G) Whole mount images were quantified using a custom image 
analysis program. Quantification of fully-traced crypts, as determined by the colony size, in the 
whole-mount images is plotted. * is p<0.05, ** is p<0.01, *** is p<0.001 by one-tailed, students 
t-test of arcsine transformed data. 
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Figure 4.4. Fasting alters the early response of Lgr5+ stem cells to etoposide.  
All experiments were performed with male and female, Lgr5EGFP-IRES-CreERT/+ mice at 4-6 weeks 
of age. Mice were randomly assigned to either a 24 h food deprivation (fasting) or ad libitum 
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feeding, followed by injection with etoposide (80 mg/kg, i.v) (n=4 per group unless otherwise 
noted). Immediately after etoposide injection, food was returned to the fasted mice. Mice were 
injected with 150 mg/kg BrdU (i.p) at 1 h prior to sacrifice. (A) Small intestines were harvested 
from mice at indicated time post etoposide-treatment. Apoptotic bodies were counted in 50 
crypts per mouse and the average of 4 mice is plotted. * is p <0.05 by two-tailed, students t-test. 
(B-H) Small intestines sections of indicated treatment and timepoint were stained with antibodies 
against GFP, and either BrdU, Cleaved Caspase 3 (CC3) or γH2AX and were counterstained 
with DAPI. To be identified as a GFP+ Lgr5+ cell, the crypt base had to be touching the lamina 
propia and only GFPhigh cells in the curved portion of the base were counted as positive. 200 
crypts were analyzed for each mouse. (B) The number of GFP+ cells was counted. (C) The 
percentage of Lgr5+ cells that were positive for BrdU incorporation was quantified, *** is 
p<0.001 by two-tailed, students t-test. (D) The percentage of Lgr5+ cells that co-stained with 
γH2AX was quantified and representative images are shown in (E,F). * is p<0.05 by two-tailed, 
students t-test of arcsine transformed data. (G) The percentage of Lgr5+ cells that co-stained 
with CC3 was quantified and representative images from 3 h post-etoposide are shown in (H). 
For all images, scale bar is 50 µm. In G, n=2 for both groups at 1.5 h, n=3 for both groups at 3 h 
and 6 h. 
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Supplemental Figures 
 
Figure S4.1. Overall architecture of large intestines similar in fed and fasted groups. 
Experiments were performed with male and female wild-type mice at 4-6 weeks of age. Mice 
were randomly assigned to 4 treatment groups. These included mice that were allowed to feed ad 
libutum (fed) and treated with either saline or etoposide, and mice that were deprived of food for 
24 h (fasted), and treated with either saline or etoposide. Etoposide was administered i.v. at a 
dose of 100 mg/kg on day 1. Food was replenished in each treatment group immediately after 
treatment. Transverse colons were harvested on day 5 post-treatment. Representative H & E 
stains of transverse colons are shown. Scale bar is 200 µm. 
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Figure S4.2. Number of cells per small intestinal crypt per animal on day 5 post-treatment. 
Experiments were performed with male and female wild-type mice at 4-6 weeks of age. 27 Mice 
were randomly assigned to 4 treatment groups. These included mice that were allowed to feed ad 
libutum (fed) and treated with either saline or etoposide, and mice that were deprived of food for 
24 h (fasted), and treated with either saline or etoposide. Etoposide was administered i.v. at a 
dose of 100 mg/kg on day 1. Food was replenished in each treatment group immediately after 
treatment. Small intestines were isolated at 5 days post-treatment and the number of cells present 
within a single cypt was counted. Dots represent the number of cells counted in a single crypt.  
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Figure S4.3. Neutrophil depletion results in bacteria colonization of intestinal epithelial 
cells in fed, etoposide-injected mice.  
Experiments were performed with male and female Lgr5GFP::CreER mice at 4-6 weeks of age. Mice 
were allowed to feed ad libutum (fed) or were deprived of food for 24 h (fasted) prior to 
etoposide treatment. Etoposide was administered i.v. at a dose of 80 mg/kg on day 1. Food was 
replenished in all cases immediately after treatment. Mice were then injected daily with 
neutrophil depleting α-Ly6G antibody or with isotype-matched α-IgG beginning at 9 h post 
etoposide-treatment. (A) Representative images of H & E stained sections of small intestine from 
mice of the indicated treatment group. Arrows indicate bacterial colonization. Scale bars are 400 
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µm (left panels) and 50 µm (right panels). (B) The presence of bacteria was confirmed by 
staining tissue sections with DAPI (blue) and using autofluorescence (green) to identify small 
intestinal epithelium. Scale bar is 50 µm.  
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Figure S4.4. Fed and fasted mice exhibit equivalent levels of crypt proliferation, DNA 
damage, and cell death two days post-etoposide.  
Experiments were performed with male and female wild-type mice at 4-6 weeks of age. Mice 
were randomly assigned to 4 treatment groups. These included mice that were allowed to feed ad 
libutum (fed) and treated with either saline or etoposide, and mice that were deprived of food for 
24 h (fasted), and treated with either saline or etoposide. Etoposide was administered i.v. at a 
dose of 100 mg/kg on day 1. Food was replenished in each treatment group immediately after 
treatment. Wild-type mice were injected with 150 mg/kg BrdU (i.p) 90 min prior to sacrifice. 
Small intestines were isolated on day 1 and day 2 post-treatment. (A) tissue collected on days 1 2 
were immunostained for BrdU incorporation and percentage of BrdU-positive cells per crypt was 
plotted. 30 crypts were counted per treatment group. (B) Day 2 samples were immunostained 
with antibodies against γH2AX and the percentage of γH2AX positive cells were counted in 10 
crypts per treatment group. (C) Day 2 samples were immunostained with antibodies against 
cleaved-caspase 3 (CC3) and the number of CC3-positive cells was counted in 100 crypts per 
treatment group.  
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Figure S4.5. Spheroids grown from small intestinal crypts of fasted, etoposide-treated mice 
can be successfully passaged.  
Small intestinal crypts were isolated from fed and fasted, etoposide- or saline-injected 
Bmi1CreER/+; R26R mice on day 2 post-treatment. Isolated crypts were plated in matrigel with 
50% L-WRN conditioned media (See Fig 4.3A, B). Spheroids cultures were trypsinized 3 d post-
initial plating and then cultured in fresh matrigel. Representative images of spheroid cultures at 
passage one, 2 d post-splitting are shown. Scale bar is 250 µm. 
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Figure S4.6. Fasting protects tamoxifen-inducible stem cell reporter mice from lethal doses 
of etoposide.  
Experiments were performed with male and female wild-type mice at 4-6 weeks of age. Mice 
were allowed to feed ad libitum or were fasted for 24 h. Mice were treated with indicated dose of 
etoposide on day 1. Food was replenished in each treatment group immediately following 
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treatment. (Left panels) Survival was monitored daily for two weeks. (Right panels) Individual 
mouse body weights were measured daily and normalized to the starting weight.  
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Figure S4.7. Flow chart for MatLab image processing program.  
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A flow chart is provided to explain the logic and display the processing of the images embedded 
within program, as well as subsequent image analysis for graphing. 
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Figure S4.8. Matlab code for image processing program. 
Code: Extract Images 
 
function path_list = extract_images(cur_dir,folder_regexp,imgtype) 
  
% EXTRACT_IMAGES extract images using specific subfolder criteria. 
%     EXTRACT_IMAGES searches a main directory specified by cur_dir 
%     through subfolders specified by folder_regexp for images 
specified at imgtype at the  
%     end of each sub_folder tree. it does not find images in 
intermediate subfolders but only searches for 
%     images at the end of the subfolder tree. 
%  
%     A recursive search is used where the path of an image is defined 
as the path of the current folder concatenated with the path of the 
nextsubfolder that might contain the image. 
%  
% Written by Andrew Loza 
% Updated 4/7/2014 
  
path_list = {}; 
  
if isempty(folder_regexp) 
    img_fname_list = dir(cur_dir); 
    img_fname_list = {img_fname_list(:).name}; 
    img_idxs = regexpi(img_fname_list,imgtype); 
    img_idxs = cellfun(@isempty,img_idxs); 
    img_fname_list(img_idxs) = ''; 
    
    img_path = 
repmat({[cur_dir,'/']},size(img_fname_list,1),size(img_fname_list,2)); 
    path_list = 
cellfun(@horzcat,img_path,img_fname_list,'UniformOutput',false); 
    path_list = reshape(path_list,numel(path_list),1); 
else 
  
    subfolders = dir(cur_dir); 
    subfolders_ic = regexpi({subfolders(:).name},folder_regexp{1}); 
    subfolders_ic = cellfun(@isempty,subfolders_ic); 
    subfolders(subfolders_ic) = ''; 
  
    for i = 1:length(subfolders)       
        path_list = 
vertcat(path_list,extract_images([cur_dir,'/',subfolders(i).name],folde
r_regexp(2:end),imgtype)); 
    end 
  
end 
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Code: Process Images 
 
% Batch Processing of LacZ Stained Images 
%  
% This script searches a user supplied directory for LacZ stained 
images 
% and runs the function detect_clusters_shapeversion on these images to 
% find and record regions of positive LacZ staining. The images must be 
% stored using a specific file structure detailed below (see FILEPATH 
% REQUIREMENTS). 
%  
% INPUTS (USER SUPPLIED VIA POP-UP DIALOG BOXES): 
%   Input Dialog Box (see step 1): 
%     Region Specifier - see FILEPATH REQUIREMENTS 
%     Size Threshold - minimum size of region 
%     Shape Factor Threshold - maximum non-circularity of regions  
%   Main Image Folder 
%   Training Set 
%   Save Locatios 
%  
% Outputs are organized by a "unique ID" generated from the folder ID 
and 
% the image ID. They are saved in the folder save_path specified by the 
% user. 
%  
% OUTPUTS: 
%   savepath/Data_Analysis.txt - text file containing analysis on all 
%       regions; organized by image ID. 
%   savepath/unique_ID_BW.png - BW image of identified regions (white) 
%   savepath/unique_ID_Label.png - pseudocolored version of BW image to 
%       show individual regions 
%  
% 
***********************************************************************
** 
% FILEPATH REQUIREMENTS 
% Search through the main folder using defined criteria to find images 
% /Volumes/Kelsey External HardDrive 1/Kelsey 
stereoscope/###/shaved/90x.2 (#,#,#)\Image###.jpg 
%  
% Variations: shaved is sometimes shave 
% image number is between 1-999, but 1 is not 001 
% occasionally we get a tif in there 
% There will be between 3-9 images within the "90x.2 (#,#,#) folder 
%  
% Main Folder Example:  
%       /Volumes/Kelsey External HardDrive 1/Kelsey stereoscope 
% First Subfolder (regular expression for "three numbers"): 
%       \d{3} 
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% Second Subfolder: 
%       shave 
% Third Subfolder (region specifier): 
%       90x.2  
% Image specifier: 
%       Image 
% 
***********************************************************************
** 
%  
%  
% Script designed and written by Andrew Loza and Kelsey Tinkum 
% Updated 4/7/2014 
  
clear all 
close all 
clc 
addpath functions 
  
%% Step 1: Get user inputs using pop-up window. These are for file-path 
% searching and cutoffs for image processing 
prompt = {'Region Specifier:','Size Threshold:','Shape Factor 
Threshold:'}; 
dlg_title = 'Input for image processing'; 
num_lines = 1; 
def = {'90x.3','3','2'}; 
answer = inputdlg(prompt,dlg_title,num_lines,def); 
reg_spec = answer{1}; 
size_cutoff = str2double(answer{2}); 
shape_fac = str2double(answer{3}); 
  
  
%% Step 2: Get the required directory information for (a) the images 
(b) the 
% training set (c) the save location 
  
% (a) get main image folder 
img_main_path = uigetdir(cd,'Select Main Image Folder'); 
% (b) get training set to use 
[train_name train_path] = uigetfile(img_main_path,'Select Training 
Set'); 
% (c) set the save location 
save_path = uigetdir(img_main_path,'Select Save Location'); 
  
% run the training set to get the variables samplePositivePixel and  
% sampleNegativePixel in the workspace 
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run([train_path,train_name]) 
  
img_path_filter = {'\d{3}','shave','90x.3'}; 
img_file_filter = 'image'; 
  
% Find all the images on the path using FILEPATH REQUIREMENTS 
img_pathlist = 
extract_images(img_main_path,img_path_filter,img_file_filter); 
  
%% Step 3: Main processing loop 
  
% First initialize data storage variables 
num_imgs = size(img_pathlist,1); 
total_areas = zeros(num_imgs,1); 
raw_areas = cell(num_imgs,1); 
id_list = raw_areas; 
tic 
h = waitbar(0,'Processing Images...'); 
% Cycle through all the images 
for i = 1:num_imgs 
    % extract the folder and image name. these are the unique ID of the 
    % specific image. 
    fname = img_pathlist{i}; 
    [m folder_ID] = 
regexp(fname,[img_main_path,'/(\d{3})'],'match','tokens'); 
    folder_ID = folder_ID{1}; 
    [m img_ID] = regexp(fname,'mage(\d+)','match','tokens'); 
    img_ID = img_ID{1}; 
    unique_ID = ['ID_',folder_ID{:},'_',img_ID{:}]; 
     
    % the heart of the script is calling this function to do the image 
    % segmentation 
    [a_l t_a BW L_rgb] = 
detect_clusters_shapeversion(fname,size_cutoff,shape_fac,samplePositive
Pixel,sampleNegativePixel,0.15); 
     
    % collect the results of this single segmentation for later 
    total_areas(i) = t_a; 
    raw_areas(i) = {a_l}; 
    id_list(i) = {unique_ID}; 
     
    % write the "analyzed images" as we go using the unique ID 
    imwrite(BW,[save_path,'/',unique_ID,'_BW.png']) 
    imwrite(L_rgb,[save_path,'/',unique_ID,'_Label.png']) 
    waitbar(i/num_imgs); 
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end 
close(h); 
toc 
  
%% Step 4: Save Data 
% Generate Output File 
fid = fopen([save_path,'/Data_Analysis.txt'],'w'); 
  
% Print out header data 
fprintf(fid,['Analysis Performed on:\t',date,'\n\n']); 
fprintf(fid,'Parameters used:\n'); 
fprintf(fid,'Size Cutoff:\t%d\n',size_cutoff); 
fprintf(fid,'Filtering specs:\t%s\t%s\t%s\n',img_path_filter{:}); 
fprintf(fid,'Shape Factor:\t%d\n\n',shape_fac); 
  
  
% Print out region analysis data 
col_names = {'Image ID','Total Analytical Area', 'Region Areas'}; 
col_spec = '%s\t%s\t%s\n'; 
fprintf(fid,col_spec,col_names{:}); 
for i = 1:num_imgs 
    areas = raw_areas{i}; 
    num_regions = length(areas); 
    col_spec = ['%s\t%f\t',repmat('%f\t',1,num_regions),'\n']; 
    fprintf(fid,col_spec,id_list{i},total_areas(i),areas(:)); 
end 
fclose(fid); 
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Code: Detect Clusters 
 
function [Areas tot_img_a BW L_rgb] = 
detect_clusters_shapeversion(image_fname,size_cutoff,shape_fac,samplePo
sitivePixel,sampleNegativePixel,lab_cut) 
  
% DETECT_CLUSTERS_SHAPEVERSION segments a color image into "positive" 
and 
% negative" regions. 
%  
% This function segments an RGB image specified by the file name 
% IMAGE_FNAME.  This is done by performing LAB Color space pixel 
% classification and watershed algorithm based region refining. 
  
% PART 1, PIXEL CLASSIFICATION: The RGB image is first converted to LAB 
% color space. Distance between these image pixels and user supplied 
% example positive colors (samplePositivePixel) and negative colors 
% (sampleNegativePixel) is then computed.  Image pixels are classified 
as 
% positive if the distance to the nearest positive training color is 
% smaller than the distance to the nearest negative training color. 
They 
% are otherwise classified as negative. 
%  
% PART 2: REGION REFINING: The positive regions created by classifiying 
% pixels refined by morphological opening (erosion followed by 
dilation) 
% and a size threshold to remove small objects. It is often the case 
that 
% two regions are close enough to be detected as a single region by 
pixel 
% classification.  To overcome this, watershed segmentation of the 
positive 
% regions is performed (note - not the whole image). Using the L-
channel to 
% define catchment basins (darkest staining corresponds to center of 
the 
% regions), merged regions are split into their individual components. 
%  
% INPUTS 
%     image_fname - filename of the RGB image 
%     size_cutoff - cutoff for minimum region size 
%     shape_fac - cutoff for circularity 
%     samplePositivePixel - positive examples in LAB space 
%     sampleNegativePixel - negative examples in LAB space 
%     lab_cut - local minima suppression threshold 
%      
% OUTPUTS 
%     Areas - areas of each identified region 
%     tot_img_a - total usable area in image 
%     BW - BW image of segmentation 
%     L_rgb - pseudocolored version of BW to highlight segmentation  
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%  
% Based on an initial function written by Robert Pless 
% Revised and expanded by Andrew Loza 
% Updated 4/7/2014 
  
% read in the image and convert to LAB space 
im = imread(image_fname);           
LabImage = RGB2Lab(im);       
imSize = size(im);            
  
% convert image to a number of pixels by 3 array 
imVec = reshape(LabImage, [], 3);    
nP = size(imVec,1);  % nP == Number of Pixels. 
  
% next 7 lines try to find the minimum difference between a pixel and 
all 
% the positive examples.  First, we initialize our positive distance to 
% something large: 
posDistance = 0.*imVec(:,1) + 100000; % initialize distance to positive 
  
% then we loop through each positive example and take the minimum of 
the 
% distance to that positive example, and the min distance we've seen so 
far 
for ix = 1:size(samplePositivePixel,1);  % loop through all sample 
positive pixels 
    % get the color of the "ix"-th positive pixel. 
    posPixelLabColor = samplePositivePixel(ix,:);  
     
    % replicate it to be the same size as all the pixels so we can 
subtract. 
    replicatedPosPixel = repmat(posPixelLabColor,nP,1);   
     
    % distance == sqrt( sum of the squared differences ). 
    distToThisPixel = sqrt(sum( (replicatedPosPixel-imVec).^2, 2));  
  
    % update our distance where this is better than before. 
    posDistance = min(posDistance, distToThisPixel); 
end 
  
% now, let's do the negative distances 
negDistance = 0.*imVec(:,1) + 100000; % initialize distance to positive 
  
for ix = 1:size(sampleNegativePixel,1);  % loop through all sample 
positive pixels 
    negPixel = sampleNegativePixel(ix,:); 
    replicatedNegPixel = repmat(negPixel,nP,1); 
    distToThisPixel = sqrt(sum( (replicatedNegPixel-imVec).^2, 2)); 
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    negDistance = min(negDistance, distToThisPixel); 
end 
  
% classify each pixel by which is closer. Note that closer to negative 
= 1 
% so positive pixels have a value of zero. 
classifications = negDistance < posDistance; 
  
% Create the initial BW output image. This will be modified before 
being 
% returned 
BW = reshape(classifications, imSize(1), imSize(2)); 
  
% Simple Region Identification 
  
% Convert image back into 1=positive regions and 0=false 
BW = ~BW; 
  
% Morphological opening to remove small features and noise 
BW_ed = bwmorph(BW,'erode'); 
BW_ed = bwmorph(BW_ed,'dilate'); 
  
% impose minimum size cutoff 
BW_szth = bwareaopen(BW_ed,size_cutoff); 
BW = BW_szth; 
  
% Extract Lchannel for the positive regions.  
L_channel = LabImage(:,:,1); 
L_channel(~BW) = NaN; 
L_channel = 1-mat2gray(L_channel); 
% suppress local minima to avoid oversegmentation. then watershed 
transform 
rm = imhmin(1-L_channel,lab_cut); 
rm1 = watershed(rm); 
  
% set the regions in the initial BW image where watershed ridgelines 
occur 
% to zero. 
BW2 = BW; 
BW2(rm1==0) = 0; 
tot_img_a_raw = numel(BW2); 
  
  
% Throw out regions that are not circular enough 
L_pre = bwlabeln(BW2); 
rp = regionprops(L_pre,'Area','Perimeter','Eccentricity'); 
Areas = cat(1,rp(:).Area); 
Perims = cat(1,rp(:).Perimeter); 
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EqCPerims = sqrt(Areas./pi).*(pi*2); 
ShapeFac = Perims./EqCPerims; 
for_del = find(ShapeFac>shape_fac); 
if ~isempty(for_del) 
    a_del = sum(Areas(for_del)); 
    L_post = L_pre; 
    L_post(ismember(L_post,for_del)) = 0; 
else 
    a_del = 0; 
    L_post = L_pre; 
end 
  
%  Create the final BW image, calculate the areas, and make the 
%  pseudo-colored image 
BW = L_post; 
BW(BW>0) = 1; 
L_post = bwlabeln(BW); 
rp = regionprops(L_post,'Area'); 
Areas = cat(1,rp(:).Area); 
  
L_rgb = label2rgb(L_post,'jet','k','shuffle'); 
tot_img_a = tot_img_a_raw-a_del; 
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Code: Analyze Image Data 
 
% Region Size Analysis: Analyze Treatments by Stem Cell Line and 
Harvest 
  
% This script runs through a data set that fits the DATA FORMAT 
specified 
% below to analyze the data for different treatments applied to the 
same 
% Stem Cell Line (SCL) and Tam/Harvest (TH). 
  
% For each SCL/TH combination, mice are stratified by treatment. Region 
% number and region area distributions are computed: 
%  
%   REGION NUMBER: a region number distribution describes how many (or 
what 
%   fraction of) regions are at or below a certain size. It is a type 
of 
%   cumulative/empirical distribution function. 
%  
%   REGION AREA: a region area distribution describes how much positive 
%   area (or what fraction of total positive area) is contributed by 
%   regions at or below a certain size. It is a type of 
%   cumulative/empirical distribution function. 
%  
% Each mouse contributes equally to the treatment-specific 
distributions 
% regardless of number of images for that mouse (accomplished by 
% normalizing) 
%  
% 
***********************************************************************
** 
% DATA FORMAT  
% Load in the data for Processing. 
% Data should be in a .csv file or tab delimited text with the 
following 
% format. 
%  
% Column1             Column2         Column3     Column4      Column 5               
Column 6-end  
% Stem Cell Line      Tam/Harvest     Treatment   MID_IID      Total 
Analytical Area  Region areas 
%  
% 
***********************************************************************
** 
%  
% INPUTS: 
%   User specified data file that fits DATA FORMAT 
%   Crypt size threshold 
%  
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% OUTPUTS: 
%   Text file for each SCL and Tam/Harvest combination.  Has columns: 
%      'SCL','TH','TRT','MouseID','Regions Larger','Regions 
Smaller','Area Larger','Area Smaller','Total Area Analyzed' 
%   Figure showing signal per analyzed area per mouse as a function of 
region size  
% 
% 
% Written by Andrew Loza 
% Updated 4/8/2014 
  
clear all 
close all 
addpath Functions 
  
% input the data.  Text data in a 4xn cell array where n=num mice 
[fname fpath] = uigetfile('*.*','Select Data file'); 
importfile([fpath,fname]); 
save_path = uigetdir(fpath,'Select Results Folder'); 
  
prompt = {'Crypt Size Threshold:'}; 
dlg_title = 'Input for region analysis'; 
num_lines = 1; 
def = {'1000'}; 
answer = inputdlg(prompt,dlg_title,num_lines,def); 
  
reg_th = str2double(answer{1}); 
  
% Figure out the identity of all of the images: which stem cell line, 
which 
% tam/harvest, which treatment, which mouse, which image. 
% Use this to give each image a unique identifying code 
% (SCL,TH,TRT,MID,IID) 
textdata(1,:) = ''; 
textdata = strtrim(textdata); %remove leading/trailing whitespace 
SCL = textdata(:,1); 
TH = textdata(:,2); 
TRT = textdata(:,3); 
[SCL_IDs SCL_key] = list2IDs(SCL); 
[TH_IDs TH_key] = list2IDs(TH); 
[TRT_IDs TRT_key] = list2IDs(TRT); 
num_SCL = length(SCL_key); 
num_TH = length(TH_key); 
num_TRT = length(TRT_key); 
  
% Now Process the ID field 
[m t] = regexpi(textdata(:,4),'.+(\d{3}).(\d+)','match','tokens'); 
MID = cell(length(t),1); 
IID = cell(length(t),1); 
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for i = 1:length(t) 
    MID(i) = t{i}{:}(1); 
end 
[MID_IDs MID_key] = list2IDs(MID); 
  
num_MID = length(MID_key); 
% Process the numerical data 
numobs = length(SCL); 
data_cell = cell(numobs,1); 
an_area = data_cell; 
for i = 1:numobs 
    temp_dat = data(i,:); 
    temp_dat(isnan(temp_dat)) = ''; 
    data_cell(i) = {temp_dat(2:end)}; 
    an_area(i) = {temp_dat(1)}; 
end 
  
% Counter for figures produced 
fignum = 1; 
  
% Set up some plotting specific things. 
treat_colors = 0.8.*[1 0 0;0 0 1;0 1 0;0 0 0;0 1 1;1 0 1]; 
mouse_colors = treat_colors; 
mouse_colors(mouse_colors==0) = 0.5; 
  
  
% Outer 2 for loops to cycle through the stem cell lines and 
Tam/Harvest 
% Inner 2 loops cycle through the treatments and mice 
  
% Cycle through all Stem Cell Lines that are present 
for i = 1:num_SCL 
    % Cycle through all Tam/Harvests that are present 
    for j = 1:num_TH 
         
        % Prepare to cycle through treatments by seting up data output 
        % files and figure for display. 
        fid_crypt_data = 
fopen([save_path,'/Crypt_Threshold_Data_',SCL_key{i},'_',TH_key{j},'.tx
t'],'w'); 
        
fprintf(fid_crypt_data,'%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\n','SCL','TH
','TRT','MouseID','Regions Larger','Regions Smaller','Area 
Larger','Area Smaller','Total Area Analyzed'); 
        figh(fignum) = figure(fignum); 
        set(gcf,'Name','Signal Density Per Area 
Analyzed','Units','Normalized','Position',[0.33 0.5 0.31 0.4]); 
        trt_legend = cell(''); 
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        % cycle through the treatments 
        for k = 1:num_TRT       
             
            % Find the images with the current SCL, TH, TRT combo 
            % If there are any, proceed to analyze them. If not, skip 
to 
            % next. 
            sel_idx = SCL_IDs==i&TH_IDs==j&TRT_IDs==k; 
            if any(sel_idx) 
                trt_legend = horzcat(trt_legend,TRT_key{k}); 
                temp_data = data_cell(sel_idx); 
                temp_an_area = an_area(sel_idx);       
  
                % To find distributions for this treatment, we need to 
go mouse 
                % by mouse and combine the data weighted by total 
analyzed area 
                % for that mouse instead of just pooling all data from 
the 
                % whole treatment 
                 
                % Figure out which mice fit the current treat/tam/SCL 
combo 
                sel_mice_ID = MID_IDs(sel_idx); 
                sel_mice_name = MID_key(sel_mice_ID); 
                [smID_new smkey_new] = list2IDs(sel_mice_name); 
                num_m = length(smkey_new); 
                 
                % prepare variables 
                tot_pos_m = cell(num_m,1); % collection of total 
positive signal  
                regions_m = cell(num_m,1); % list of pooled regions for 
a single mouse 
                numreg_m = zeros(num_m,1); % how many regions per mouse 
                numim_m = zeros(num_m,1); % how many images per mouse 
                an_area_m = cell(num_m,1); % area that contributed to 
the analysis for a mouse 
                CSPIedf = cell(num_m,1); % empirical distribution 
function for "Cumulative Signal Per Image" 
                CFSedf = cell(num_m,1); % empirical distribution 
function for "Cumulative Fractional Signal" 
                 
                % Cycle through the mice  
                for p = 1:num_m 
                     
                    % determine quantities for the specific mouse in 
                    % question 
                    cm = smID_new==p; 
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                    num_im_cm = sum(cm); % figure out how many images 
for each mouse 
                    regions_cm = horzcat(temp_data{cm}); %pool all the 
regions for this mouse 
                    tot_pos_cm = sum(regions_cm); % figure out the 
total positive signal for this mouse 
                    num_reg_cm = numel(regions_cm); %figure out how 
many regions there are 
                    an_area_cm = horzcat(temp_an_area{cm}); %pool all 
analysis areas for this mouse               
                     
                    % determine quantities for regions above and below 
a 
                    % threshold (crypt size) 
                    reg_above_th_cm = sum(regions_cm>=reg_th); 
                    area_above_th_cm = 
sum(regions_cm(regions_cm>=reg_th)); 
                    reg_below_th_cm = sum(regions_cm<reg_th); 
                    area_below_th_cm = 
sum(regions_cm(regions_cm<reg_th)); 
                    tot_an_area_cm = sum(an_area_cm);             
                     
                    % print the mouse data 
                    col_spec = '%s\t%s\t%s\t%s\t%d\t%d\t%f\t%f\t%f\n'; 
                    
fprintf(fid_crypt_data,col_spec,SCL_key{i},TH_key{j},TRT_key{k},smkey_n
ew{p},reg_above_th_cm,reg_below_th_cm,area_above_th_cm,area_below_th_cm
,tot_an_area_cm); 
                     
                    % add this mouse data to the overall record 
                    CSPIedf(p) = {regions_cm./tot_an_area_cm./num_m}; 
                    CFSedf(p) = 
{regions_cm./tot_an_area_cm./num_m./sum(tot_pos_cm)}; 
                    tot_pos_m(p) = {tot_pos_cm}; 
                    regions_m(p) = {regions_cm}; 
                    numreg_m(p) = num_reg_cm; 
                    numim_m(p) = num_im_cm; 
                    an_area_m(p) = {an_area_cm};  
  
  
                end 
  
                % 1) Calculate the "Cumulative Signal per analysis area 
per 
                %    mouse" EDF. This is how much signal is found at or 
                %    below a certain region size. 
                %       X: sorted region sizes 
                %       Y: weighted cumulative signal = 
regsize/numimg*1/nummice 
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                CSPIedf_x = horzcat(regions_m{:}); 
                [CSPIedf_x sortIDX] = sort(CSPIedf_x); 
                CSPIedf_y = horzcat(CSPIedf{:}); 
                CSPIedf_y = CSPIedf_y(sortIDX); 
                CSPIedf_y = cumsum(CSPIedf_y); 
                 
                % 2) Calculate the "Cumulative Frac total signal per 
                % analysis area per mouse" EDF. This is the fraction of 
                % signal found at or below a certain region size. 
                %       X: sorted region sizes 
                %       Y: weighted frac signal = 
regsize/totposformouse*1/nummice 
                CFSedf_x = horzcat(regions_m{:}); 
                [CFSedf_x sortIDX] = sort(CFSedf_x); 
                CFSedf_y = horzcat(CFSedf{:}); 
                CFSedf_y = CFSedf_y(sortIDX); 
                CFSedf_y = cumsum(CFSedf_y); 
  
                % 7) Fractional Signal PDF. Convert the EDF to a PDF 
using 
                %    kernal density smoothing. 
                if ~isempty(CFSedf_x) 
                    CFS_weights = [CFSedf_y(1),diff(CFSedf_y)]; 
                    CFSpdf_x = 
linspace(0.5*min(log(CFSedf_x)),max(log(CFSedf_x))*1.1,500); 
                    CFSpdf_y = 
ksdensity(log(CFSedf_x),CFSpdf_x,'weights',CFS_weights,'function','pdf'
,'width',0.25); 
                    CFScdf_x = CFSpdf_x; 
                end 
       
                % Plot the PDF, but normalize it to total signal amount. 
                if ~isempty(CFSedf_x) 
                    figure(fignum) 
                    hold on 
                    ph1(k) = 
plot(exp(CFSpdf_x),CFSpdf_y.*CSPIedf_y(end),'Color',treat_colors(k,:),'
LineWidth',2); 
                    set(gca,'XScale','log','Xlim',[1 10^5]) 
                    hold off 
                     
                end 
             
            % what to do if nothing matches the current combo 
            else 
                display(['No Mice with SCL/TamHvst/TRT combination: 
',SCL_key{i},' ',TH_key{j},' ',TRT_key{k}]) 
            end 
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        end 
         
        % print the figure 
        figure(fignum) 
        ph1 = ph1(ph1~=0); 
        set(gca,'FontSize',16,'FontWeight','bold','LineWidth',2) 
        print('-depsc2','-
loose',[save_path,'/SignalDensity_SizeDist_',SCL_key{i},'_',TH_key{j},'
_nolegend']) 
        legend(ph1,trt_legend,'Location','NorthWest') 
        print('-depsc2','-
loose',[save_path,'/SignalDensity_SizeDist_',SCL_key{i},'_',TH_key{j}]) 
        fclose('all'); 
        fignum = fignum+1; 
         
    end 
end 
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Figure S4.9. Both CBC and +4 stem cells give rise to villus epithelial cells in fasted, 
etoposide-injected mice.  
Lgr5GFP::CreER/+; R26R, Bmi1CreER/+; R26R, and HopXCreER/+; R26R mice were fasted for 24 h. 
Etoposide was administered i.v. at doses indicated in Fig. S6. Mice then received I.P. injections 
of tamoxifen 1 and 3 h post etoposide-treatment. Mice were sacrificed on day 8 post etoposide-
treatment, small intestines were isolated and whole-mount tissue was stained for LacZ-
expression. Scale bar is 500 µm. 
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Figure S4.10 Fasting protects Lgr5GFP::CreER/+ mice from lethal doses of etoposide. 
Experiments were performed with male and female wild-type mice at 4-6 weeks of age. Mice 
were allowed to feed ad libitum or were fasted for 24 h. Mice were treated with 80 mg/kg 
etoposide on day 1. Food was replenished in each treatment group immediately following 
treatment. (A) Survival was monitored daily for two weeks. (B) Individual mouse body weights 
were determined and normalized to starting weight 
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CHAPTER 5 
Summary and Future Directions 
 161 
Summary 
 The initial purpose of my dissertation was to determine novel regulation of p21. Our 
interest in p21 was two-fold. First, p21 is a major transcriptional target of p53 in response to 
DNA damage. Second, both in vitro and in vivo studies have shown that p21 is upregulated in a 
variety of stress responses; however, little is known about the in vivo regulation of p21 during 
stress responses. Therefore, our lab generated two knock-in reporter mice that enabled real-time, 
noninvasive imaging of p21 expression. I found that p53 inhibits a previously identified p53-
independent, ERK-mediated upregulation of the p21 promoter during cell cycle re-entry. Using a 
whole-body reporter mouse, I identified that p21 was expressed in all organs. I further 
investigated the p21 signal in the brain and found that p21 is expressed at baseline in the 
metabolic-regulating regions of the hypothalamus and that this expression increases upon food 
deprivation (fasting). Fasting also increased p21 in the liver and pancreas, independent of p53. I 
found that FOXO1 was bound to the p21 promoter and that it was also necessary for liver-
specific upregulation of p21 during fasting. Given that p21 is upregulated during both DNA 
damage and fasting, I hypothesized that p21 was involved in fasting-mediated protection from 
lethal doses of DNA damage (Raffaghello et al., 2008). Through the use of p21 knockout mice, I 
determined that while p21 was not required for this protection, the main site of fasting-mediated 
protection from lethal doses of etoposide was the small intestine. This protection is mediated 
through protection of both the +4 and crypt base columnar (CBC) intestinal stem cells. The exact 
mechanism of the protection is still unclear; however, it likely involves an increased DNA 
damage repair and inhibition of infiltrating neutrophils. 
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Results and Future Directions 
Generation of two knock-in Luciferase reporter mice to monitor p21 expression. 
We generated and characterized two knock-in p21 Luciferase reporter mice that enable 
non-invasive, real-time monitoring of endogenous p21 promoter activity, both spatially and 
temporally, in the context of living mice and in cells derived from these mice. The first mouse 
expressed FLuc under control of p21 promoter in the whole mouse. The second mouse 
conditionally expressed CBRLuc under the control of the p21 promoter, whereby Cre-mediated 
excision was required to allow expression of Luciferase. I found that both mice accurately 
reported p21 expression. 
Using the whole-body reporter mouse, I determined p21 is expressed in every organ. 
Furthermore, due to the sensitivity of bioluminescence, I was able to find p21 expression in 
regions of the brain critical for maintaining metabolic homeostasis of the mice. 
These mice will be of great use to the p21 field and the possible future directions are vast. 
To date, we have sent the mice to three different groups who will use them to study the role of 
p21 in autism, heart defects, neural tube defects, and skin regeneration. We have also provided 
the mice to Jackson labs to increase their availability. 
 
Fasting increases p21 expression 
Since I found p21 expression in regions of the brain that are responsible for controlling 
organismal metabolism, I tested if food deprivation (fasting) could alter the expression of p21 
throughout the mouse. Intriguingly, fasting induced significant increases in p21 expression in 
post-mitotic cells of the brain and liver. Enhanced p21 expression following fasting was also 
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measured in other relatively quiescent organs including pancreas, lung, salivary gland, heart and 
kidney.  
The question remains whether p21 induction provides cells with a survival advantage 
under conditions of low nutrient availability. Loss of p21 protein did not impact levels of blood 
glucose, free fatty acids, triglycerides and cholesterol or liver glycogen at either baseline or after 
fasting. Thus, p21 has no apparent intrinsic role in metabolic regulation. However, other family 
members (p27, p57) may compensate for loss of p21 function under these conditions. Additional 
studies will be required to fully decipher the contributions of p21 protein under conditions of 
metabolic stress. These studies could be addressed in two ways. First, generation of a p21, p27 
and p57 triple knockout mouse will enable us to better understand the role of p21 and its family 
members in metabolic regulation. Second, a conditional p21 knockout mouse could be developed. 
This conditional knockout could be crossed to a tamoxifen-inducible Cre; thereby, allowing the 
mouse to develop normally with functional p21 and only removing p21 prior to testing. 
Alternative approaches include using lentiviral delivery of shRNA targeting p21 to the 
hypothalamus by intracranial injection (Satoh et al., 2013) or to the liver by tail-vein injection.  
 
ERK-mediated expression of p21 for cell cycle re-entry is inhibited by p53 
p21 expression is increased in response to serum stimulation through the ERK/MAPK 
pathway. This leads to assembly of Cyclin D/CDK4 complexes in order to promote cell cycle 
progression (Bottazzi et al., 1999; Cheng et al., 1999; LaBaer et al., 1997; Liu et al., 1996; 
Macleod et al., 1995). We observed activation of p21 expression and increases in p21 protein 
when quiescent MEFs were stimulated by serum, but only in Trp53 null cells. The addition of 
serum to early passage quiescent Trp53 wild-type MEFs induced MEK activation as evidenced 
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by increases in ERK phosphorylation but the p21 promoter was not activated. Thus, p53 appears 
to block quiescent wild-type MEFs from activating p21 expression upon serum stimulation at a 
point downstream of ERK/MAPK activation.  
To date, it is unknown which transcription factor is responsible for increasing p21 
expression under cell cycle re-entry. To test this, I would identify all transcription factors 
downstream of MEK that have binding sites on the p21 promoter. Then, I would infect the p53-
null, p21FLuc/+ MEFs with lentivirus producing shRNA against each transcription factor and 
determine which transcription factors are required for p21 expression during serum stimulation. 
Subsequently, I would use ChIP to test if the identified transcription factor was directly binding 
to the p21 promoter. Furthermore, these data suggest that future in vitro studies to identify p53-
independent activation of p21 must be completed in either p53-null cells or use genetically 
modified cells harboring mutations of the p53 binding sites on the p21 promoter. 
 
Fasting protects mice from lethal doses of etoposide by protecting the small intestinal stem 
cells 
In order to better understand how fasting protects mice from lethal doses of etoposide, I 
set out to first determine the organ within the mouse that was being protected by fasting and then 
determine how that organ was protected. I demonstrated that fasting protects the small intestine 
from lethal doses of etoposide. I found that fasting alters the DNA damage response in the 
intestinal stem cells and alters the immune response to high-dose etoposide.  
As part of the lineage tracing experiments, I collaborated with two computer scientists to 
generate a program to analyze whole mount, lineage-traced small intestines. In doing so, I was 
able to increase the number of crypts I could analyze by over twenty-fold.  
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Using knock-in mice for inducible lineage tracing, I tested if fasting protected both the 
CBC and +4 stem cells from etoposide-mediated DNA damage and found that fasting protected 
both stem cells equally. However, it was clear that not every stem cell of each type was protected 
as I saw a substantial reduction in the frequency of fully traced crypts compared to the saline-
injected controls. Therefore, fasting may activate a protective response in a subset of CBC and 
+4 stem cells. 
In order to understand the mechanisms underlying fasting-mediated protection from DNA 
damage, I took two complementary approaches which are discussed in next three sections. First, 
I performed a microarray to provide an unbiased examination of all cellular pathways involved. 
Second, I asked if there were differences in the levels of DNA damage and subsequent cellular 
response to DNA damage. Finally, I tested if there was a difference in the immune response.  
 
Microarray analysis revealed many pathways are differentially expressed in fed and fasted 
mice post-etoposide. 
We conducted a microarray of RNA isolated from the lower crypt at 3 h post-etoposide. 
Due to the sheer size and complexity of the microarray results, a complete analysis is unavailable 
at this time. However, I have completed a first pass of KEGG pathway and GO term analysis. 
Unsurprisingly, pathway analysis showed a large number of metabolic pathways were 
upregulated in the fasted, etoposide-injected mice compared to fed, etoposide-injected. What was 
striking was that the large majority of pathways altered have to do with some form of cellular 
metabolism. It is unclear, though possible, if these pathways are drivers in the protection of the 
stem cells. Furthermore, every stem cell is not protected from damage and therefore, the 
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microarray data from the fasted, etoposide-injected samples contains the profiles of both 
protected and unprotected cells.  
There have been great advances in single-cell gene analysis and single cell analysis of the 
top hits would be extremely useful. This would require careful statistical consultation before a 
robust plan could be made as it is unclear to me the number of cells that would be needed as well 
as the number of mice in each treatment. However, I propose that this analysis would find one 
signature in the CBC cells isolated from fed, etoposide-injected mice but two signatures in those 
isolated from fasted, etoposide-injected mice. Of the two fasted, etoposide-injected signatures, 
one would be identical to the signature of the fed, etoposide cells (i.e. a death or dying signature) 
and the remaining would be the signature of the protected cells 
 
DNA damage may be resolved more quickly in fasted, etoposide-injected mice 
 As both the CBC and +4 stem cells were protected, I focused on CBC stem cells to test if 
either the DNA damage or the DNA damage response pathways was altered in these cells upon 
fasting and eptoposide treatment. I found that etoposide-treated fed and fasted mice exhibited an 
equivalent percentage of CBC stem cells with DNA double strand breaks at 1.5 h post-etoposide; 
however, the average level of DNA damage was not determined. Therefore future experiments 
using a comet-assay on sorted-Lgr5GFP cells, at 1.5 h post-etoposide from both fed and fasted 
mice are required. 
 Investigation into the resolution of DNA double strand breaks at 3 h post-etoposide 
demonstrated that the breaks are repaired more quickly in fasted compared to fed mice. 
Furthermore, analysis of cleaved caspase 3 levels suggested that fasted mice have less CBC cell 
apoptosis after DNA damage. Together, these data suggest that the DNA repair process is 
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heighted in fasted, CBC stem cells and that this leads to less apoptosis after DNA damage. 
Future work will focus on determining the exact mechanism of repair and how repair is 
expedited under the fasted condition. 
 
Neutrophil recruitment is reduced in the fasted, etoposide-treated mice 
 We noticed that there was a striking immune response in fed mice post-etoposide. At 48 h 
post-etoposide, there were a substantial number of neutrophils localized to the top of the 
intestinal crypts of fed mice, which were absent in fasted mice. We hypothesized that the 
neutrophils were contributing to the break of a continuous epithelium between the villus and its 
adjoining crypt.This suggested that the neutrophils were playing a detrimental role in etoposide 
mediated intestinal damage. 
 I propose several experiments to address the differential immune response. First, I would 
test for differences in the neutrophil-recruiting chemokines CXCL1, CXCL2 and CXCL8. This 
could be done either by LCM or by the crypt isolation technique used in the crypt culture 
experiments, followed by qPCR for the chemokines. 
 Beyond the recruitment of neutrophils to the crypt epithelium, I would determine whether 
the availability of neutrophils were equivalent in the two conditions. First, a complete blood 
profile would be conducted over a time course pre- and post-etoposide treatment. This would 
determine if the original pool of circulating neutrophils is equivalent in both mice, as neutrophils 
are short lived and their levels may be altered by fasting and/or etoposide. Next, I would test if 
the original pool of neutrophils were equivalently reactive. By testing the myeloperoxidase 
activity of neutrophils, we may find that neutrophil function was reduced in the fasted, 
etoposide-injected mice.  
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APPENDIX 
Figure S4.11. Microarray of stem-cell enriched RNA reveals pathways that are 
differentially regulated between etoposide treated fed and fasted mice.  
Male and female Lgr5GFP::CreER/+mice at 4-6 weeks of age were allowed to feed ad libutum or 
were fasted for 24 h. Mice were treated with 80 mg/kg etoposide on day 1. Food was replenished 
in each treatment group immediately following treatment. Mice were sacrificed and small 
intestines were isolated 3 h post etoposide-treatment, fixed in methacarn and processed with 
standard paraffin embedding procedures. Laser capture microdissection was performed to isolate 
the lower portion of small intestinal crypts (enriched for stem cells). Microarray analysis was 
performed on isolated RNA. KEGG and GO pathway analysis was performed using DAVID and 
the pathways with each specific gene list and statistical data are shown.  
Figure S4.11 starts on pg 178 
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1, 
SESN
1, N
C
A
PD
3, FA
M
83D
, C
C
N
D
2, M
A
PR
E2, 
C
LA
SP2, SK
A
1, STA
G
1
238
393
13588
1.89
1.00E+00
8.51E-01
4.78E+01
G
O
:0007031~peroxisom
e 
organization
3
0.29
5.12E-02
LO
N
P2, PEX
19, PEX
6
238
21
13588
8.16
1.00E+00
8.80E-01
5.40E+01
G
O
:0009101~glycoprotein 
biosynthetic process
6
0.58
5.40E-02
ST6G
A
L1, SEC
1, G
A
L3ST4, ST3G
A
L4, B
3G
N
T6, 
FU
T10
238
117
13588
2.93
1.00E+00
8.77E-01
5.60E+01
G
O
:0007605~sensory 
perception of sound
5
0.48
5.91E-02
D
FN
A
5, M
Y
O
1A
, STR
C
, U
SH
2A
, G
JB
2
238
84
13588
3.40
1.00E+00
8.86E-01
5.94E+01
G
O
:0070085~glycosylation
5
0.48
7.47E-02
ST6G
A
L1, SEC
1, ST3G
A
L4, B
3G
N
T6, FU
T10
238
91
13588
3.14
1.00E+00
9.26E-01
6.83E+01
G
O
:0006486~protein am
ino 
acid glycosylation
5
0.48
7.47E-02
ST6G
A
L1, SEC
1, ST3G
A
L4, B
3G
N
T6, FU
T10
238
91
13588
3.14
1.00E+00
9.26E-01
6.83E+01
G
O
:0043413~biopolym
er 
glycosylation
5
0.48
7.47E-02
ST6G
A
L1, SEC
1, ST3G
A
L4, B
3G
N
T6, FU
T10
238
91
13588
3.14
1.00E+00
9.26E-01
6.83E+01
G
O
:0050954~sensory 
perception of m
echanical 
stim
ulus
5
0.48
7.71E-02
D
FN
A
5, M
Y
O
1A
, STR
C
, U
SH
2A
, G
JB
2
238
92
13588
3.10
1.00E+00
9.22E-01
6.95E+01
G
O
:0007264~sm
all G
TPase 
m
ediated signal transduction
9
0.87
8.15E-02
A
R
L5A
, A
R
H
G
A
P32, R
A
B
L3, R
A
SL11A
, 
R
A
SL10B
, A
R
L5C
, A
R
L4D
, N
K
IR
A
S1, A
R
L4A
238
258
13588
1.99
1.00E+00
9.24E-01
7.15E+01
G
O
:0009185~ribonucleoside 
diphosphate m
etabolic process
2
0.19
8.42E-02
N
U
D
T9, EN
TPD
7
238
5
13588
22.84
1.00E+00
9.21E-01
7.28E+01
G
O
:0015858~nucleoside 
transport
2
0.19
8.42E-02
SLC
29A
3, SLC
29A
2
238
5
13588
22.84
1.00E+00
9.21E-01
7.28E+01
G
O
:0009191~ribonucleoside 
diphosphate catabolic process
2
0.19
8.42E-02
N
U
D
T9, EN
TPD
7
238
5
13588
22.84
1.00E+00
9.21E-01
7.28E+01
